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Regulation of Release Factor 2 in Non-canonical Translation Pathways 
 
Bridget Yih Jiin Huang 
 
Protein synthesis, or translation, is a complex, multi-step process that requires 
regulatory and quality control mechanisms to ensure the accurate production of proteins. 
Two major challenges during bacterial protein synthesis are maintaining the accuracy of 
translation during the elongation stage and resolving stalled ribosomal complexes. 
Interestingly, bacteria have evolved two mechanisms, a post-peptidyl transfer quality 
control (post PT QC) and a ribosome rescue mechanism, to counter these challenges. 
Both of these mechanisms make use of a protein factor that normally functions during 
translation termination, Release Factor 2 (RF2), along with an additional protein factor, 
Release Factor 3 (RF3) for post PT QC and Alternative ribosome-rescue factor A (ArfA) 
for ribosome rescue, to achieve these non-canonical functions. The mechanistic role of 
RF3 and ArfA in these two pathways remains unclear; however, they may play a role in 
regulating RF2 in context of these non-canonical pathways. As a step toward 
understanding the role of RF3 and ArfA in post PT QC and ribosome rescue and, in 
particular, their role in the regulation of RF2, I sought to determine the effect of RF3 and 
ArfA on the binding kinetics of RF2 in post PT QC and ribosome rescue pathways. Using 
a single-molecule fluorescence resonance energy transfer (smFRET) signal between the 
P-site peptidyl-tRNA and RF2, the binding and dissociation of RF2 can be directly 
monitored in the absence or in the presence of RF3 or ArfA. 
In Chapter 2, I describe the development of smFRET signals using different 
chromophores, cyanine 3 to cyanine 5 (Cy3-Cy5) or to a fluorescence quencher (Cy3-
 
QSY9). The Cy3-Cy5 and Cy3-QSY9 smFRET signals complement each other for 
monitoring RF2 binding; whereas Cy3-Cy5 is suitable for observing stable binding using 
low substrate concentration, Cy3-QSY9 is suitable for observing transient binding using 
high substrate concentration. The RF2 binding and dissociation to ribosomal complexes 
was first examined in the absence of other factors thus providing the foundation for 
studying the regulation of RF2 binding by RF3 or ArfA. 
In the bacterial post PT QC mechanism, RF3 enhances the rate of RF2-mediated 
peptide release to catalyze premature termination of miscoded protein, thus ultimately 
increasing the fidelity of protein synthesis1. Without addition of RF3, the rate of RF2-
mediated peptide release is too slow to compete with the rate of protein synthesis. In 
Chapter 3, the role of RF3 on RF2 binding kinetics in post PT QC was investigated using 
both an fMet-Lys-tRNALys(Cy3) to RF2(Cy5) smFRET signal and an fMet-Lys-
tRNALys(Cy3) to RF2(QSY9) smFRET signal.  
The ArfA-RF2 ribosome rescue pathway is a backup mechanism for trans-
translation, which relieves stalled ribosomal complexes by providing an open reading 
frame coding for both a degradation tag and a stop codon2. Because the expression of 
ArfA is under strict control by trans-translation, the ArfA-RF2 pathway only functions in 
the absence of active trans-translation. More importantly, deletion of both the trans-
translation and ArfA-RF2 pathways leads to synthetic lethality in E. coli, highlighting the 
critical role of ribosome rescue in vivo3. In Chapter 4, I used an fMet-Phe-tRNAPhe(Cy3) 
to RF2(Cy5) smFRET signal to evaluate the role of ArfA on RF2 binding and 
dissociation in the ribosome rescue pathway. Collectively, these studies survey the 
 
regulation of RF2 binding kinetics by RF3 or ArfA in performing non-canonical 













Table of Contents 
 
 
List of Figures……………………………………………………………...……………..v 
 




Chapter 1 Introduction ................................................................................................. 1 
1.1 Overview: bacterial protein synthesis ................................................................... 1 
1.2 Challenges in protein synthesis: translational elongation accuracy................... 4 
1.2.1 Two major translation mechanisms controlling missense errors ....................... 4 
1.2.2 Preventing errors during the tRNA selection step of the translation elongation 
cycle by kinetic proofreading...................................................................................... 5 
1.2.3 Consequence of aa-tRNA misincorporation during translation elongation ....... 8 
1.2.4 Resolving the aECs to prevent further translational errors: the role of RF2-RF3 
in post PT QC............................................................................................................ 11 
1.3 Challenges in protein synthesis: stalled ribosome rescue .................................. 13 
1.3.1 Stalled ribosome formation .............................................................................. 13 
1.3.2 Trans-translation rescue stalled ribosome ....................................................... 14 
1.3.3 Backup mechanism of rescuing stalled ribosome: RF2-ArfA pathways ......... 15 
1.4 Discussion of RFs in termination as an insight into understanding non-
canonical mechanisms ................................................................................................ 17 
1.4.1 Structure and domain functions of RF1/2 ........................................................ 18 
1.4.1.1 Domain 1 of RF1/2 directly interacts with RF3........................................ 19 
1.4.1.2 Domain 2 of RF1/2 carries the mRNA codon recognition motif.............. 20 
1.4.1.3 Domain 3 of RF1/2 is critical for catalyzing peptide hydrolysis .............. 22 
1.4.2 Autoregulation of RF2 concentration .............................................................. 23 
1.4.3 RF1/2 and ribosomal conformations ................................................................ 24 
1.4.4 RF3 accelerates the dissociation of RF1/2 from TCs ...................................... 26 
1.4.5 RF3 structure .................................................................................................... 27 
1.4.6 Recognition of near-stop codons and the effect of RF3 .................................. 29 
1.5 Proposed mechanisms and hypothesis ................................................................ 30 
1.5.1 Proposed role of RF3 in post PT QC mechanism ............................................ 30 
1.5.2 Proposed role of ArfA in ArfA-RF2 ribosome rescue pathway ...................... 32 
1.6 smFRET and TIRF microscopy .......................................................................... 32 
1.6.1 Fluorescence resonance energy transfer .......................................................... 32 
1.6.4 Use of fluorescence quencher .......................................................................... 35 
1.6.2 Single-molecule FRET..................................................................................... 36 
1.6.3 Total internal reflection fluorescence microscopy ........................................... 36 
1.6.5 smFRET data analysis...................................................................................... 39 
1.7 Dissertation motivation and overview ................................................................. 40 
Chapter 2 Interaction of RF2 with ribosomal complexes........................................ 43 
ii 
 
2.1 Introduction ........................................................................................................... 43 
2.2 Design of smFRET signal for monitoring RF2 binding .................................... 43 
2.3 Preparation of the experimental system ............................................................. 46 
2.3.1 Buffers.............................................................................................................. 46 
2.3.2 Ribosome ......................................................................................................... 46 
2.3.3 mRNAs Preparation ......................................................................................... 47 
2.3.4 tRNAs Preparation ........................................................................................... 47 
2.3.4.1 Design of tRNALys pull-down purification DNA oligomer ...................... 48 
2.3.4.2 Purification of tRNALys ............................................................................. 49 
2.3.4.3 Validation of the purified tRNALys ........................................................... 51 
2.3.4.4 Fluorophore-conjugation of tRNALys ........................................................ 52 
2.3.5 Preparation of ribosomal complexes ................................................................ 54 
2.3.6 Preparation of RF2 ........................................................................................... 55 
2.3.6.1 Construct Design and Purification of RF2 ................................................ 56 
2.3.6.2 Fluorophore Conjugation of RF2 .............................................................. 57 
2.3.6.3 Investigation of two fluorophore-conjugated peaks ................................. 60 
2.4 Real-time observation and characterization of RF2 binding using Cy3-Cy5 
smFRET signal at low RF2(Cy5) concentration ...................................................... 62 
2.4.1 RF2 catalyzed rapid peptide release on TCs .................................................... 62 
2.4.2 The peptide release rate is enhanced on the aEC compared with the EC ........ 63 
2.4.3 RF2(Cy5) demonstrated distinct binding to ribosomal complexes with P-site 
fMet-Lys-tRNALys(Cy3) ........................................................................................... 65 
2.4.4 RF2(Cy5) demonstrated distinct binding to ribosomal complexes with P-site 
fMet-Phe-tRNAPhe(Cy3) ........................................................................................... 69 
2.5 Real-time observation and characterization of RF2(QSY9) binding using Cy3-
QSY9 smFRET signal at high RF2(QSY9) concentrations..................................... 70 
2.5.1 Evaluating peptide release activity of RF2(QSY9) on TCs using dipeptide 
release assay .............................................................................................................. 70 
2.5.2 RF2(QSY9) catalyze enhanced peptide release on aECs at room temperature 71 
2.5.3 RF2(QSY9) quenches Cy3-tRNA signal on TCs ............................................ 72 
2.5.4 RF2(QSY9) binding: presence of fluctuating and non-fluctuating time 
trajectories ................................................................................................................. 74 
2.5.5 RF2(QSY9) binding and Cy3 photophysical noise on both ECs and aECs .... 76 
2.5.6 Estimation of Cy3-photoblinking by unlabeled-RF2184 and identification of 
kinetic subpopulations on the aEC ............................................................................ 77 
2.5.6 Calculation of RF2(QSY9) binding kinetics to the aEC .................................. 82 
2.6 Summary ................................................................................................................ 83 
Chapter 3 The role of RF3 in post PT QC pathway ................................................ 85 
3.1 Introduction ........................................................................................................... 85 
3.2 Studying Effect of RF3 on RF2 Binding using Cy3-Cy5 smFRET signal ....... 85 
3.2.1 RF3 enhancement of peptide release rate on wtRF2 ....................................... 85 
3.2.2 RF3 enhances RF2(Cy5) peptide release rate .................................................. 87 
3.2.3 Effect of RF3 on RF2(Cy5) binding on ECs and aECs ................................... 88 
iii 
 
3.3 Studying Effect of RF3 on RF2 Binding at high concentration of RF2 ........... 90 
3.3.1 Measurement of RF3 enhancement of RF2(QSY9)-mediated peptide 
hydrolysis rate ........................................................................................................... 90 
3.3.2 Characterization of RF3-dependent three-state time trajectories ..................... 91 
3.3.3 RF3 affects RF2 affinity for both ECs and aECs ............................................. 96 
3.3.4 Investigating the lack of three-state time trajectories in Cy3-Cy5 smFRET 
signal ....................................................................................................................... 100 
3.4 Investigating the role of nascent polypeptide on the P-site tRNA on RF2 
binding ....................................................................................................................... 102 
3.4.1 RF2(QSY9) binding to puromycin-treated aECs ........................................... 103 
3.4.2 RF2GAQ(QSY9) binding to ribosomal complexes is similar to RF2(QSY9) . 104 
3.4.2.1 RF2GAQ(QSY9) mutant is defective in peptide hydrolysis but not binding 
to the TCs ............................................................................................................ 104 
3.4.2.2 Binding of RF2GAQ(QSY9) to the ECs and aECs ................................... 105 
3.5 Discussion............................................................................................................. 107 
3.5.1 Mechanistic role of RF3 in post PT QC pathway .......................................... 107 
3.5.2 Implication and future direction..................................................................... 111 
Chapter 4 The role of ArfA in ribosome rescue pathway ..................................... 113 
4.1 Introduction ......................................................................................................... 113 
4.2 Monitoring the effect of ArfA on RF2(Cy5) binding ....................................... 113 
4.2.1 ArfA enhances RF2-mediated peptide release on nTCs ................................ 113 
4.2.2 ArfA stabilizes RF2(Cy5) on nTCs ............................................................... 115 
4.3 Discussion............................................................................................................. 119 
4.3.1 Mechanistic role of ArfA in ribosome rescue pathway ................................. 119 
4.3.2 Future direction .............................................................................................. 121 
Chapter 5 Materials and methods ........................................................................... 123 
5.1 Preparation and Assessment of Reagents ......................................................... 123 
5.1.1 Preparation of Ribosome................................................................................ 123 
5.1.1.1 Purification of MRE600 Ribosomes ....................................................... 123 
5.1.1.2 Assessment of Ribosome by tripeptide formation Assay ....................... 125 
5.1.2 Preparation of tRNAs ..................................................................................... 129 
5.1.2.1 Preparation of fMet-tRNAfMet ................................................................. 129 
5.1.2.2 Preparation of Phe-tRNAPhe .................................................................... 131 
5.1.2.3 Purification of tRNALys ........................................................................... 132 
5.1.2.4 Preparation of Lys-tRNALys .................................................................... 134 
5.1.2.5 Cy Dye Labeling of tRNA Body ............................................................ 138 
5.1.2.6 Cy Dye Labeling of tRNA AA ............................................................... 139 
5.1.3 Preparation of mRNAs ................................................................................... 141 
5.1.3.1 In vitro transcription of mRNAs ............................................................. 141 
5.1.3.2 Preparation of biotinylated-DNA Hybridized mRNAs for microscope . 142 
5.1.4 Preparation of ribosomal complexes .............................................................. 143 
iv 
 
5.1.4.1 Preparation of ribosomal complexes for radioactive experiments .......... 143 
5.1.4.2 Preparation of ribosomal complexes for fluorescence experiments ....... 145 
5.1.5 Preparation of Release Factors....................................................................... 148 
5.1.5.1 Purification of RF1 and RF2 ................................................................... 148 
5.1.5.3 Purification of RF3 ................................................................................. 150 
5.1.5.4 Cy Dye Labeling of RF2 ......................................................................... 151 
5.1.5.5 Quencher dye conjugation of RF2 .......................................................... 152 
5.2 Biochemical assays for determining rate of peptide release ........................... 154 
5.3 Microscope data collection ................................................................................. 155 
5.3.1 Preparation of microscope slide for smFRET experiments ........................... 155 
5.3.2 Preparation of microscope flow-cell .............................................................. 157 
5.3.3 General experimental setup and imagining for steady-state smFRET 
experiments ............................................................................................................. 158 
5.4 smFRET data analysis ........................................................................................ 158 
References ...................................................................................................................... 160 
Appendix A A list of mRNA constructs .................................................................. 168 
Appendix B Mass spectrometry of tRNALys ........................................................... 169 
Appendix C Mass spectrometry of RF2 .................................................................. 171 
Appendix D RF2(QYS9) kinetic subpopulations with photophysical 
subpopulation 172 
Appendix E EFRET histograms compiled from two-state or three-state time 
trajectories from EC and aEC ..................................................................................... 176 
Appendix F Bacterial cell strains ............................................................................ 177 






List of Figures 
 
Figure 1-1 The bacterial 70S ribosome and protein synthesis ............................................ 4 
Figure 1-2 Cartoon representation of kinetic proofreading ................................................ 8 
Figure 1-3 X-ray Crystallographic Stuctures of RF2-bound TC and free RF2. ............... 20 
Figure 1-4 X-ray Crystallographic Stuctures of RF3-bound TC and free RF3 ................ 28 
Figure 1-5 Physical principal of FRET. ............................................................................ 34 
Figure 1-6 TIRF microscopy setup and smFRET data collection .................................... 38 
Figure 2-1 smFRET signals for monitoring RF2 binding to ribosomal complexes. ........ 45 
Figure 2-2 Preparation and validation of purified tRNALys. ............................................. 50 
Figure 2-3 Cy3-conjugation and aminoacylation of purified tRNALys. ............................ 53 
Figure 2-4 Preparation of ECs and aECs. ......................................................................... 55 
Figure 2-5 FPLC chromatographs showing the purification of different RF2 variants. ... 59 
Figure 2-6 Cy5 and QSY9 double-conjugation reaction. ................................................. 62 
Figure 2-7 Radioactive Dipeptide Assays Measuring the RF2-mediated peptide release 
activity............................................................................................................................... 64 
Figure 2-8 RF2(Cy5) binding to various ribosomal complexes carrying fMet-Lys-
tRNALys(Cy3) .................................................................................................................... 68 
Figure 2-9 RF2(Cy5) binding to various ribosomal complexes carrying fMet-Phe-
tRNAPhe(Cy3) .................................................................................................................... 69 
Figure 2-10 Peptide hydrolysis of RF2(QSY9) on ribosomal complexes. ....................... 71 
Figure 2-11 RF2(QSY9) binding to the TC. ..................................................................... 73 
Figure 2-12 Cy3-QSY9 smFRET signal and RF2(QSY9) binding. ................................. 75 
Figure 2-13 smFRET measurements reveal two distinct RF2 binding subpopulations to 
mismatched complexes. .................................................................................................... 81 
Figure 2-14 RF2 binding and dissociation rates from aECs. ............................................ 83 
Figure 3-1 Effect of RF3 on RF2(Cy5) binding kinetics .................................................. 89 
Figure 3-2 RF3 enhancement of RF2-mediated peptide hydrolysis rates. ........................ 91 
Figure 3-3 RF3 stabilizes an RF2 binding intermediate on ECs ...................................... 94 
Figure 3-4 RF3 stabilizes an RF2 binding intermediate on aECs ..................................... 95 
Figure 3-5 RF3 titration on aECs ...................................................................................... 98 
Figure 3-6 RF2 binding kinetics using inactive RF2GAQ(QSY9) and puromycin treatment.
......................................................................................................................................... 104 
Figure 3-7 RF2 binding kinetics using inactive RF2GAQ(QSY9) and puromycin treatment 
in presence of RF3. ......................................................................................................... 106 
Figure 3-8 Mechanistic model of the role of RF3 in post PT QC pathway .................... 110 
Figure 4-1 fMet-Phe dipeptide release catalyzed by RF2 and ArfA. ............................. 115 
Figure 4-2 the role of ArfA on RF2(Cy5) binding ......................................................... 117 






List of Tables 
 
Table 1-1 aa-tRNA selection: cognate versus near-cognate aa-tRNA14* ........................... 9 
Table 2-1 A table showing measured dipeptide peptide release rates at 37ºC. ................ 65 
Table 2-2 Number of time trajectories showing FRET .................................................... 67 
Table 2-3 Rates of peptide release measured at room temperature in Buffer M. ............. 72 
Table 2-4 Time trajectories Counts for 1µM unlabeled-RF2 and RF2(QSY9) on 
ribosomal complexes ........................................................................................................ 75 
Table 2-5 Comparison of Transition Rates Between unlabeled-RF2 versus RF2(QSY9) 76 
Table 2-6 Time trajectories counts for RF2 binding subpopulations on aEC................... 79 
Table 2-7 Transition rates between B and N of RF2 titration on aEC for subpopulations 79 
Table 2-8 Transition rates between B and N of RF2 titration on aEC .............................. 80 
Table 3-1 Rates of Peptide Release Measured at 37°C .................................................... 87 
Table 3-2 Number of time trajectories showing FRET .................................................... 88 
Table 3-3 The rate of RF2(Cy5) binding and dissociation in presence of RF3 ................ 90 
Table 3-4: Rates of Peptide Release Measured at Room Temperature in Buffer M ........ 91 
Table 3-5 Number of time trajectories showing two-state or three-state transitions ........ 92 
Table 3-6 FRET Efficiency Calculated using Two-state or Three-state Time Trajectories
........................................................................................................................................... 93 
Table 3-7 Transition Rates and Calculated RF2 Fractional Occupancy of 1μM 
RF2(QSY9) and RF3 Titration on aEC ............................................................................ 97 
Table 3-8 transition in and out of B ................................................................................ 100 
Table 3-9 RF2(QSY9) titration with 10μM RF3 ............................................................ 102 








This dissertation would have been impossible without the constant support of my 
family, friends, colleagues and mentors. Foremost, I thank my mother, Ms. Susan Ho, my 
sister, Ms. Chanel Huang, my cousin, Ms. Louise Ho, and my aunt, Ms. Elizabeth Liou, 
for their continuous emotional and financial support throughout my entire graduate 
career. I would like to thank my grandfathers, Mr. Show-Shan Ho and Mr. Yu-Lin 
Huang, who are no longer with me, but help shaped my vision and still support me until 
today. I also like to thank my best friend, Dr. Zhanna Hakhverdyan, for all the support 
and over 30 Met Opera that we have watched together. 
I thank my graduate research advisor, Professor Ruben L. Gonzalez, Jr. who has 
been extremely patient in training me as both a biochemist and a biophysicist. Ruben 
provides constant guidance on my dissertation study and leads a very special research 
group, with members creating a working environment that is both inspirational and 
supportive. First I need to thank Mr. Jason Hon for his contribution to my dissertation 
research and his friendship. This dissertation would not be possible without his 
knowledge on machine learning. I am grateful to Dr. Kelvin Caban who is not only a 
great friend but also a mentor who provided scientific guidance throughout. I also want to 
thank Dr. Colin Kinz-Thompson for his numerous input in the project. I thank my 
colleagues and friends, Dr. Dan MacDougall, Dr. Jiangning Wang, Dr. Jingyi Fei, Dr. 
Mike Englander, Dr. Dileep Pulukkunat, Dr. Wei Ning, Corey Perez, Dr. Bo Chen, Dr. 
Jan-Willem van der Meent, Alexandre Alloy, Nevette Bailey, Elizabeth Bailey, Dr. 
Nathan Daly, Dr. Bijoy Desai, Dr. Margaret Elvekrog, Dr. Rachel Fleisher, Nathaniel 
Jaffe, Dr. Jinrang Kim, Ritam Nepane and Amanda Olivo. They are a constant source of 
viii 
 
inspiration and help making the ups and downs in my graduate study a wonderful life 
experience. 
I thank my dissertation committee (alphabetical order): Professor Israel 
Fernandez, Professor Joachim Frank, Professor Eric Greene, Professor Ruben L. 
Gonzalez, Jr., Professor Ann McDermott and Professor Arthur G. Palmer, III. In 
particular, I am in debt to Joachim, Eric and Ruben, who have spent countless hours in 
my doctoral committee meetings and provide feedback on my dissertation.  
 
  
Chapter 1 Introduction 
1 
 
Chapter 1  Introduction 
 
1.1 Overview: bacterial protein synthesis 
 
The central dogma of molecular biology describes the two-step decoding of 
genetic information that ends in the production of proteins, which perform the vast 
majority of biological processes. In the first step, known as “transcription,” genetic 
information stored in the form of a deoxyribonucleic acid (DNA) sequence is used as a 
template for the synthesis of a ribonucleic acid (RNA) intermediate known as messenger 
RNA (mRNA). In the next step, known as “translation,” mRNA is used as a template for 
protein synthesis, a process catalyzed in all domains of life by a ribonucleoprotein 
complex known as the ribosome. In bacteria, the complete 70S ribosome consists of two 
distinctly sized subunits: a small, or 30S, subunit and a large, or 50S, subunit. The 
structure of the bacterial ribosome is shown in Figure 1-1 A with a corresponding cartoon 
representation. Both ribosomal subunits consist of ribosomal RNA (rRNA) and protein 
components which collaborate to form all the functionally important sites of the 
ribosome4.    
The ribosome decodes the mRNA sequence three nucleotides (or a codon for 
every three nucleotides) at a time by utilizing a variety of aminoacylated transfer RNA 
(aa-tRNA) substrates. There are three distinct aa-tRNA binding sites formed at the 
interface between the 30S and 50S subunits: the incoming aa-tRNA binding site (A site), 
peptidyl-tRNA binding site (P site) and tRNA exit site (E site). During the process of 
protein synthesis, the incoming aa-tRNA carrying a specific amino acid binds in the A 
site, moves through the P site and dissociates from the E site as deacylated tRNA after 
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adding a single amino acid to the growing nascent polypeptide. The mRNA is located at a 
cleft on the 30S subunit contiguous to all three tRNA binding sites (Figure 1-1 A). The 
initial pairing between the codon of the mRNA and the anticodon of the aa-tRNA initially 
forms in a specialized site on the 30S subunit called the decoding center (DC). The 
addition of a single amino acid to the growing nascent polypeptide occurs at a specialized 
site on the 50S subunit called the peptidyl-transferase center (PTC), the end of which 
forms an exit tunnel where the growing polypeptide extrudes from the ribosome. Finally, 
a group of ribosome-dependent guanosine triphosphatases (GTPases) binds to a highly 
conserved region on the ribosome called the GTPase-associated center (GAC) to mediate 
GTP hydrolysis as a mean of performing their respective functions4.  
Translation can be categorized into four stages: initiation, elongation, and 
termination, which directly produce a polypeptide chain, and finally, recycling, which 
prepares the ribosome for subsequent rounds of protein synthesis (Figure 1-1 B). Each 
stage of protein synthesis is achieved with the help of additional protein translation 
factors. While the overall process of translation is similar in all three domains of life, 
translation factors and kinetic details vary greatly; in this thesis, I will focus on bacterial 
translation.  
During initiation, the initiator tRNA, formyl-methionine-tRNA (fMet-tRNAfMet), 
base pairs with the start codon (a nucleotide triplet with sequence AUG) of the mRNA at 
the P site of the 30S subunit with the help of three protein initiator factors, IF1, IF2 and 
IF3, to form a 30S initiation complex (Figure 1-1 B). The 70S ribosome forms by the 
association of the 30S initiation complex with the 50S subunit and is accompanied by 
dissociation of the IFs and re-orientation of fMet-tRNAfMet into the PTC in the P site. The 
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next stage, elongation, is a cyclical process in which single amino acids are sequentially 
added to the growing nascent polypeptide in response to the codons in the mRNA 
template. During each elongation cycle, the mRNA codon in the DC of the A site is 
decoded by the cognate aa-tRNA. Decoding involves the formation of a complementary 
base-pairing interaction between the mRNA codon and the anticodon of the incoming aa-
tRNA, which is delivered as a ternary complex with elongation factor Tu (EF-Tu) and 
GTP. Once the cognate aa-tRNA has been recognized, peptidyl transfer occurs from the 
polypeptide on the P-site peptidyl-tRNA to the single amino acid on the aa-tRNA in the 
A site, thus extending the polypeptide chain by one amino acid residue. The ribosome 
prepares the next cycle of elongation by translocating the polypeptide-tRNA in the A site 
into the P site, a motion precisely coordinated with translocation of one codon of the 
mRNA and facilitated by elongation factor G (EF-G). Therefore, the elongation cycle 
involves aa-tRNA selection, followed by peptidyl transfer and translocation. Elongation 
continues until a stop codon on the mRNA enters the A site, which begins the process of 
termination. During termination, a stop codon is recognized by one of the two class 1 
release factors, release factor 1 (RF1) or release factor 2 (RF2). RFs catalyze the 
hydrolysis of the polypeptide from the peptidyl-tRNA in the P site, thus releasing the 
nascent polypeptide from the ribosome. The dissociation of RF1 or RF2 is mediated by 
the class 2 RF, release factor 3 (RF3). At this stage, the production of a newly 
synthesized protein is complete, and the ribosome is recycled by ribosome recycling 
factor (RRF) and EF-G, which together catalyze the splitting of the ribosome into the 30S 
and 50S subunits, and thus completing one cycle of translation4.  
 




Figure 1-1 The bacterial 70S ribosome and protein synthesis 
(A) X-ray crystallographic structure of the bacterial 70S ribosome (PDB ID: 4V5E)5, 
consisting of the large 50S subunit (cyan), the small 30S subunit (yellow) and the E- 
and P-site tRNAs (orange). The lower left panel is a corresponding cartoon 
representation with the nascent polypeptide shown as circles. (B) Cartoon 
representation of bacterial protein synthesis in four stages: initiation (lower left) with 
IF1 (pink), IF2(purple), IF3 (orange), elongation cycle (upper circular diagram) with 
EF-Tu (red) and EF-G (blue), termination (lower right) with RF1/2 (green) and RF3 




1.2 Challenges in protein synthesis: translational elongation accuracy   
1.2.1 Two major translation mechanisms controlling missense errors 
 
Translation proceeds with high accuracy, with roughly one misincorporated 
amino acid every 103 to 104 residues6,7,8. In bacteria, two key processes contribute to the 
majority of misincorporation events. In the first, when amino acids are chemically 
attached to tRNAs, known as aa-tRNA synthesis, the tRNA can be misaminoacylated 
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with the wrong amino acid which would lead to a missense error. The rate of this type of 
error, measured in isolation, is remarkably low, approximately one mistake in 104 to 105 
aminoacylation events, a result of both stringent amino acid selection and editing 
mechanisms9. Because the observed missense error rate from aa-tRNA synthesis is an 
order of magnitude lower than the measured missense error rate of overall translation, it 
is thought that the primary source of translational errors derives from the second process, 
the translation elongation cycle. Notably, the missense error rate during elongation is 
codon-dependent and, therefore, can differ dramatically between codons. A systematic 
study performed by Kramer and Farabaugh evaluated all possible near-cognate missense 
errors involving tRNALys using an in vivo firefly luciferase reporter system6. Within this 
system, the missense error of tRNALys, with anticodon UUU, ranged from 2.0×10-4 per 
codon for GAA to 3.6×10-3 per codon for AGA, reflecting the complexity of controlling 
translation accuracy6.  
During elongation, accuracy is maintained via prevention through kinetic 
proofreading and a quality control mechanism. Below, I will briefly review the 
mechanisms of kinetic proofreading. However, while the ribosome is highly accurate, 
misincorporation of aa-tRNA has unexpected consequences for overall subsequent 
translational accuracy. After discussing kinetic proofreading and the consequences of 
misincorporation during elongation, I will describe the quality control mechanism 
responsible for resolving ribosomal complexes with misincorporated aa-tRNAs. 
1.2.2 Preventing errors during the tRNA selection step of the translation elongation 
cycle by kinetic proofreading 
 
The ribosome maintains accurate tRNA selection during elongation using a 
complex series of disproportioned equilibria separated by irreversible chemical 
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transformations, a mechanism known collectively as kinetic proofreading. The principal 
difficulty is that many substrates, such as leucine and isoleucine, are nearly chemically 
identical, and yet accurate discrimination is necessary for proteins to be synthesized 
accurately and function correctly. Broadly speaking, this problem may be recast as: there 
is a negligible free energy difference between many similar aa-tRNAs; therefore, the 
ribosome must expend energy to figure out which is which in order to facilitate accurate 
protein synthesis. This operation manifests in two substrate-selection steps that are 
separated by an irreversible GTP hydrolysis step, which increases the specificity of 
enzyme-substrate selection by utilizing the free energy difference of the aa-tRNAs twice. 
These steps, or stages, are referred to as initial selection and proofreading, and precede 
peptidyl transfer (Figure 1-2). 
During the first step, known as initial selection, the ternary complex, consisting of 
an aa-tRNA, EF-Tu and GTP, encounters the A site of the ribosome to form an 
encounter-complex (initial binding, k1 and k-1 in Figure 1-2). The aa-tRNA of the ternary 
complex is then selected in a codon recognition step, where the dissociation rate of the 
cognate (correct) ternary complex (k-2, Figure 1-2) is stabilized by ~1000-fold, from 34s
-1 
with near-cognate aa-tRNA compared with 0.5s-1 for ternary complexes with cognate aa-
tRNA10 (Table 1-1). Next, EF-Tu in the ternary complex prepares for the chemically 
irreversible GTP hydrolysis step by undergoing a conformational change known as 
GTPase activation, followed shortly by GTP hydrolysis (k3, k-3 and kGTP, Figure 1-2). 
The forward rate of GTPase activation is strongly dependent on the codon-anticodon 
pairing of the mRNA and tRNA in the A site. The cognate ternary complexes have a 
GTPase activation forward rate (k3, Figure 1-2) of 120-500s
-1, which should be compared 
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to the dramatically reduced rate of forward activation in the near-cognate ternary 
complexes, 0.06-1.3s-1 (Table 1-1)10–12. Subsequently, GDP-bound EF-Tu dissociates 
from the ribosome, dividing the initial selection step from the proofreading step.  
During the second step, known as proofreading, the pathway branches into two 
outcomes, one in which the aa-tRNA is accepted into the A site, known as 
accommodation (k5, Figure 1-2), and one in which the aa-tRNA is dissociated from the 
ribosome, known as rejection (k7, Figure 1-2). Accommodation is accelerated relative to 
rejection when the codon-anticodon pairing can form complementary base pairing. After 
cognate aa-tRNA selection, the post-accommodation aa-tRNA proceeds to the peptidyl 
transfer step (kpep, Figure 1-2), and the polypeptide on the peptidyl-tRNA in the P site 
transfers to the aa-tRNA in the A site, increasing the nascent polypeptide by one amino 
acid in length. Shortly afterward, the A-site peptidyl-tRNA translocates in the P site. 
Overall, the discrimination factor for cognate versus near-cognate aa-tRNA substrates is, 
depending on the aa-tRNA pair compared, 30-60 fold for the initial aa-tRNA selection 
step and 20-100 fold for the proofreading step10,13. 
 




Figure 1-2 Cartoon representation of kinetic proofreading 
During kinetic proofreading of translation elongation, a ribosomal complex (50S 
subunit colored cyan and 30S subunit colored yellow) go through two major steps: 
initial selection and proofreading (shaded gray). The first step of initial selection, initial 
binding of the ternary complex (EF-Tu colored red, aa-tRNA colored orange and GTP) 
is governed by k1 and k-1. The codon in the A site of the ribosome is recognized by the 
anticodon of the aa-tRNA with the rate constants k2 and k-2. The G-domain of EF-Tu 
undergoes a conformational change, which is also known as GTPase activation, 
governed by k3 and k-3. Transition into the proofreading step is preceded by two 
irreversible steps, GTP hydrolysis (kGTP) and EF-Tu conformational change (k4). 
During proofreading, the aa-tRNA is either accommodated (k5) and proceed to 
peptidyl transfer (kpep), or rejected (k7). 
 
1.2.3 Consequence of aa-tRNA misincorporation during translation elongation  
 
Occasionally, a near-cognate aa-tRNA escapes kinetic proofreading during the 
elongation cycle to become incorporated into the P site of the ribosomal complex. This 
leads to varying degrees of mismatch between one of the three nucleotides of the 
peptidyl-tRNA anticodon and the codon of the mRNA template, creating an aberrant 
elongation complex referred as “aEC.” In contrast to elongation complexes, or “EC”, 
with complementary P-site codon:anticodon interaction, the codon:anticodon mismatch 
in the P site of aEC leads to a decrease in translation accuracy with an increased 
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propensity of additional misincorporation in the following rounds of elongation cycles, 
thus leading to formation of polypeptides with accumulated missense errors. 
The effects of mismatched P site on the kinetics steps of tRNA selection have 
been carefully examined using a combination of biochemical and fluorescence assays by 
Zaher and Green14. Rate constants at each step of aa-tRNA selection are measured for 
both the cognate and near-cognate aa-tRNA substrate in the ternary complex for ECs and 
aECs to identify the effect of a mismatched interaction in the P site (aa-tRNA selection: 
cognate versus near-cognate aa-tRNA).The mismatched interaction in the P site affects 
multiple critical selection steps throughout aa-tRNA selection and greatly reduces the 
discrimination between the cognate aa-tRNA against the near-cognate aa-tRNA. As 
described in the previous section, cognate and near-cognate aa-tRNA are not 
discriminated in the k2. Instead, the k-2 of the cognate aa-tRNA is greatly stabilized 
compared with a near-cognate aa-tRNA on an EC (k2 and k-2, Figure 1-2)
10. The 
mismatched P site of aECs has a dramatic effect on the k-2 of the near-cognate aa-tRNA. 
Instead of discriminating near-cognate aa-tRNA with increased k-2
 of 34s-1 compared 
with the cognate aa-tRNA k-2 of 0.5s
-1, the near-cognate aa-tRNA is stabilized as if it is a 
cognate aa-tRNA14 (Table 1-1). This effect on the k-2 abolishes the discrimination at the 
k-2 step, thereby decreasing the fidelity of tRNA selection.  
Table 1-1 aa-tRNA selection: cognate versus near-cognate aa-tRNA14* 
 Cognate aa-tRNA Near-cognate aa-tRNA 
 EC aEC EC aEC 
k2 32 ±4.6 30 ±3.1 26 ±5.4 30 ±3.9 
k-2 0.5 ±0.013 0.25 ±0.0025 34 ±1.5 0.5 ±0.04 
kGTP 18 ±1.6 7.5 ±0.44 0.29 ±0.022 3.3 ±0.23 
kpep 6.9 ±0.47 8.1 ±0.50 0.2 ±0.004 2.3 ±0.46 
k5±k7 5.0 ±1.1 4.1 ±0.63 0.16 ±0.060 2.2 ±0.23 
 
*Table reproduced from Zaher and Green14. 





The subsequent steps in tRNA selection were measured as a combination of 
multiple steps, making the interpretation of the effect of P-site mismatch more difficult; 
however, the trend is consistent with the loss of discrimination between the cognate and 
near-cognate aa-tRNAs. The GTP activation and GTP hydrolysis steps were evaluated 
together as kGTP, where the P-site mismatch leads to a slight decrease in the kGTP of the 
cognate aa-tRNA from 18s-1 to 7.5s-1 and an increase in the kGTP of the near-cognate aa-
tRNA from 0.29s-1 to 3.3s-1 (Table 1-1)14. The kGTP of the near-cognate tRNA on the aEC 
is nearly 10-fold faster than the EC, which is consistent with loss of substrate 
discrimination on the aEC. The proofreading steps in aa-tRNA selection consist of the 
accommodation (k5) or rejection (k7) of aa-tRNA, where peptidyl transfer occurs 
subsequent to accommodation of the tRNA14. The rate of peptidyl transfer (kpep) is 
measured directly from a tripeptide formation assay, and a combination of k5+k7 was 
obtained from a fluorescence stopped-flow assay14. Both the kpep and k5+k7 of the cognate 
aa-tRNA on ECs and aECs showed insignificant differences, however, both kpep and 
k5+k7 of near-cognate aa-tRNA on aEC are increased by approximately 10-fold compared 
with the EC14. 
As indicated by changes in the kinetics during translation elongation, examining 
the purity of the peptide products formed on an aEC revealed that the aa-tRNA selection 
fidelity on the aEC is in fact compromised. Tripeptide formation reactions were 
performed in the presence of total tRNA mix using both EC and aEC (ribosomal 
complexes carrying mRNA coding for fMet-Lys-Ile and fMet-Asn-Ile with fMet-Lys-
tRNALys in the P site, respectively) in vitro1. As resolved using a two-dimensional thin 
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layer chromatography, the EC produced predominantly fMet-Lys-Ile, which is the 
tripeptide encoded by the mRNA; however, the aEC produced a wide range of miscoded 
tripeptide product1. 
1.2.4 Resolving the aECs to prevent further translational errors: the role of RF2-
RF3 in post PT QC 
 
As discussed above, both kinetic proofreading steps and peptidyl transfer rates are 
affected on aECs relative to ECs1,14. Intriguingly, peptide release catalyzed by the class 1 
RFs was also enhanced by the mismatched P-site codon:anticodon interaction1,14. In the 
canonical termination, class 1 RFs recognize the stop codons in the A site of termination 
complexes (TCs) carrying stop codons and not the A site of the ECs containing sense 
codons. In the presence of a perturbed P-site codon:anticodon interaction, the rate of 
peptide release catalyzed by one of the class 1 RF, RF2, is faster than those without the 
perturbation1,14,15. This observation is analogous to the loss of A-site specificity as 
observed during aa-tRNA selection during translation elongation cycles.  
In the presence of the class 2 RF, RF3, the RF2-mediated peptide release rates on 
the aECs was found to be substantially accelerated to the point where it competes with 
the aEC elongation cycle1. The RF3-dependent enhancement of RF2-mediated peptide 
release was verified on three types of aECs, with P-site codon:anticodon mismatch 
located at the first, second and third position of the P-site lysine mRNA codon on a 
ribosomal complex carrying mRNA coding for fMet-Lys-Phe1. The aEC with a 
codon:anticodon mismatch at the second position showed the most dramatic RF3 
enhancement factor of 30-fold, from ~0.002s-1 to ~0.06s-1. 1 Most importantly, the RF3 
enhancement factor on the EC, whose codons and anticodons match, is negligible in 
comparison with the RF3 enhancement factor on the aECs, thereby resulting in a post 
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peptide-bond formation quality control mechanism (post PT QC), which catalyzes the 
premature release of the miscoded polypeptide on aECs1. It is estimated that this quality 
control mechanism contributes to translation fidelity by approximately one order of 
magnitude1. This mechanism is particularly important under cellular stress conditions 
which promote the likelihood of misincorporation during elongation, such as amino acid 
starvation or antibiotic challenges.  
In contrast to the biochemical results, in vivo studies of this quality control 
mechanism have been controversial. The initial in vivo study demonstrated that under 
streptomycin challenge, an antibiotic which leads to an increase in elongation miscoding, 
the RF3 gene (prfC) became essential for cell survival and the quality control mechanism 
contributes to translation fidelity up to a factor of 10 based on an in vivo reporter assay16. 
However, it was noted that this study utilized K-12 E. coli strain, a strain carrying a 
natural variant of RF2 with reduced activity17–20. The streptomycin-sensitivity experiment 
was repeated using K-12 E. coli with RF2 mutated to create a more active RF2 variant 
and found that, with a more active RF2 variant, deletion of RF3 has no effect on the cell 
survival21. While it is difficult to evaluate the contribution of RF3 in the post PT QC 
mechanism in vivo, especially since the prfC gene is a nonessential gene, the biochemical 
measurements described above have clearly demonstrated that RF3 accelerates the rate of 
RF2-mediated hydrolysis of miscoded polypeptide on an aEC, making the rate of peptide 
release competitive with the rate of translation elongation1. 
Efficient premature peptide release of these aECs catalyzed by RF2 and RF3 
forms an error resolution mechanism known as post PT QC, which contributes to the 
fidelity of protein synthesis by terminating error prone elongation by aECs. In contrast to 
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the plethora of studies on the canonical bacterial termination of RF2 and RF3, little is 
known about their role in the bacterial post PT QC mechanism. This thesis will 
investigate the mechanism by which RF3 enhances RF2-mediated peptide hydrolysis 
from aECs.  
1.3 Challenges in protein synthesis: stalled ribosome rescue  
1.3.1 Stalled ribosome formation 
 
Unlike missense errors, translational stalling imposes a different challenge for 
protein synthesis. Translational stalling can occur either on truncated mRNAs or in the 
middle of mRNAs. The most deleterious form of ribosome stalling results from 
translation of an mRNA containing no in-frame stop codon, forming a non-termination 
complex (nTC) with the ribosome stalled with the 3’-end of mRNA in the P site and with 
an empty A site. The truncated mRNAs lacking in-frame stop codons are most likely 
generated by 3’-5’ exonucleases, which are normally responsible for mRNA turnover in 
bacteria22. Due to the strong stabilization effect of P-site peptidyl-tRNA, which holds the 
50S and 30S subunits of nTCs tightly together, and the lack of an in-frame stop codon, 
nTCs cannot enter the canonical termination step of translation. The P-site peptidyl-tRNA 
further prevents the downstream recycling of ribosomal complexes, which is deleterious 
to the cell because ribosomes are steadily depleted as nTCs gradually accrue in the 
absence of rescue mechanisms23,24.  Induction of endoribonuclease toxins, such as MazF 
and RelE, also cleaves mRNAs and generates nTCs under cellular stress conditions25,26.  
In addition to mRNA-cleavage-induced stalling, elongating ribosomal complexes 
can stall on an intact mRNA due to a shortage of aa-tRNAs, inefficient peptidyl transfer, 
frameshifting, stop codon readthrough or antibiotic stress24,27–29. Elongating ribosomes 
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stalled or paused, as a result of aa-tRNA depletion or inefficient peptidyl transfer, either 
resume translation elongation or the mRNA template becomes a target of cleavage by 
RNases. The precise mechanism of mRNA cleavage is less well understood, however, it 
is believed that multiple mechanisms and RNases participate in the generation of nTCs. 
One of the mechanisms involves the shortening of mRNAs by RNase II, a 3’-5’ 
exonuclease, and cleavage of the mRNA in the A site by an unknown nuclease30,31.  
The number of nTCs in E. coli is unexpectedly abundant with an estimation of 
~2-4% of elongating ribosomal complexes being stalled after inactivation of ribosome 
rescue pathways24,32. Based on ribosome profiling data in E. coli, Bacillus subtilis and 
Caulobacter crescentus, 0.5-1.0% of elongating ribosomal complexes are in one of the 
ribosome rescue pathways24,33. Taking into account the speed of translation in E. coli, at 
any given time, approximately 2% of all elongating ribosomal complexes are in a 
ribosome rescue pathway24.  
1.3.2 Trans-translation rescue stalled ribosome 
 
Although peptidyl-tRNAs carrying a nascent polypeptide with fewer than five 
amino acids have been shown to have a higher rate of dissociation from the elongation 
complex, stalled ribosomes with longer peptidyl-tRNA require a more intricate rescue 
mechanism34. The most well studied bacterial mechanism in resolving nTCs is known as 
trans-translation, which requires a specialized RNA known as transfer-messenger RNA 
(tmRNA) and small protein B (SmpB)2,35. The tmRNA complex mimics delivery of a 
ternary complex, consisting of tmRNA, SmpB, EF-Tu and GTP. The tRNA-like domain 
of tmRNA is aminoacylated with alanine by the canonical alanyl-tRNA synthetase36,37. 
The mRNA-like domain of tmRNA contains a short open reading frame that terminates 
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with a stop codon36,37. Therefore, upon delivery of the complete tmRNA complex, the 
nascent polypeptide in the P site of the stalled ribosomal complex is transferred to the 
tRNA-mimicking portion of the tmRNA and, following translocation, the mRNA-
mimicking portion of the tmRNA replaces the missing codon of the nTC2. Canonical 
termination can occur at the stop codon of the tmRNA open reading frame, followed by 
ribosome recycling via the canonical recycling mechanism. Finally, the short peptide 
sequence coded by the tmRNA open reading frame forms a signal that promotes 
degradation by proteases2,38,39.  
1.3.3 Backup mechanism of rescuing stalled ribosome: RF2-ArfA pathways 
 
 
Based on the high conservation of the trans-translation mechanism among 
bacterial species (more than 99% of known bacterial genomes), it is surprising that the 
gene coding for tmRNA, ssrA, is essential in Neisseria gonorrhoeae40, but not essential in 
E. coli41. This led to the discovery of a backup mechanism of trans-translation from a 
synthetic lethality genetic screen for ssrA3. A mutant with a single point mutation 
(adenine to guanine at 52nd nucleotide leads to an A18T mutation) at the yhdL gene 
(219bp) strictly requires ssrA for growth. The yhdL gene was then proposed to be 
renamed as arfA gene, which stands for alternative ribosome-rescue factor A (ArfA), for 
its role in complementing ssrA and rescuing nTC.  
The synthetic lethality of the double deletion of ssrA and arfA was confirmed 
using a W3110 based E. coli strain with both genomic deletions of ssrA and arfA carrying 
a plasmid coding for a ssrA gene under the pBAD promoter. In this context, ssrA deletion 
is accompanied by a loss of cell viability measured by colony forming unit and growth 
impairment, compared with the control where ssrA was not depleted. As described 
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earlier, trans-translation not only resolved nTCs, it also attaches a tag on the polypeptide 
for degradation. A ssrA variant encoding the proteolysis-refractory tag sequence, SsrADD, 
was used to examine if the tagging is responsible for the synthetic lethality phenotype in 
the ssrA and arfA double deletion. It was shown that SsrADD complements the ssrA and 
arfA double deletion, suggesting that stalled ribosome rescue has a more direct 
consequence on cell viability and that the degradation tag on the polypeptide is 
secondary3. The experiment using puromycin, an antibiotic that mimics the 3’-end of aa-
tRNA and causes premature release of nascent polypeptides, further support this idea. 
Low concentrations of puromycin alleviated the growth defect under double deletion of 
ssrA and arfA3. Puromycin enhanced the growth of cells lacking both ssrA and arfA, but 
not the single deletions of either ssrA or arfA, suggesting that the lack of peptide release 
activity is necessary for the lethality phenotype associated with ssrA and arfA deletion3. 
ArfA has been isolated with the 50S subunit, but not the 30S subunit, based on 
co-sedimentation experiments of ribosomal subunits isolated from an arfA deletion strain 
incubated with His6-tagged ArfA
3. Consistent with this finding, the dissociation 
constants, determined using fluorescently labeled ArfA, of ArfA to the 70S ribosome and 
50S subunits are essentially equivalent, ~30nM42. While ArfA associates directly with 
nTCs, ArfA alone is insufficient to catalyze peptide release. Using a cell-free translation 
system with a model nTC mRNA, Chadani et. al demonstrated that one of the two class 1 
RFs, RF2, is required for catalyzing peptide release on nTC43. Similar to the post PT QC 
mechanism, RF1 does not participate in this ArfA-RF2 ribosome rescue mechanism43. 
The polypeptide of nTCs can be efficiently released by the ArfA-RF2 pathway when the 
A site of the nTCs is fully empty or partially occupied by up to 3 nucleotides42,44. 
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Directed hydroxyl radical probing of the ArfA-bound nTC suggests that ArfA binds near 
the empty mRNA channel of nTCs and may have a role in the direct recruitment of 
RF242.  
The ArfA-RF2 pathway catalyzes peptide release on nTCs without the addition of 
a degradation tag to the polypeptide. While it has been proposed that ArfA is primarily 
responsible for the recruitment of RF2 to nTCs for peptide hydrolysis, direct evidence 
showing that ArfA influences the RF2 affinity to nTCs is lacking. Elucidating the effect 
of ArfA on RF2 binding, discussed in Chapter 4 of this thesis, would lead to a better 
understanding of the mechanistic role of ArfA in the ArfA-RF2 ribosome rescue 
pathway. 
 
1.4 Discussion of RFs in termination as an insight into understanding 
non-canonical mechanisms 
 
The quality control of nascent polypeptide synthesis via the post PT QC pathway 
and ribosome rescue via the ArfA-RF2 pathway both utilize release factors; therefore, an 
understanding of the role of RFs in post PT QC and ribosome rescue can be developed 
through comparison with their well-known and characterized roles in canonical 
termination. Bacterial termination of protein synthesis begins when one of the three stop 
codons enters the A site of the elongating ribosome. In contrast to translation elongation 
where codons on the mRNA template are decoded using aa-tRNA substrates, stop codons 
are directly recognized by the protein class 1 RFs, RF1 or RF2, which catalyze peptide 
hydrolysis and subsequent dissociation of the nascent polypeptide chain from the 
ribosome-bound peptidyl-tRNA in the P site. The bacterial class 1 RFs share overlapping 
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specificity, where RF1 recognizes UAG and UAA and RF2 recognizes UGA and 
UAA45,46. After catalyzing peptide hydrolysis of the nascent polypeptide, RF1 or RF2 
remain stably bound to the TC47. The class 2 RF, RF3, accelerates the dissociation of the 
class 1 RFs thereby preparing the ribosome for the recycling phase of protein synthesis48. 
The role of RF3 as a recycling factor for RF2 in canonical termination must therefore be 
distinct from its role as an enhancement factor for RF2-mediated peptide release in post 
PT QC, because RF3 has been shown to have no effect on the rate of RF2-mediated 
peptide release in canonical termination48. In addition, RF2, with the help of ArfA, 
catalyzes peptide release on a ribosomal complex lacking an A-site stop codon, which is 
quite distinct from termination. On the other hand, termination, post PT QC and ribosome 
rescue mechanisms likely shared similar mechanistic features. Therefore, I will highlight 
studies in termination as a means to build toward the proposed mechanisms for both post 
PT QC and ribosome rescue. 
 
1.4.1 Structure and domain functions of RF1/2 
 
Bacterial class 1 RFs, both RF1 and RF2, are structurally similar and consist of 
four globular domains: domain 1 interacts with RF3, domain 2 contains the codon 
recognition motifs, domain 3 contains the tripeptide motif responsible for catalyzing 
peptide release and domain 4, along with domain 2, makes up the protein core domain 
(Figure 1-3). Below, I will review what is known about the role of RF1, RF2 and RF3 in 
termination, highlighting what is known about how near and non-stop codons are 
discriminated against, which might provide insight into the non-canonical functions of 
the RFs. 
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1.4.1.1 Domain 1 of RF1/2 directly interacts with RF3 
 
The N-terminal domain 1 of the class 1 release factors (RF1/2) is located furthest 
away from the P-site aa-tRNA where it interacts with both the 50S ribosomal subunit and 
with the class 2 release factor RF3. Deletion of domain 1 has little impact on the peptide 
hydrolysis activity of class 1 RFs49. However, when the concentration of RF1/2 is 
reduced such that RF3-mediated recycling of RF1/2 is necessary to catalyze peptide 
release in the presence of a stoichiometric excess of TCs, deletion of domain 1 has a 
significant impact on the peptide release from TCs49.  
This biochemical result is consistent with a cryo-electron microscopy (cryo-EM) 
reconstruction of a TC carrying RF1 and apo-RF3 (no bound guanosine nucleotides, such 
as GDP or GTP), showing that domain 1 of RF1 directly interacts with apo-RF350. The 
model shows that the domain 1 of RF1 and domain 3 of RF3 are connected by several 
salt bridges, forming a charged-based protein-protein interface where the interface on 
domain 1 of RF1 is more negatively charged and the interface on domain 3 of RF3 is 
more positively charged50. Alanine scanning of the bridges revealed that mutation of 
residue histidine 13 in domain 3 of RF3 to alanine and/or a glutamic acid 18 to alanine in 
domain 1 of RF1 leads to a decrease in RF3-mediated recycling of RF150.  
  




Figure 1-3 X-ray Crystallographic Stuctures of RF2-bound TC and free RF2. 
(A) X-ray crystallographic structure of T. thermophilus RF2 (green) bound to a post-
hydrolysis TC in the non-rotated state with the P-site and E-site tRNA (orange) in the 
P/P and E/E configuration (PDB ID: 4V5E)5. RF2 is shown in both surface 
representation on the TC and the cartoon representation in the zoom-in with each 
domain colored: domain 1 (orange), domain 2 (blue), domain 3 (pink) and domain 4 
(green). The GGQ motif of domain 3 and SPF tripeptide recognition motif in domain 2 
are colored in yellow. (B) X-ray crystallographic structure of free E. coli RF2 (PDB 
ID:1GQE)51. Each domain is colored the same: domain 1 (orange), domain 2 (blue), 
domain 3 (pink) and domain 4 (green).  
 
1.4.1.2 Domain 2 of RF1/2 carries the mRNA codon recognition motif 
 
Domains 2 and 4 of RF1/2 are packed against each other, forming a structural 
“core” domain, where domain 2 contains a codon recognition tripeptide motif that 
recognizes stop codons. The two RFs have different recognition motifs for recognizing 
their corresponding stop codons. RF1 contains a Proline-X-Threonine (PXT, where X 
varies based on organisms, for example, alanine in E. coli and valine in T. thermophilus) 
motif for recognizing the TC containing either the RF1-specific UAG stop codon or the 
universal UAA stop codon. RF2 contains a Serine-Proline-Phenylalanine (SPF) motif for 
recognizing the TC containing either the RF2-specific UGA stop codon or the universal 
UAA stop codon45,46. Swapping either the entire domain 2 or the 13-amino-acid loop near 
the recognition motif between RF1 and RF2 changes the stop codon specificity 49,52, 
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suggesting that the recognition motifs is sufficient with respect to the rest of the RF for 
decoding the respective stop codon on the mRNA. In addition, RF1/2 mutation with 
charge change of E/D to K at positions in domain 2, near the interface of domain 3, alter 
the codon specificity53,54. Since these residues are far away from the codon recognition 
motifs, it is suspected that these mutations change inter-domain movements that are 
important for catalyzing peptide release. 
The four X-ray crystallographic structures of class 1 RFs bound to different TCs 
provide detailed pictures of how RFs decode stop codons: 1) an RF1-bound TC carrying 
an A-site UAG codon55, 2) an RF1-bound TC carrying an A-site UAA codon56, 3) an 
RF2-bound TC carrying an A-site UGA codon5 and 4) an RF2-bound TC carrying an A-
site UAA codon57. Surprisingly, the decoding of the uridine at the first position of any of 
the stop codons is achieved by interaction with residues surrounding the PXT or SPF 
recognition motifs of RF1 or RF2, respectively. The specificity of the first position as 
uridine is governed by strict Watson-Crick interactions and hydrogen bonds with the 
residues on RFs, such that no other nucleotide bases are allowed46,58. At the second 
position, RF1 can only recognize adenosine because of the peculiar geometry of the 
threonine of the PXT motif, whereas RF2 recognizes either adenine or guanine with the 
serine of the SPF motif46,58. RF1 recognizes both adenosines and guanosines at the third 
position by forming hydrogen bonds with surrounding residues. On the other hand, RF2 
discriminates against guanosines at the third position by only forming a hydrogen bond 
with its residues46,58.  
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1.4.1.3 Domain 3 of RF1/2 is critical for catalyzing peptide hydrolysis  
 
Domain 3 of RF1/2 carries a universally conserved Glycine-Glycine-Glutamine 
(GGQ) motif, which is essential for RF1/2-mediated peptide release from TCs59. The 
post-translational methylation of the glutamine residue (Q235) of the GGQ motif, 
catalyzed by the enzyme N5-glutamine methyltransferase, is critical for the peptide 
hydrolysis activity of both RFs17,60. On the RF-bound TCs, which are in a post-release 
state, domain 3 is extended into the PTC, and, the GGQ motif is adjacent to the 3’ end of 
the deacylated P-site tRNA5,55–57.  
Peptide release involves cleavage of the ester bond connecting the nascent 
polypeptide to the 3’-adenosine (A76) of the P-site peptidyl-tRNA, releasing the nascent 
polypeptide from the P-site tRNA. It has been proposed that the N5-methylated glutamine 
of the GGQ motif, confers unusual flexibility to the preceding glycine pair and 
contributes to the coordination of a nucleophile (either a water molecule or a hydroxide 
ion) that attacks the ester bond of the P-site peptidyl-tRNA61–63. This proposed 
mechanism is supported by the fact that mutation of the two glycine residues impairs 
peptide release, but mutation of the glutamine has a less dramatic effect64. The most 
notable mutation is the mutation of the second glycine of the GGQ motif to alanine, 
referred to as the GAQ mutant, which has the most dramatic decrease in the peptide 
hydrolysis activity of RFs in all GGQ motif mutants64.   
In addition to the N5-methyl modification on Q235, the identity of residue 246 of 
RF2, and not RF1, has critical implications for the RF2-mediated peptide release. The 
function of residue 246 was originally discovered due to the difference in overexpression 
of RF2 in E. coli and S. typhimurium, where overexpression of RF2 in E. coli inhibited 
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cell growth, but not S. typhimurium18–20. The residue 246 of E. coli RF2 is threonine, 
whereas the residue 246 of S. typhimurium is alanine. Mutating residue 246 of E. coli 
from threonine to alanine (T246A) caused RF2 overexpression without impairing E. coli 
growth20. Interestingly, threonine at residue 246 is a mutation specific to E. coli K12 
strains, whereas residue 246 of E. coli B or MRE600 strains are both alanine17. In vitro 
biochemical data revealed that the RF2-mediated peptide release rate depends greatly on 
both the identity of residue 246, (the A246 variant is more active than the T246 variant), 
and the post-translational methylation of Q235, and that the effects of the two are 
cumulative17.  
1.4.2 Autoregulation of RF2 concentration 
 
The peptide hydrolysis activity of RF2 has an important consequence in its 
cellular concentration due to an in-frame regulatory UGA stop codon at position 2665. 
When the peptide hydrolysis activity or concentration of RF2 is high, the UGA stop 
codon is efficiently recognized and RF2 protein synthesis terminates at position 26, 
generated a short truncated peptide. However, when the peptide hydrolysis activity or 
concentration of RF2 is low, the termination at UGA becomes inefficient, leading to 
increased probability of +1 frameshift at position 26. The remainder of the RF2 sequence 
is coded in the +1 frame, therefore, efficient +1 frameshifting is required for the 
generation of the full-length RF266. The cellular concentration of RF2 in E. coli K-12 
strain ranges between 5900 to 24900 molecules per cell, dependent on the growth rate67. 
This concentration is much higher than the RF1 concentration of 1200 to 4900 molecules 
per cell, measured in the same context67. At exponential growth phase, changing the 
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residue 246 of E. coli K-12 strain RF2 from threonine to alanine decreases the RF2 
concentration from 26000 to 13500 molecules per cell68.  
1.4.3 RF1/2 and ribosomal conformations  
Both ribosomal and protein conformational dynamics have important roles in the 
catalysis of peptide hydrolysis. When the A site of the ribosome is empty, the 
electrophilic carbon of the P-site peptidyl-tRNA is protected by 23S rRNA nucleotides of 
the 50S ribosomal subunit, which sterically block access to the labile ester, and the P-site 
substrate is rotated away from the A site, thereby preventing premature hydrolysis and 
release of the nascent polypeptide69. Comparative structural analysis of a 50S structure 
with an empty A site and the 50S structure of RF1/2-bound TCs, suggests that RF1/2 
binding induces conformational changes of the PTC, thereby accommodating the GGQ 
loop of RF1/2 and opening the PTC for nucleophilic attack on the P-site peptidyl-
tRNA70,71. In addition, the DC of the 30S subunit and the PTC of the 50S subunit are 
located approximately 75Å apart. When bound to the TCs, the GGQ motif in domain 3 
and the tripeptide recognition motif in domain 2 of RF1/2 in the A site span the entire 
distance and induced unstacking of adenosine 1492 (A1492) from Helix 4456,57. This is 
distinct from the ribosomal conformational changes induced by cognate A-site aa-tRNA 
binding, which leads to unstacking of both A1492 and A149372.  
Ribosomal complexes are known to exist in two major conformations: 1) a non-
rotated state where the tRNAs are in the classical A/A, P/P (where the A, P or E site 
position is noted in the order of 30S/50S) configuration, and 2) a rotated state where the 
tRNAs are in the hybrid A/P, P/E configuration and the 30S subunit is rotated 
counterclockwise relative to the 50S subunit73–76. The conformation of the L1 stalk 
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correlates with the two ribosomal conformations during translation elongation, where the 
L1 stalk in the “open” conformation correlates with the non-rotated state of the ribosome 
and the L1 stalk in the “closed” conformation interacts with the P/E tRNA and correlates 
with the rotated state of the ribosome77. The TCs carrying a peptidyl-tRNA in the P site 
are locked in the non-rotated state; however, after treatment with puromycin, which 
generates a deacylated P-site tRNA, the TCs fluctuate between the non-rotated and the 
rotated states78. RF1 binds stably to the TCs and stabilizes the non-rotated state of the 
TCs, which is consistent with the two X-ray crystallographic structures of RF1-bound 
TCs55,56,78.  
In addition to ribosomal conformational changes, it is thought that RF1/2 
conformation plays a role in recognition of the stop codons. As described earlier, when 
RF1/2 is bound to TCs, the RF1/2 were observed in a conformation where domain 2 and 
domain 3 span the DC and PTC of the TC. However, the X-ray crystallographic 
structures of free RF1 and RF2 isolated without any ribosomal complexes show a 
dramatically different conformation. In the isolated structure, domain 3 of RF1/2 closely 
interacts with domain 2, forming a “closed” RF conformation in which the distance 
between the GGQ motif and the tripeptide recognition motif is less than 25Å79,80. In 
contrast to the “open” RF conformation observed when bound to TCs, the closed 
conformation of RFs is insufficient to span the 75Å distance between the DC and PTC on 
a 70S ribosome. While the isolated RF structures might be more susceptible to the effect 
of crystal packing, the closed conformation of RF1 was also observed in the co-crystal 
structure of RF1 in complex with the N5-glutamine methyltransferase, suggesting that the 
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closed conformation is a functionally relevant conformational state required for its post-
translational modification81.  
It has been postulated that RF1/2 undergoes protein conformational changes upon 
recognition of the correct stop codons, thereby increasing the accuracy of termination 
using both a codon recognition and a post-binding conformation change step. The open 
and closed conformations of RF1/2 may exist in equilibrium when free in solution. Two 
independent small angle X-ray scattering (SAXS) experiments suggested that E. coli RF1 
is most consistent with the open conformation in solution, whereas the T. thermophilus 
RF2 is mostly in the closed conformation in solution82,83. In a structural probing 
experiment using Fe(II)-derivatized RF1 on a TC or on ribosomal complexes carrying an 
A-site near-stop codon (CAA,UCA or UAC), the variations of the cleavage patterns 
induced by the derivatized RF1 strongly suggests that the RF1 docking position in the A 
site of these ribosomal complexes is different84. More recently, Trappl and Joseph 
observed a conformation change of RF1 upon binding to a TC using transition ion 
fluorescence resonance energy transfer (tmFRET)85.  
1.4.4 RF3 accelerates the dissociation of RF1/2 from TCs  
 
Unlike the class 1 RFs, the only class 2 RF in E. coli and one of the four 
translational GTPases, RF3, has no direct role in catalyzing peptide release during 
bacterial translation termination. Instead, RF3 promotes dissociation of the stably bound 
RF1/2 from post-peptide release TCs, thereby speeding up translation by promoting entry 
into the ribosome recycling phase of protein synthesis48. The recycling role of RF3 was 
proposed based on the biochemical finding that under limiting RF1/2 and excess TCs, 
RF3 is required for efficient peptide released catalyzed by the class 1 RFs. The recycling 
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of RF3 is a GTP-dependent process; however, GTP hydrolysis is not required since the 
nonhydrolyzable analog, GDPNP, also leads to the recycling of RF1/2. By using limiting 
amounts of RF3 and GDPNP, it was suggested that the role of GTP hydrolysis is to 
promote dissociation of RF3 from the ribosome47.   
The dissociation constant (KD) of guanosine nucleotides for RF3 was originally 
determined using filter binding assay and reported as ~5nM for GDP, 2.5µM for GTP and 
8.5µM for GDPNP47. However, recent studies have suggested that the gap between the 
three KDs is much less dramatic. Koutmou and colleagues determined the KD of 13-23nM 
for GDP and 76-108nM for GTP using both competition and fluorescence binding 
assays86. Since the absolute KD, especially those with high affinity, could be difficult to 
determine, Peske and colleagues reported the relative KD where GDP has approximately 
four-fold higher KD for RF3 than GTP
87. Interestingly, a GTP hydrolysis assay of RF3 on 
different ribosomal complexes indicates that RF3 hydrolyzes GTP each time it binds to 
the ribosomal complexes regardless of the peptide on the P-site peptidyl-tRNA or 
presence of class 1 RFs, which is contrary to the observation that the GTP hydrolysis 
activity of RF3 is controlled by the peptide on the P-site aa-tRNA86,88.  
1.4.5 RF3 structure  
 
RF3 consists of three distinct protein domains89. The N-terminal domain 1 of RF3 
is made of a classic GTPase domain (G domain) and a G’ subdomain, highly similar to 
that found in EF-G89. The TC-bound X-ray crystallographic structures of RF3 were 
isolated in the form of GDPNP- or GDPCP-bound, RF3(GDPNP) or RF3(GDPCP)90,91. 
In contrast to the RF1/2-bound TC, the conformation of the RF3-bound ribosome is in the 
rotated state, where the 50S and 30S subunits are rotated with respect to each other and 
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the deacylated tRNA is bound in the P/E hybrid state5,55–57,90,91. In the rotated state, 
domain 1 of RF3 interacts with the sarcin-ricin loop (SRL) and ribosomal protein L6 of 
the 50S subunit, whereas domains 2 and 3 contact helices h5, h15 and ribosomal protein 
S12 of the 30S subunit90,91. Similar to the other translation GTPases such as EF-G and 
EF-Tu, RF3 undergoes guanosine-nucleotide-induced protein conformation change89. 
When bound to the ribosome, domain 2 and 3 of GDPCP-bound RF3 are rotated 
compared with the free GDP-bound RF389,90. Given the similarity of the G domains of 
translational GTPases, the mechanism of RF3 GTP hydrolysis might be similar to the 
mechanism proposed for EF-Tu92. 
 
Figure 1-4 X-ray Crystallographic Stuctures of RF3-bound TC and free RF3 
(A) X-ray crystallographic structure of E. coli RF3 (magenta) bound to a post-
hydrolysis TC in rotated state with tRNAfMet (orange) in the P/E configuration (PDB 
ID: 4v8o)90. RF3 is shown in both surface representation on the TC and in cartoon 
representation in the zoom-in with each domain colored: domain 1 (orange), domain 2 
(blue) and domain 3 (magenta). The non-hydrolyzable GTP analog, guanosine 5-β,γ-
methylenetriphosphate (GDPCP, lime-green), is located in the binding packet of 
domain 1.  (B) X-ray crystallographic structure of free E. coli RF3 bound with GDP 
(PDB ID:2H5E)89. Each domain is colored the same as RF3(GDPCP) for comparison: 
domain 1 (orange), domain 2 (blue) and domain 3 (magenta). The GDP (yellow) is 
located in the binding packet of domain 1. 
 
Interestingly, as predicted by the biochemical recycling assay of RF3, ribosomal 
complexes formed with RF1 and apo-RF3, which has been extensively purified to 
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remove any guanosine nucleotides, form a more stable complex than RF3(GDP)47,50. As 
described in previous sections, domain 1 of RF1 forms an interface with domain 3 of 
RF350. Since disruption of this interface or deletion of RF1 domain 1 leads to defects in 
the recycling function of RF350, it is possible that the class 1 and class 2 RF interaction 
have important implications in both recycling and post PT QC. The mechanism of 
recycling by RF3 has been proposed and is thought to involve steric clashes of the rotated 
ribosomal state induced by RF350,78,89. The RF1/2-bound TCs are in the non-rotated state; 
by inducing TCs into the rotated state, steric clashes at the binding site of RF1/2 would 
eject RF1/2 off the ribosome. On the other hand, it is also possible that the transition of 
the TC from the non-rotated to the rotated state was triggered by the dissociation of 
RF1/2. Most of the experimental setups used thus far have been unable to distinguish 
between these two possibilities.  
1.4.6 Recognition of near-stop codons and the effect of RF3 
 
The accuracy of stop codon recognition by RF1/2 has been an active area of 
research. With a read-through of 1 in every 105 in vivo, RF1/2 are extremely accurate in 
correctly recognizing the stop codons93, and the premature termination by class 1 RFs 
was determined as approximately 1 in 105 in vivo, where a sense codon was misread as a 
stop codon93. To better understand the accuracy of RFs, the peptide release rates (kcat) and 
the concentration at half of maximum peptide release rate (KM) were biochemically 
measured for sense codons that differ by only one nucleotide from stop codons (referred 
to as near-stop codons from here on)94. Interestingly, the kcat varies up to 3 or 4-orders of 
magnitude between different near-stop codons, yet there is only a small difference in KM 
between near-stop codons94. This observation suggests that the discrimination between 
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stop codons and near-stop codons occurs mainly through the kcat and not KM, which is 
often a reflection of affinity in biochemical assays. Interestingly, the partition of 
discrimination factor between the kcat and KM of near-stop versus stop codons differs for 
RF1 and RF2. RF1 showed approximately 1- to 2-orders of magnitude in kcat and 
approximately 3-order of magnitude in KM in discriminating near-stop from stop codons; 
however, this trend is reversed in RF2, where the discrimination in kcat ranges between 2- 
to 3-orders of magnitude and KM is typically only 2-orders of magnitude
94. This points to 
some fundamental differences in how fidelity is maintained by the two class 1 RFs. 
Compared with RF1, RF2 is more likely to interact with ribosomal complexes carrying a 
near-stop or sense codon in the A site. Aside from the role of RF3 in recycling class 1 
RFs, RF3 has no significant contribution to peptide release under single-turnover 
conditions for the class 1 RFs48. Surprisingly, in the context of near-stop codons, RF3 
negatively affects the accuracy of stop codon recognition by the class 1 RFs up to 5-fold 
in kcat and up to 2-fold in KM
94. The role of RF3 in this context may be analogous to post 
PT QC mechanism. 
1.5 Proposed mechanisms and hypothesis 
1.5.1 Proposed role of RF3 in post PT QC mechanism 
 
In contrast to termination where RF2 alone is sufficient to catalyze peptide release 
on TCs, RF2 has limited peptide release activity on aECs in the post PT QC 
mechanism1,48. Importantly, in the absence of RF3, while RF2 can catalyze peptide 
release, the peptide release rate is not competitive with the overall rate of the translational 
elongation cycle1. Because enhancement of the peptide release rate by RF3 is essential to 
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make post PT QC mechanism competitive with translational elongation, I propose to 
investigate the mechanistic role of RF3 in post PT QC.  
Based on both biochemical and structural studies of RF2-mediated translational 
termination, RF2 must associate with the ribosomal complex to catalyze peptide 
hydrolysis. However, there has never been a direct study of RF2 binding to ribosomal 
complexes, and the high KD of RF1 binding to ribosomal complexes carrying a near-stop 
codon in the A site suggests that the RF2 binding to an EC carrying a cognate sense 
codon in the A site is likely very unfavorable and associated with a high KD
95. This 
speculation is consistent with the measured KM of ~1µM reported by Zaher and Green
1. 
Therefore, RF3 may have a role in increasing the affinity of RF2 for aECs. However, the 
peptide release rates measured at a saturating concentration of RF2 alone and with RF3 at 
30µM each suggests that while RF3 may increase the affinity of RF2 for aECs, RF3-
enhanced peptide release rate via mechanisms other than promoting RF2 occupancy, 
which is maximized at saturating concentrations. Therefore, RF3 may also contribute to a 
post-RF2 binding mechanistic step toward productive peptide hydrolysis. 
Based on the hypothesis that RF3 can contribute in both initial RF2 binding and a 
post-binding mechanistic step, I propose to use single-molecule fluorescence resonance 
energy transfer (smFRET) to monitor RF2 binding in the absence and the presence of 
RF3 and to evaluate the mechanistic role of RF3 in post PT QC. The smFRET technique 
provides great advantages, allowing both real-time observation of RF2 binding to 
ribosomal complexes and permitting the observation of rare events that might be involved 
in post-RF2 binding steps and that may be obscured in ensemble studies.  
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1.5.2 Proposed role of ArfA in ArfA-RF2 ribosome rescue pathway 
 
The most conserved ribosome recuse pathway for resolving nTCs in bacteria is 
trans-translation, which is non-essential in a subset of bacteria, such as E. coli, due to the 
presence of a backup ribosome rescue mechanism. When trans-translation fails in E. coli, 
the ArfA-RF2 ribosome rescue pathway is activated by stable expression of ArfA, 
translation of which is normally under direct regulation of trans-translation. However, 
ArfA alone is insufficient for catalyzing peptide release on nTCs for ribosome rescue. 
Instead, both ArfA and RF2 are required for catalyzing peptide release on nTCs carrying 
mRNA with 0 to 3 nucleotides in the A site. This leads to an open question of, what is the 
precise mechanistic role of ArfA in this ribosome rescue mechanism. 
Hydroxyl radical probing of nTCs in the presence of ArfA indicates that ArfA 
binds near the A-site mRNA channel, where RF2 normally interacts with an A-site stop 
codon42. It has been suggested that ArfA may have a role in recruiting RF2. Interestingly, 
ArfA has been shown to associate with ECs, but not catalyze peptide release on ECs. 
Taken together, I propose that ArfA stabilizes RF2 on nTCs, but not ECs. Using a tRNA 
to RF2 smFRET signal to directly monitor the effect of ArfA on RF2 binding and 
dissociation in real-time on both nTCs and ECs, I can investigate the mechanistic role of 
ArfA in the ArfA-RF2 ribosome rescue mechanism. 
1.6 smFRET and TIRF microscopy 
 
1.6.1 Fluorescence resonance energy transfer  
 
Fluorescence resonance energy transfer (FRET), or also known as Förster 
resonance energy transfer, is a non-radiative energy transfer process between two light-
sensitive molecules (chromophores or fluorophores), originally proposed by Theodor 
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Förster96. When an electronically excited fluorophore (FRET donor) is in proximity of a 
chromophore or fluorophores (FRET acceptor), a distance-dependent energy transfer 
from the FRET donor to the FRET acceptor can occur given that the fluorescence 
emission spectrum of the FRET donor overlaps with the absorption spectrum of the 
FRET acceptor (Figure 1-5 A and B, overlap colored grey)97. The mechanism of energy 
transfer may be understood as dipole-induced dipole interaction; therefore, the orientation 
of the transition dipoles between the FRET donor and acceptor plays a critical role in the 
energy transfer. The orientation factor, κ2, is defined by the angles between the FRET 
donor and acceptor as:  
𝜅2 =  cos 𝜃⟙ − 3 cos 𝜃𝐴 cos 𝜃𝐷 (Equation 1-1) 
  
where, θ⟙ is the angle between the FRET donor and acceptor moments, θA and θD are the 
angles between the separation vectors. Assuming rapid, isotropic tumbling of both FRET 
donor and acceptor, κ2 averages to be 2/397.This dynamic average value is used to 
calculate the Förster’s radius (R0), which is defined as the distance between the FRET 
donor and acceptor with 50% energy transfer efficiency: 
𝑅0 = 8.79 × 10
−5 √
𝑄 × 𝜅2 × 𝐽(𝜆)
𝑛4
6
 (Equation 1-2) 
  
where, Q is the quantum yield of the FRET donor in the absence of the acceptor, J(λ) is 
the spectral overlap of the FRET donor and acceptor and n is the refractive index of the 
medium in the range of overlap97. Each FRET donor-acceptor pair has a distinct R0, 
typically in the range between 10Å to 100 Å (Figure 1-5 C). One of the most commonly 
used FRET pair, Cyanine 3 (Cy3) and Cyanine 5 (Cy5), has an R0 of approximately 55Å 
(Figure 1-5 C)97.  




Figure 1-5 Physical principal of FRET. 
(A) The absorbance and emission spectra of Cy3 and Cy5 fluorophores, where the 
spectra overlap between the Cy3 emission and Cy5 absorbance is colored in gray. (B) 
The absorbance and emission spectra of Cy3 fluorophores with the absorbance spectra 
of the QSY9 chromophore, where the spectra overlap between the Cy3 emission and 
QSY9 absorbance is colored in gray. (C)A plot of FRET efficiency versus distance for 
Cy3-QSY9 and Cy3-Cy5 smFRET pairs, with R0 of 45Å and 55Å, respectively as 
indicated by the dotted lines (based on manufacturer’s data). 
 
 The efficiency of energy transfer, or FRET efficiency (EFRET), is inversely 








6 (Equation 1-3) 
  
FRET is most sensitive to distance change near the R0. Cy3-Cy5 FRET pair is most 
sensitive to distance change between approximately 40Å to 70Å, making Cy3-Cy5 FRET 
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pair a popular choice for studying biomolecular interactions such as protein-protein, 
protein-nucleic acid or nucleic acid-nucleic acid interactions. Furthermore, FRET is also 
ideal for reporting on intramolecular dynamics, such as conformational rearrangements 
within a molecular complex97.  
1.6.4 Use of fluorescence quencher 
 
 The limitation of Cy5-labeled substrates for single-molecule studies is often 
referred to as the “concentration barrier.” This technical difficultly greatly limited the 
studies of biomolecular interactions with reasonably low affinity when the substrates are 
fluorescently-labeled. Many approaches have been proposed to address this problem. An 
increasingly popular approach involves using a nano-fabricated device, known as a zero-
mode waveguide, to reduce the excitation volume, thereby allowing the use of a higher 
concentration of fluorescently-labeled substrates98. However, the production of this 
device involves significant effort in the nano-fabrication of these devices, thus limiting 
the robustness of experiments. An alternative method is the use of fluorescent quenchers 
as the FRET acceptor99. Fluorescent quenchers are chromophores which can be excited to 
a higher electronic state, but relax to the ground state by nonradioactive processes. The 
lack of background fluorescence due to cross-excitation thus allows a much higher 
concentration of substrate to be used in smFRET studies99.  
 Unfortunately, donor-quencher FRET pairs lack some of the advantages of the 
conventional donor-acceptor FRET pairs. The lack of anti-correlated fluorescence signals 
would lead to difficulty in discerning a change of donor fluorescence due to an authentic 
FRET process from other photophysical events, such as blinking of the donor 
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fluorophore. For these experiments, the donor photophysics in the absence of the 
quencher needs to be determined prior to experiments.  
 
1.6.2 Single-molecule FRET  
 
Ensemble FRET has been widely used to study biomolecular interactions. In 
ensemble FRET, the fluorescence of the entire sample is measured as an average of all of 
the molecules in the ensemble (ensemble averaging), which masks asynchronized 
dynamic molecular events that could be critical for biological processes100. In contrast to 
ensemble FRET, smFRET offers the advantages of identifying asynchronized molecular 
events, such as intramolecular conformational changes or transient intermediates, without 
requiring additional perturbation to synchronize molecular events101. Since a single FRET 
donor-acceptor pair is detected at a time, smFRET can also deal with highly 
heterogeneous samples showing distinct dynamics101.  
Notably, fluorophore selection and microscopy setup for smFRET is distinct from 
ensemble FRET. Fluorophores suitable for single-molecule studies should be bright, with 
an extinction coefficient of >50,000M-1cm-1 and quantum yield of >0.1, and photo-stable, 
with minimal undesirable photophysical properties such as fast photobleaching time or a 
temporary excursion into dark triplet state (also known as blinking). To further increase 
the photostability of fluorophores, triplet state quenchers, such as β-mercaptoethanol, 
1,3,5,7-cyclooctatetreaene and 3-nitrobenzyl alcohol, and oxygen scavenging systems, 
such as a mixture of glucose oxidase, catalase and β-D-glucose, are used during imaging.  
1.6.3 Total internal reflection fluorescence microscopy 
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Total internal reflection fluorescence (TIRF) microscopy, in particular, the prism-
based configuration, is a popular fluorescence microscopy for single-molecule 
fluorescence studies due to its high signal-to-noise ratio and ease of. By taking 
advantages of a phenomenon created during total internal reflection of light known as the 
evanescent field, TIRF microscopy setup illuminates only a small volume near the quartz 
microscope slide surface, thus greatly increasing the signal-to-noise ratio in comparison 
to standard epifluorescence microscopy. Total internal reflection occurs when light 
propagating through a medium with higher refractive index encounters a medium with a 
lower refractive index at an angle of incidence larger than what is known as the “critical” 
angle. Under this condition, the propagating light is completely reflected back into the 
medium with a higher refractive index, generating an electromagnetic field known as the 
evanescent field, which penetrates approximately 100 nm in depth. In a prism-based 
TIRF configuration, the excitation laser enters and reflects off the prism on top of a 
microscope slide with an objective lens beneath for collecting the emitted fluorescence, 
which is typically separated into multiple wavelengths with a beam-splitter for 
simultaneous imaging of two colors (Figure 1-6 A). Each separated light beam is 
projected onto half of the monochromatic electron-multiplying charge-coupled device 
(EMCCD) camera chip for detecting the images at a frame rate of 15ms to 100ms per 
frame.  




Figure 1-6 TIRF microscopy setup and smFRET data collection 
(A) Schematic of a conventional prism-based TIRF microscopy setup, where the Cy3 
(green) or Cy5 (red) emission collected from the objective lens is separated with a 
dichroic beamsplitter, filtered through emission filters and collected at the EMCCD 
camera. (B) The immobilization strategy of the ribosomal complex on the PEG-
passivated surface using biotin-streptavidin linkage. (C) A section of a dual view 
movie showing co-localized Cy3 and Cy5 fluorescence intensity versus time trajectory 
for Cy3-Cy5 smFRET signals. (D) A section of Cy3 channel showing the Cy3 
fluorescence intensity versus time trajectory for Cy3-QSY9 smFRET signals. 
 
As the evanescent field only penetrates near the surface of the microscope slide, 
fluorescent samples must be immobilized near the surface. To facilitate rapid exchange of 
samples, microfluidic flowcells were prepared using microscope slides and coverslips as 
shown in Figure 1-6 A. The surface of the microscope slide is modified with 
polyethylene glycol (PEG) mixed in with a small ratio of biotinylated PEG. The strong 
biotin-streptavidin interaction is used to tether ribosomal complexes assembled on an 
mRNA hybridized with a 3’-biotinylated DNA oligomer. The PEG-passivated surface 
serves to reduce non-specific binding of biomolecules to the surface (Figure 1-6 B).  
In a standard smFRET experimental setup, each ribosomal complex carrying a 
Cy3-labeled tRNA is immobilized on the microscope surface via a biotin-streptavidin 
linkage (Figure 1-6 B). The Cy3 donor fluorophore is directly excited with a green 
532nm laser, leading to the emission of Cy3 fluorescence. If a Cy5-labeled substrate is 
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within FRET distance of the excited Cy3, energy transfer can occur to Cy5, leading to the 
emission of Cy5 fluorescence. The fluorescence emission is monitored as fluorescence 
intensity over time (Figure 1-6 C). The use of the Cy3-Cy5 FRET pair provides the 
advantage of observation of anti-correlated signals, which can be easily converted into 






However, the cross-excitation of the 532nm laser to Cy5 fluorophores also generates 
background fluorescence. As a consequence, the concentration of Cy5 fluorophores in the 
solution in a TIRF microscopy setup is limited to ~40nM.  
1.6.5 smFRET data analysis 
 
The kinetic information obtained from smFRET experiments provides invaluable 
insights into the mechanisms of biomolecular processes. Conventional TIRF microscopy-
based smFRET experiments return data in the form of a movie of a given field of view, 
which typically contains hundreds of individual fluorescence molecules that can be 
isolated from the donor and acceptor channels. These two channels are aligned to obtain 
co-localized donor and acceptor fluorescence intensities, which are plotted as a function 
of time to obtain fluorescence intensity versus time trajectories (Figure 1-6 C). The 
fluorescence intensity versus time trajectories are converted into FRET efficiency versus 
time trajectories by calculating EFRET using (Equation 1-4. For the Cy3-QSY9 smFRET 
pair, the Cy3 fluorescence intensities versus time trajectories are prepared for each 
molecule (Figure 1-6 D). A non-trivial task in smFRET data processing is the extraction 
Chapter 1 Introduction 
40 
 
of the kinetic information governing the change of smFRET signals for inferring the 
underlying molecular mechanism of interest.  
A widely adopted method is simplifying the noisy signal versus time trajectories 
into idealized states versus time trajectories by using hidden Markov model (HMM) 
based methods, which infers the “hidden” states governing the measurable experimental 
signal102,103. HMM methods learn the optimal parameters for the system based on two 
major parameters, an emission probability function and a transition probability matrix. In 
smFRET, the transition probability matrix describes the probability of a molecule 
transitioning from current state to another state within an observation time period, 
whereas the emission probability function is a Gaussian function describing the 
likelihood of observing an EFRET value at a particular state
104. The stochastic rate 
constants of smFRET transitions between states can be calculated using the transition 
probability matrix from HMM analysis by:  
 
𝑘𝑖 =
−ln (1 − 𝑃𝑖)
𝜏
 (Equation 1-5) 
where 𝑘𝑖 is the stochastic rate constant, 𝑃𝑖 is the transition probability and 𝜏 is the 
measurement time period105. A detailed description of smFRET analysis approaches can 
be found in the work by Kinz-Thompson et. al105. The HMM-based smFRET data 
analysis provides a powerful tool to extract kinetic information from single-molecule 
data, which can be used to understand the underlying biomolecular mechanisms. 
1.7 Dissertation motivation and overview 
 
Protein synthesis is a complex multi-step process, which requires regulatory and 
quality control mechanisms to ensure the accurate production of proteins. I identified two 
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major challenges affecting the fidelity and quality of bacterial protein synthesis: 1) 
maintaining translation accuracy during elongation following misincorporation errors and 
2) resolving stalled ribosomal complexes when the mRNA is truncated and lacks an in-
frame stop codon. Bacteria have evolved two mechanisms, post PT QC and ArfA-RF2 
ribosome rescue mechanisms, to counter these challenges. Interestingly, both 
mechanisms utilize a protein factor that normally functions in canonical translational 
termination, RF2, with the help of another factor: RF3 for post PT QC, and ArfA for 
stalled ribosome rescue. Importantly, the mechanistic role of RF3 or ArfA in these non-
canonical pathways remains elusive. In addition, the dearth of direct RF2 binding studies 
has further limited our understanding of these two mechanisms.  
As a step toward understanding the role of RF3 and ArfA in post PT QC and 
ribosome rescue, I propose to investigate the effect of RF3 and ArfA on RF2 binding 
kinetics in the context of these two pathways. Using a smFRET signal between the P-site 
peptidyl-tRNA and RF2, the binding and dissociation of RF2 can be directly monitored in 
the absence or in the presence of RF3 or ArfA. 
In Chapter 2, smFRET signals using different chromophores, Cy3-Cy5 or Cy3-
QSY9, were developed to capture different RF2 binding kinetics. The Cy3-Cy5 smFRET 
signal is ideal for monitoring stable binding with low substrate concentration, whereas 
Cy3-QSY9 smFRET signal is suitable for monitoring transient binding with high 
substrate concentration. The RF2 binding and dissociation to ribosomal complexes, such 
as ECs, aECs, TCs or nTCs, was first examined in the absence of other factors. In 
Chapter 3, the role of RF3 on RF2 binding kinetics to both ECs and aECs was 
investigated using both fMet-Lys-tRNALys(Cy3) to RF2(Cy5) smFRET signal and fMet-
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Lys-tRNALys(Cy3) to RF2(QSY9) smFRET signal. In addition, I also examined the effect 
of the polypeptide chain attached to the P-site tRNA on the RF2 binding kinetics. In 
Chapter 4, the role of ArfA on RF2 binding and dissociation to ECs and nTCs was 
evaluated using fMet-Phe-tRNAPhe(Cy3) to RF2(Cy5) smFRET signal. Together, these 
studies survey the modulation of RF2 binding kinetics by RF3 or ArfA in performing 
non-canonical functions during post PT QC and ribosome rescue in bacteria. 
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RF2 plays a direct role in various translational processes, such as canonical 
translation termination, post-peptidyl transfer quality control and stalled ribosome rescue, 
but RF2 binding to ribosomal complexes in the context of these processes have never 
been directly investigated. This chapter discusses the development of a novel P-site 
peptidyl- tRNA to RF2 smFRET signal, which directly reports on RF2 binding and 
dissociation from ribosomal complexes, using two distinct fluorophore pairs: 1) a Cy3-
Cy5 smFRET pair, which reports on RF2 binding kinetics up to 40nM RF2(Cy5), and 2) 
a Cy3-QSY9 smFRET pair, which reports on RF2 binding kinetics up to 2000nM 
RF2(QSY9) (Section 2.2). The preparation of the experimental system is described 
together with additional technical developments such a purification method of tRNALys, a 
necessary precursor to the design of the relevant complexes (Section 2.3). The 
biochemical validation and steady-state smFRET measurements are discussed separately 
for the Cy3-Cy5 smFRET signal (Section 2.4) and the Cy3-QSY9 smFRET signal 
(Section 2.5).  
2.2 Design of smFRET signal for monitoring RF2 binding 
 
To monitor the intermolecular interaction of RF2 to ribosomal complexes, a 
smFRET signal was designed with an FRET-donor fluorophore, Cy3, on the P-site 
                                                 
1 Bridget Huang performed all of the smFRET and biochemical experiments. Bridget Huang and Jason Hon 
performed the data analysis of the smFRET experiments. A manuscript detailing this material is currently 
in preparation. 
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tRNALys (or tRNAPhe at the exact same position for the ribosome rescue studies). Because 
the ribosomal complexes are not normally fluorescent, Cy3 fluorescence acts as a stable 
readout for identifying correctly assembled complexes (Figure 2-1 A). The FRET-
acceptor fluorophore, Cy5, is conjugated to an engineered cysteine mutation inserted into 
the core domain (domain 2 and 4) of RF2. This domain is predicted to have minimal 
potential protein conformational change based upon smFRET studies of the closely 
related class 1 release factor RF178, thus this signal provides a simple and direct readout 
of RF2 binding kinetics in real time. Based on the X-ray crystallographic structure of 
RF2-bound TCs with an A-site stop codon57,5 (Figure 2-1 A), the distance between the 
two fluorophore-conjugation positions is approximately 21Å. Under the assumption of 
rapid isotropic tumbling of both the Cy3 and Cy5 transition dipoles and a Forster radius 
of ~55 Angstroms for Cy3-Cy5 FRET pair, the predicted FRET efficiency (EFRET) is 
nearly 1.00 (Figure 2-1 B).  
While the Cy3-Cy5 FRET pair has highly desirable advantages for single-
molecule studies, the concentration of excess fluorescently-labeled substrates is limited to 
tens of nanomolar due to the high background fluorescence generated by minor cross-
excitation of Cy5 in TIRF microscopy setup. This limitation often prohibits single-
molecule binding measurements of weak biomolecular interactions. A recent technical 
development towards circumventing this “concentration barrier” in TIRF-based single-
molecule studies is the use of non-fluorescent FRET acceptor chromophores (also known 
as fluorescence quenchers)106,107,99. Similar to FRET-acceptor fluorophores, FRET 
quenchers are chromophores that can be excited upon absorption of photons from the 
corresponding FRET-donor fluorophores; however, unlike typical FRET-acceptor 
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fluorophores, such as Cy5, FRET quenchers relax to the ground state preferentially by 
nonradiative processes, which can circumvent the background fluorescence problem99. 
Thus, a smFRET signal analogous to the Cy3-Cy5 signal described above was developed 
with a FRET donor, Cy3, on P-site tRNALys and its corresponding FRET quencher, 
QSY9, on RF2 with an estimated quenching FRET efficiency of EFRET~0.99 (Figure 2-1 
C).The two types of smFRET signals complement each other, where Cy3-Cy5 smFRET 
signals are more suitable for detection of stable enzyme-substrate interaction at low 
substrate concentration and Cy3-QSY9 smFRET signals are suitable for detection of 
transient enzyme-substrate interaction at high substrate concentration.  
 
 
Figure 2-1 smFRET signals for monitoring RF2 binding to ribosomal complexes. 
(A) A TC (50S, cyan; 30S, yellow) with P-site tRNA (orange) and A-site RF2 (green); 
the circular red highlight indicates the position of peptidyl transfer center (PTC); the 
lower left-hand shows a cartoon representation of the TC (PDB ID: 4V5E)5. (B) 
Zoomed-in view showing conjugation positions of Cy3 on P-site fMet-Lys-tRNALys for 
aEC studies or fMet-Phe-tRNAPhe for nTC studies and Cy5 on RF2 core domain with 
estimated EFRET of 1.00. (C) Zoomed-in view showing conjugation positions of Cy3 on 
P-site tRNALys and QSY9 on RF2 core domain with estimated EFRET of 0.99. 
 
Chapter 2 Interaction of RF2 with ribosomal complexes 
46 
 




The initial biochemical studies on the post PT QC mechanism were done in a 
reaction buffer containing 50mM Tris-HCl, pHRT=7.5, 70mM NH4Cl, 30mM KCl, 7mM 
MgCl2, 1mM dithiothreitol (DTT), as previously described
1,15. Pilot smFRET 
experiments revealed that RF2 binding kinetics in this buffer are still too fast for the time 
resolution of the current camera, 100ms/frame. Increasing the camera acquisition speed 
up to 30ms/frame did not significantly improve the amount of observable data (data not 
shown). To resolve this challenge, two lower monovalent salt conditions were tested in 
an attempt to optimize the smFRET experiments. Both biochemical assays and smFRET 
experiments were used to assess the optimal buffer which minimizes the decrease in the 
RF2-mediated peptide release activity and improves the smFRET data quality. The 
optimized buffer, from now on referred as Buffer M, contains 25mM Tris-HCl, 
pHRT=7.5, 35mM NH4Cl, 15mM KCl, 7mM MgCl2, 10mM β-mercaptoethanol (BME), 
1% beta-D-glucose. Buffer M is the primary buffer system used in the post PT QC 
studies for both ensemble biochemical assays and single-molecule experiments. Other 
buffers, such as those used in protein purification or ribosomal complex preparation, are 
further described in greater details in Chapter 5. 
2.3.2 Ribosome 
 
Tightly coupled 70S ribosomes from E. coli MRE600 strain were purified using 
sucrose gradients as previously described108 and in Chapter 5. The purified tightly 
coupled 70S ribosomes were stored in single-use aliquots at -80°C. A tripeptide 
formation assay was used to assess ribosome activity after purification: ~60-70% 
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tripeptide formation after 15s is typical in the laboratory. The procedure is described in 
Chapter 5. 
2.3.3 mRNAs Preparation 
 
All mRNA variants used in the studies are based on the mRNA encoding gene 
product 32 from T4 bacteriophage (T4gp32) truncated to the first 20 amino acids, similar 
to mRNA constructs described in the previous publications78,108. The mRNAs were 
prepared by in vitro transcription with T7 RNA polymerase as described in Dr. Jingyi 
Fei’s thesis and Chapter 5. The mRNA sequences after the start codon AUG varies 
between mRNA constructs. However, the general mRNA construct contains a DNA 
hybridization sequence immediately downstream of T7 RNA polymerase promoter, for 
annealing 3’-biotinylated single-stranded DNA oligomers for surface-immobilization to 
microscope slide surface via a biotin-streptavidin linkage. Immediately downstream of 
the DNA hybridization site is a short 18-nucletide spacer region containing the Shine-
Dalgarno sequence UAAGGA. The exact sequence of each mRNA construct is listed 
under Appendix A. 
2.3.4 tRNAs Preparation 
 
Commercially available tRNAs, such as initiator N-formylmethionine-specific 
tRNA (tRNAfMet) from E. coli and phenylalanine-specific tRNA (tRNAPhe), were directly 
purchased from MP Biomedicals or Sigma-Aldrich. Lysine-specific tRNA (tRNALys). 
Reagents from multiple commercial sources (MB Biomedicals, Sigma-Aldrich, tRNA 
Probe) were found to contain a large amount of non-lysine-specific tRNA (the 
contaminating tRNAs were not identified). This led to a huge challenge in preparation of 
fluorescently-conjugated tRNALys for the single-molecule studies. Therefore, a protocol 
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for purifying tRNALys was developed based on a previously published method for 
purification of E. coli initiator tRNAfMet and yeast tRNAPhe 109.  
 
2.3.4.1 Design of tRNALys pull-down purification DNA oligomer 
 
The general strategy for tRNA purification involves direct pull-down of target 
tRNA using a solid-phase DNA oligomer from a mixed tRNA pool. Based on Transfer 
RNA database (Universitat Leipzig), tRNALys has only one isoform, thus a DNA 
oligomer was designed to bind around the D-loop of tRNALys between nucleotide 14 to 
43. The design of the oligomer and the hybridization conditions (room temperature, 45°C 
and 65°C) were validated by testing DNA oligomer hybridization to commercially 
purchased tRNALys (MP Biomedical) for simplicity of visualization on a native PAGE 
(Figure 2-2 A). The tRNA pool (lane 1), commercial tRNALys (lane 2) and DNA 
oligomer (lane 6) were loaded individually as controls (Figure 2-2 A). Incubating the 
DNA oligomer with commercial tRNALys at room temperature, 45°C and 65°C for 10 
minutes led to the formation of a larger supershift product, labeled as 
“tRNALys:oligomer,” suggesting successful hybridization of DNA oligomer to tRNALys 
(lane 3, 4, 5 in Figure 2-2 A). A large fraction of the commercial tRNALys is not 
hybridized with the DNA oligomer, suggesting either the DNA oligomer design is not 
optimal or a large fraction of the commercial tRNALys consists of contaminants. 
Assessment of commercial tRNALys using hydrophobic interaction chromatography 
(HIC) revealed two large peaks, consistent with the presence of other contaminating 
tRNA in the commercial source (data not shown). 
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2.3.4.2 Purification of tRNALys 
 
The detailed, step-by-step procedure is described in Chapter 5. Briefly, the 
biotinylated DNA oligomer was first conjugated to streptavidin-agarose beads in a 
centrifugal filtration device, which enabled the simple exchange of buffers and reagents. 
The suspended MRE600 tRNA pool was incubated with streptavidin-conjugated beads in 
hybridization buffer, which contains tetraalkylammonium salt for destabilizing tertiary 
structure, at 65°C for 10 minutes. After removing the excess tRNA, the beads were 
washed three times with 500mM NaCl to remove non-specifically attached tRNAs. The 
hybridized tRNALys was eluted by incubation in the same hybridization buffer at 65°C, 
followed by a spin down in a centrifuge. The eluted tRNALys was buffer exchange into a 
storage buffer containing MgCl2 to promote refolding of tRNA
Lys. The purified tRNALys 
ran as a single band on 12% D-PAGE (data not shown) and assessed on HIC for 
comparison with commercial tRNALys (Figure 2-2 B). Three peaks were observed on the 
HIC chromatograph. The first peak is consistent with aminoacylated Lys-tRNALys, which 
likely originated from the tRNA pool. The second peak is the major species in the 
purified tRNALys sample and is likely the deacylated tRNALys based on retention volume 
of ~22mL and ~20% Buffer B. The third peak, showed up as a shoulder peak from the 
major product, is likely a contaminating tRNA, which is not identified.  
 





Figure 2-2 Preparation and validation of purified tRNALys. 
(A) A native PAGE gel, stained with toluidine blue, showing the supershift of tRNALys 
hybridized with the DNA oligomer; the notation 14.43 means the DNA oligonucleotide 
targets nt14-43 of the tRNALys. (B) FPLC HIC chromatograph showing the 
composition of purified tRNALys, absorbance at 260nm (A260) tracks the elution of 
tRNAs. (C) TLC showing the 3’ end of the [32P]-radioactively labeled tRNALys with or 
without aminoacylated lysine amino acid; the bottom table shows the condition of the 
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2.3.4.3 Validation of the purified tRNALys 
 
The identity of the purified tRNALys was further validated using a radioactive 
aminoacylation assay110 and mass-spectrometry. In the radioactive aminoacylation assay, 
the efficiency of aminoacylation by lysyl-tRNA synthetase111, which has high enzyme 
specificity for its cognate substrate lysine, was used to assess the purified sample. A 
purified tRNA sample with additional RNA refolding step was tested in an attempt of 
improving the quality of the purified tRNA. The tRNAs were first radioactively labeled 
by exchanging the endogenous phosphate of position 76 at 3’ CCA end with tRNA 
nucleotidyltransferase with a P32 labeled phosphate110. The radioactively-labeled tRNA 
samples were then placed in lysl-aminoacylation conditions lysyl-tRNA synthetase in 
three distinct conditions: in the absence of either amino acid, in the presence of lysine 
substrate and in the presence of the incorrect phenylalanine substrate (Figure 2-2 C). The 
3’-end of tRNA was cleaved with P1 nucleases, leaving the 3’ AMP or 3’ AMP-lysine, 
and subsequently run on a thin-layer chromatography plate (TLC) for visualization. The 
aminoacylated 3’AMP with an amino acid substrate, such as Lys-[32P]-AMP migrated 
further than the unaminoacylated 3’AMP (Figure 2-2 C). The reaction mixture with 
tRNALys yet no amino acid defined the background level of Lys-[32P]-AMP (lane 1). In 
the presence of the correct substrate, lysine, approximately 50% of the sample is Lys-
[32P]-AMP, which corresponds to aminoacylation efficiency of 50% (lane 2). The 
refolding protocol did not significantly change the aminoacylation efficiency (lane 3). 
Finally, in the presence of the incorrect amino acid substrate, phenylalanine, Lys-[32P]-
AMP is similar to the background, suggesting no incorrect amino acid was aminoacylated 
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(lane 4). This result is consistent with the idea that the purified tRNA is mostly tRNALys 
and that the aminoacylation of tRNALys is not very efficient.  
The purified tRNA is further validated using signature nuclease-digested products 
on mass spectrometry in collaboration with Dr. Lewis Brown (Biology Department, 
Columbia University) using a method previously described112. Briefly, the purified tRNA 
was digested with T1 nucleases, which cleave the tRNALys into multiple fragments 
summarized in Appendix B. The unique tRNALys fragment, ACCCACCA, with the 
predicted molecular weight of 2449.398Da was detected at 2449.4032Da with internal 
calibration (Appendix B), which further supports that the purified tRNA sample contains 
mostly tRNALys. 
2.3.4.4 Fluorophore-conjugation of tRNALys 
 
To label the tRNALys with Cy3 for use in single-molecule studies, the primary 
aliphatic amino group of the naturally occurring modification 3-(3-amino-3-
carboxypropyl)-uridine at position 47 of the tRNALys was reacted with Cy3-NHS ester 
using a protocol similar to fluorescent conjugation of tRNAPhe as previously described108 
and in Chapter 5. Prior to the aminoacylation reaction, the purified tRNALys was first 
conjugated with the Cy3 fluorophore and purified using HIC to separate out the unlabeled 
and Cy3-conjugated tRNALys. Based on the quantification of FPLC peaks on HIC 
chromatograph, the Cy3-conjugation efficiency of tRNALys is approximately 30-40% 
(Figure 2-3A). While the unlabeled tRNALys contained a negligible amount of impurities, 
the tRNALys(Cy3) appeared as a single, isolated peak.  
The purified tRNALys(Cy3) was then aminoacylated with the amino acid lysine. 
Using a radioactively-labeled tRNALys(Cy3), the aminoacylation efficiency of Cy3-
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tRNALys was quantified as described earlier in the previous subsection. Both unreacted 
tRNALys and tRNALys(Cy3) were spotted as negative controls on TLC (Figure 2-3 B, lane 
1 and lane 3). The aminoacylation efficiency of tRNALys and tRNALys(Cy3) are 




Figure 2-3 Cy3-conjugation 
and aminoacylation of 
purified tRNALys. 
(A) FPLC HIC chromatograph 
showing the separation of the 
unlabeled tRNALys and the Cy3-
conjugated tRNALys, 
absorbance at 260nm tracks 
tRNAs, absorbance at 550nm 
tracks Cy3. (B) TLC showing 
the 3’ end of the [32P]-
radioactively labeled tRNALys 
and tRNALys(Cy3) with or 
without aminoacylated lysine 
amino acid. 
 
   % 




uncharged  94.9 5.1 
aminoacylated  57.6 42.4 
tRNALys(Cy3) 
uncharged  93.7 6.3 
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2.3.5 Preparation of ribosomal complexes 
 
The ribosomal complexes used in the studies include TCs containing matched P-
site tRNALys and an A-site stop codon (AUG-AAA-UGA, E-site-P-site-A-site codons) 
(Figure 2-1 A), ECs containing matched P-site tRNALys and an A-site sense codon 
(AUG-AAA-UUU) (Figure 2-4 A) and aECs containing a mismatch between the P-site 
tRNALys at the second position of the codon and the A-site sense codon (AUG-AUA-
UUU) (Figure 2-4 B). Each complex was prepared for both biochemical studies with non-
fluorescent components and for single-molecule studies with tRNALys(Cy3) and 
biotinylated mRNAs for complex immobilization. In preparation of aECs, tRNALys is 
specifically selected as the P-site tRNA for its well-known promiscuousness in 
elongation6. In addition, to promote misincorporation of tRNALys into the P site, a high-
salt, polyamine based buffer system and excess amount of tRNALys was used to increase 
the efficiency of preparing the aECs1,113. Subsequent to complex formation, this error-
prone buffer was exchanged into reaction buffer using either P6 desalting columns for 
biochemical assays or sucrose gradient ultracentrifugation for single-molecule 
experiments.  
The efficiency of complex formation was measured by quantifying the amount of 
radioactively-labeled fMet-Lys dipeptide formed. In dipeptide formation assay, S-35 
labeled fMet and fMet-Lys are resolved by electrophoretic thin layer chromatography 
(eTLC) (Figure 2-4 C). Since excess S-35 fMet were used in during complex formation, 
the spot corresponds to fMet includes contributions from both free fMet-tRNAfMet and 
unreacted fMet-tRNAfMet on the ribosomal complexes. A simple correction was applied in 
calculating the complex formation efficiency based on relative spot intensities of fMet 
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and fMet-Lys (Figure 2-4). The EC formed with an efficiency of 69.5±4.5%, whereas the 
aEC formed with a slightly lower efficiency of 48.7±3.1% (the error represents N=3 
independent formation experiments) (Figure 2-4 D). 
 
 
Figure 2-4 Preparation of ECs and aECs.  
(A) Cartoon representation showing an EC with a tRNALys in the P site. (B) Cartoon 
representation showing an aEC with mismatched at the second position of the P-site 
codon AUA. (C) eTLC images showing the formation of the fMet-Lys dipeptide in 
ECs and aECs, the reactions were treated with KOH to visualize the total dipeptide 
formation. (D) Quantification of the total fMet-Lys dipeptide after correction for the 
excess free fMet in the reaction using the equation: (fMet intensity) - 33%*(Sum of 
lane intensity) = adjusted fMet intensity; the error bar represents the difference 
between N=3 independent experiments. 
 
2.3.6 Preparation of RF2 
 
The RF2 construct for this study was carefully chosen to account for the known 
factors associated with the peptide release activity of RF2. Both in vitro and in vivo 
studies have shown that both the methylation of glutamic acid at residue 252114 and 
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amino acid identity at position 24620,17 are important for RF2 peptide release activity on 
TCs. To account for these two factors, RF2 construct was prepared by first modifying E. 
coli K-12-based RF2 with a T246A mutation, followed by removal of all surface-reactive 
cysteines to serine. Next, a single-cysteine was engineered at a carefully selected position 
on domain 2 of RF2 for chemical attachment of either Cy5 or QSY9. To obtain optimal 
RF2 activity, RF2 protein was co-overexpressed with its methyltransferase60. 
2.3.6.1 Construct Design and Purification of RF2 
 
Both E. coli C600 RF1 and RF2 genes were initially cloned into a pProEx-Htb 
plasmid vector with a hexa-histidine (His6) affinity purification tag and a TEV protease 
cleavage site at the N-terminal end by Dr. Samuel Sternberg78. To improve the efficiency 
of RF2 overexpressing, the autoregulatory stop codon was removed by deletion of 
nucleotide T76, which leads to a direct translation of aspartic acid at position 26. In S. 
typhimurium, E. coli MRE600 strains and E. coli B strains, the identity at residue 246 is 
alanine; however, in E. coli K12 strains, the residue 246 is threonine. It has been shown 
that threonine at residue 246 significantly reduces the peptide release activity of RF2 and 
T246A mutation of K-12 RF2 restored the peptide release activity17. Therefore, the 
residue 246 from the K12-dervived C600-based prfB construct was mutated from alanine 
to threonine. This RF2T246A was used as the basis for designing additional RF2 constructs 
for cysteine-maleimide conjugation of fluorophores, described in greater detail in the next 
section. In addition, both RF1 and RF2 are methylated in vivo at the residue Q252, which 
is the glutamine of the highly conserved GGQ domain, by an N5-glutamine 
methyltransferase enzyme60. Overexpression of both RF1 or RF2 without the 
methyltransferase significantly reduces their respective peptide release activity114. To 
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compensate for the overexpression of RF2, the methyltransferase enzyme prmc gene on 
pET vector was also co-overexpressed to increase the efficiency of methylation at RF2 
Q252. The RF2T246A protein expressed under methyltransferase co-expression was used 
as the “wild-type,” wtRF2, for comparison of peptide release activity against other RF2 
protein variants. 
2.3.6.2 Fluorophore Conjugation of RF2 
 
In the single-molecule studies, the RF2 is conjugated with either a Cy5 
fluorophore or QSY9 quencher by conjugation of either Cy5-maleimide or QSY9-
maleimide to the engineered cysteine at residue 184. E. coli RF2 has two native surface-
exposed cysteines at residue 128 and 274. Small-scale phylogenetic analysis of 
prokaryotic protein sequences revealed high conservation of cysteine at 274, while 
residue 128 is either a cysteine or alanine (data not shown). Both native cysteines are 
located near potentially interesting positions, where residue 128 is at the 
conformationally-stable domain 2 of RF2 and residue 274 is in domain 3 near the GGQ 
motif, which is the domain predicted to have the most significant conformational change 
during the catalytic cycle. Fluorophore conjugation at native cysteines could potentially 
have the lowest impact on RF2 function, thus either residue 128 or 274 was mutated to 
serine, which is the most chemically analogous residue. The RF2 construct with C128 
and S274 will be referred as RF2128 and the construct with S128 and C274 will be 
referred as RF2274 from here on. Cy5-conjugation to RF2128 led to ~3% labeling 
efficiency, which is essentially unlabeled (Figure 2-5 A). On the other hand, RF2274(Cy5) 
eluted at the void retention volume of ~45ml, instead of the expected ~60ml, indicating 
the formation of protein aggregate (Figure 2-5 B). Further examination of unlabeled 
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RF2274 protein revealed that C128S mutation leads to protein aggregation even without 
Cy5 conjugation reaction (data not shown). In an attempt to circumvent this problem, 
C128 was mutated to the next most conserved residue, alanine. Purified RF2 with C128A 
mutation also appeared to aggregate in the absence of Cy5 (data not shown). Since Cy5-
conjugation efficiency at residue C128 is extremely low, RF2128 was used as a 
background for engineering a cysteine at residue 184.  
The final construct, RF2184, contains C128, T246A, C274S and S184C. RF2184 
was reacted with Cy5-maleimide and purified using the FPLC as described in greater 
detail in Chapter 5. On the resulting gel filtration chromatograph, the major peak after 
RF2184 conjugation with Cy5 dye eluted at ~60ml retention volume, which is consistent 
with the expected retention volume of RF2 (Figure 2-5 C). The fractions corresponding to 
the major peak at ~60ml were collected for further purification in HIC to separate the 
unlabeled RF2184 and RF2184(Cy5) (Figure 2-5 C). The first peak, with a retention volume 
of ~40mL, is the unlabeled RF2184, which supported by the lack of Cy5 absorbance at 
650nm. Notably, two peaks with Cy5 absorbance were eluted at ~45ml and ~48ml 
retention volume, referred as RF2(Cy5)-A and RF2(Cy5)-B from here on (Figure 2-5 C). 
The fractions associated with the two peaks were independently isolated (overlapping 
fractions were discarded), concentrated and exchanged into storage buffer for further 
characterization. A similar procedure was used to conjugate RF2184 with QSY9. Notably, 
two QSY9-conjugated RF2 peaks, RF2(QSY9)-A and RF2(QSY9)-B, were also observed 
during HIC purification step (Figure 2-5 D). The unlabeled- RF2184 eluted as a single 
peak for both Cy5- and QSY9-conjugation, suggesting the difference between the two 
peaks are dependent on the fluorophore conjugation reaction. 





Figure 2-5 FPLC chromatographs showing the purification of different RF2 
variants. 
(A) FPLC gel-filtration chromatograph showing the separation of Cy5-conjugation 
reaction with RF2128; retention volume ~60ml is the expected elution volume of RF2, 
absorbance at 280nm tracks protein (or RF2), absorbance at 650nm tracks Cy5 and 
absorbance at 565nm tracks QSY9. (B) FPLC gel-filtration chromatograph showing the 
separation of Cy5-conjugation reaction with RF2274; retention volume ~45ml 
correspond to aggregated RF2. (C) FPLC gel-filtration and HIC chromatographs 
showing the Cy5-conjugation of RF2184. (D) FPLC gel-filtration and HIC 
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2.3.6.3 Investigation of two fluorophore-conjugated peaks 
 
Several possibilities may give rise to the presence of two Cy5- or QSY9- 
conjugated peaks in HIC separation: (1) presence of contaminating proteins with 
molecular weight similar to RF2, thus were not visible on SDS-PAGE gels and were not 
separated from RF2 during gel filtration purification, (2) presence of RF2 conjugated 
with two fluorophores due to the available native cysteine at residue 128, or (3) presence 
of another distinct fluorophore-based RF2184 conformation, which can be separated by 
HIC due to difference in the interaction with HIC column medium. First, Peak A and 
Peak B were run on an SDS-PAGE gel to confirm that there is no obvious difference 
between their molecular weights. The Coomassie-Blue stained gels showed the expected 
RF2 band at a molecular weight near ~40kDa with no extra bands (data not shown). The 
two samples also showed no detectable difference in their peptide release activity as 
measured by a radioactive dipeptide release assay, which will be described in greater 
detail in a later section. Together, these results suggest that both peaks contain RF2. 
As described earlier, the native cysteine at residue 128 cannot be mutated without 
causing aggregation of RF2, thus in addition to the engineered cysteine at residue 184, 
C128 is another potential location for Cy5-conjugation. Although C128 has been shown 
to have extremely poor labeling efficiency (Figure 2-5 A), it is possible that conjugation 
at C184 could lead to improved conjugation efficiency at C128, thus ultimately leading to 
double conjugation of fluorophores at both residue 128 and 184. To test if there are 
indeed two efficient labeling position on RF2184 protein, both Cy5 and QSY9 were used 
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to compete for conjugation positions. If there are two separate positions for fluorophore 
conjugation, then RF2184 with both Cy5 and QSY9 conjugation would form. Equimolar 
of Cy5-maleimide and QSY9-maleimide dyes were premixed and combined with RF2184 
under maleimide-thiol conjugation conditions at room temperature (Chapter 5). Initial 
purification using gel filtration column indicates successful labeling of RF2184 using both 
dyes (Figure 2-6). The sample was further purified on the HIC column using optimized 
buffers for QSY9-conjugated samples. Immediately after elution of the unlabeled RF2184, 
two peaks of Cy5-labeled RF2184 were eluted, followed by two peaks of QSY9-labeled 
RF2184 (Figure 2-6). Interestingly, no Cy5 and QSY9 conjugated RF2184 were observed, 
suggesting that there is only one conjugation position accessible for either Cy5 or QSY9 
conjugation and the formation of doubly labeled RF2184 is unlikely to occur.  
This result is further supported by mass spectrometry analysis of unlabeled- 
RF2184, RF2(QSY9)-A and RF2(QSY9)-B in collaboration with Dr. Emily Chen and Dr. 
Antonius Koller from the Proteomics Shared Resource facility at Columbia University 
Medical Center. The trypsin-digested RF2(QSY9)-A and RF2(QSY9)-B showed peptide 
characteristic of proper RF2(QSY9) conjugation at residue 184, whereas the unlabeled- 
RF2184 did not (Appendix C). Furthermore, we were able to identify peptide 
corresponding to the proper methylation at residue 254. 




Figure 2-6 Cy5 and QSY9 double-conjugation reaction. 
FPLC gel-filtration and HIC chromatographs showing the double Cy5- and QSY9-
conjugation of RF2184, absorbance at 280nm tracks protein (or RF2), absorbance at 
650nm tracks Cy5 and absorbance at 565nm tracks QSY9, low-salt HIC buffers were 
used, see Chapter 5 for details. 
 
 
2.4 Real-time observation and characterization of RF2 binding using 
Cy3-Cy5 smFRET signal at low RF2(Cy5) concentration 
 
Having prepared and developed the tRNA(Cy3) to RF2(Cy5) smFRET signal for 
studying RF2 binding, the peptide release activity of the experimental system was 
examined under similar experimental conditions to the corresponding smFRET 
experiments by using a radioactive dipeptide release assay. After biochemical validation, 
the binding and dissociation of RF2(Cy5) to ribosomal complexes was monitored with 
10nM RF2(Cy5) with using a TIRF microscopy setup.  
2.4.1 RF2 catalyzed rapid peptide release on TCs 
 
Using a radioactive dipeptide release assay, the RF2-mediated peptide release 
activity on TCs was assessed in the experimental buffer system, Buffer M, in time-course 
reactions from 10s up to 3 minutes (Figure 2-7A). The protein preparations of wtRF2 
(aka, RF2T246A) variant, unlabeled RF2184, RF2(Cy5)-A and RF2(Cy5)-B (isolated from 
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FPLC HIC peak A and peak B) were examined. The time-course indicates that the 
peptide release is completed as early as 10s at 37ºC, which is consistent with the peptide 
release rates reported by Ehrenberg and colleagues48,62,94. Instead of directly measuring 
the peptide release rates, the total amount of peptide released at one minute is used as an 
assessment of peptide release activity (Figure 2-7B). As indicated by the normalized 
release to wtRF2, there were no major differences in total dipeptide released for all the 
RF2 variants examined, suggesting that the absolute peptide release activity is not 
defective after engineering of a novel cysteine on RF2 (unlabeled-RF2, or RF2184) and 
subsequent Cy5-conjugation. 
2.4.2 The peptide release rate is enhanced on the aEC compared with the EC 
 
The peptide release rates of RF2 on ECs and aECs were measured using the 
radioactive dipeptide release assay at 37ºC. Unlike the fast peptide release rate from TCs, 
the slow peptide release rates allowed kinetic measurements using time course up to 2 
hours on ECs as shown in Figure 2-7C and up to 30 minutes for aECs. The intensity of 
radioactive dipeptide is plotted against time and fitted with a single-exponential equation 
in the form of 𝑦 = 𝐴(1 − 𝑒−𝑘𝑥) + 𝑐, where c variable account for the background release 
at time 0 (Figure 2-7D). As a direct comparison to the literature value, RF2 prepared 
without overexpression of methyltransferase, called hypo-methylated RF2, is also 
measured as a benchmark in the reported buffer, Buffer A (Table 2-1). The measured 
basal release rate is provided separately and not subtracted as previously described1. 
Consistent with the previous report, the peptide release rates on the aEC are indeed faster 
than from the EC (Table 2-1)1. The peptide release rates in buffer M are almost identical 
to the peptide release rates in Buffer A reported in the original publications, which justify 
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the use of the experimental Buffer M the single-molecule experiments1,15. Notably, the 
Cy5-conjugated RF2 exhibited only minor reduction in peptide release rates, thus further 
supporting the use of RF2(Cy5) as a model system to studying RF2 binding to ECs and 
aECs (Table 2-1).  
 
 
Figure 2-7 Radioactive Dipeptide Assays Measuring the RF2-mediated peptide 
release activity. 
(A) eTLC images of radioactive fMet-Lys dipeptide released from the TC carrying a 
UGA stop codon, time course from 10 to 180 seconds of wtRF2 (RF2T246A), unlabeled-
RF2 (RF2184), RF2(Cy5)-A and RF2(Cy5)-B. (B) Quantification of normalized total 
dipeptide release at 60 seconds, the error bars represent the uncertainty of eTLC 
quantification (invisibly small). (C) An example of eTLC image of the analogous 
experiment using an EC, the intensity spots show separation of different radioactive 
species in the time-course reaction, only fMet-Lys is quantified for the peptide release 
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rate measurement. (D) Normalized total radioactive fMet-Lys released versus time of 
wtRF2 on ECs (red) and aECs (black) with their respective single-exponential fits. 
 
 
Table 2-1 A table showing measured dipeptide peptide release rates at 37ºC. 
Buffers Complexes RF2 variants khyd (s-1) 




wtRF2 0.007 +0.004 
Buffer M 
EC 
wtRF2 0.0007 +0.0001 
RF2184 0.0008 +0.0002 
aEC 
wtRF2 0.008 +0.003 
RF2184 0.006 +0.002 
RF2(Cy5)-A 0.0030 +0.0007 




2.4.3 RF2(Cy5) demonstrated distinct binding to ribosomal complexes with P-site 
fMet-Lys-tRNALys(Cy3) 
 
The binding of RF2(Cy5) to various ribosomal complexes were examined using 
the fMet-Lys-tRNALys(Cy3) to RF2(Cy5) smFRET signal, which serves as the basis for 
studying post PT QC in Chapter 3. Three ribosomal complexes were prepared in the 
absence of RF2: (1) a TC containing P-site fMet-Lys-tRNALys(Cy3) with a A-site stop 
codon UGA (Figure 2-8 A), (2) an EC containing P-site fMet-Lys-tRNALys(Cy3) and a 
sense codon UUU at the A-site (Figure 2-8 B) and (3) an aEC containing a sense codon 
UUU at the A-site and a misincorporated P-site fMet-Lys-tRNALys(Cy3), where the 
mismatch is between the second position of the mRNA and the tRNA (Figure 2-8 C). As 
a general experimental setup, ribosomal complexes were enzymatically prepared with an 
mRNA pre-hybridized with a biotinylated DNA oligomer. The ribosomal complexes 
carrying Cy3-tRNA were surface-immobilized to a biotin-polyethylene glycol (PEG) 
derivatized quartz microfluidic flow cell via biotin-streptavidin linkage and visualized by 
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TIRF microscopy with an acquisition rate of 100ms/frame (described in greater details in 
Chapter 5).  
The TC carrying fMet-Lys-tRNALys(Cy3) in the P-site was imaged with 10nM 
RF2(Cy5) (Figure 2-8A). As shown by the representative Cy3 and Cy5 intensity versus 
time trajectories for isolated single molecules, RF2(Cy5) is stably bound to the TC until 
the Cy5 fluorophore photobleached, an event which occurs on average within 
approximately 5s. As an estimate of the RF2(Cy5) stability on the TC, a lower-bound of 
≥5s is indicated as the bound time of RF2(Cy5) to TC. The FRET efficiency is compiled 
into a histogram after removing data after Cy3-photobleaching (Figure 2-8 D). The 
histogram showed two peaks at 0.01 and 0.86, where the peak at 0.01 results from Cy5 
photobleaching and the peak at 0.86 results from RF2(Cy5) binding to TC. The observed 
FRET efficiency is in reasonable agreement with the predicted 1.00, based on the X-ray 
crystal structure of RF2-bound on TCs57,5. Furthermore, the binding of RF2(Cy5) from 
FPLC peak A and peak B showed no difference in binding to TC (data not shown).  
Similar to the experiment using the TC, both ECs and aECs were also imaged 
with 10nM RF2(Cy5) (Figure 2-8 B and C). In both experiments with ECs and aECs, 
very few single molecules showed anticorrelated Cy3 and Cy5 intensity versus time 
trajectories, which would have corresponded to binding of RF2(Cy5). An example of an 
EC time trajectories is shown in Figure 2-8B, where no RF2 binding is present. The Cy5 
intensity noise did not change after Cy3 photobleaching at ~40s, suggesting the relatively 
high noise is likely due to the excess RF2(Cy5) in the background or experimental setup, 
and not resulting from RF2(Cy5) binding events faster than the frame rate. An example 
of aEC time trajectories showing a single RF2-binding event is shown in Figure 2-8C. 
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The single RF2 binding at ~5s is only a single frame, but at the expected FRET efficiency 
of ~0.9, suggesting this binding event is extremely transient and last for the duration of a 
frame, ~100ms.  
To quantitate the number of ribosomal complexes showing RF2-binding, the 
number of time trajectories showing at least one RF2-binding event (at least one anti-
correlated Cy3-Cy5 intensity) was quantitated as “time trajectories showing FRET.” 
“Total time trajectories” includes both “time trajectories showing FRET” and time 
trajectories showing one-step Cy3-photobleaching (Table 2-2). Very limited RF2(Cy5) 
binding to ECs and aECs were observed (Table 2-2). The increased number of time 
trajectories showing RF2(Cy5) binding on aECs suggest RF2(Cy5) likely have a higher 
affinity for aECs than EC; however, the lack of binding events make the quantification of 
RF2 binding nearly impossible. In an attempt to increase the number of observable RF2-
binding events, the RF2(Cy5) concentration was increased to 40nM excess in the 
background. Unfortunately, the excess RF2(Cy5) lead to a huge increase in the 
background noise, leading to almost uninterpretable time trajectories (data not shown). It 
is clear that an alternative approach must be taken in order to investigate RF2 binding in 
the context of non-TCs.  
 




Total time trajectories 
EC 1 1474 










Figure 2-8 RF2(Cy5) binding to various ribosomal complexes carrying fMet-Lys-
tRNALys(Cy3) 
(A) A cartoon representation of a TC with RF2(Cy5), an example of Cy3 intensity 
(green line) and Cy5 intensity (red line) versus time trajectory and EFRET versus time 
trajectory observed. (B) A cartoon representation of an EC with RF2(Cy5), an example 
of Cy3 intensity (green line) and Cy5 intensity (red line) versus time trajectory and 
EFRET versus time trajectory observed. (C) A cartoon representation of an aEC with 
RF2(Cy5), an example of Cy3 intensity (green line) and Cy5 intensity (red line) versus 
time trajectory and EFRET versus time trajectory observed. (D) A histogram of FRET 
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efficiency using N=70 time trajectories observed on the TC, the two peaks centered at 
EFRET of 0.01 and 0.86. 
 
2.4.4 RF2(Cy5) demonstrated distinct binding to ribosomal complexes with P-site 
fMet-Phe-tRNAPhe(Cy3) 
 
Similar to the previous section, the binding of RF2(Cy5) to various ribosomal 
complexes were examined using the fMet-Phe-tRNAPhe(Cy3) to RF2(Cy5) smFRET 
signal, which serves as the basis for investigating ArfA-RF2 ribosome rescue pathway in 
Chapter 4. Three ribosomal complexes were prepared: (1) a TC containing P-site fMet-
Phe-tRNAPhe(Cy3) with a A-site stop codon UGA (Figure 2-9 A), (2) an EC containing 
P-site fMet-Phe-tRNAPhe(Cy3) and a sense codon AAA at the A-site (Figure 2-9 B) and 
(3) a TC containing P-site fMet-Phe-tRNAPhe(Cy3) and an empty A (Figure 2-9 C). In the 
presence of 10nM RF2(Cy5), no RF2(Cy5) binding was observed with both EC and nTC. 
On the other hand, RF2(Cy5) binds stably to TC carrying P-site fMet-Phe-tRNAPhe(Cy3), 
which is analogous to the result observed using TC carrying P-site fMet-Lys-
tRNALys(Cy3) from Section 2.4.3.  
 
 
Figure 2-9 RF2(Cy5) binding to various ribosomal complexes carrying fMet-Phe-
tRNAPhe(Cy3) 
(A) A cartoon representation of the RF2(Cy5) bound to a TC. (B) A cartoon 
representation of the RF2(Cy5) bound to an EC. (C) A cartoon representation of the 
RF2(Cy5) bound to an nTC.  
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2.5 Real-time observation and characterization of RF2(QSY9) binding 
using Cy3-QSY9 smFRET signal at high RF2(QSY9) concentrations 
 
Using the tRNALys(Cy3) to RF2(Cy5) smFRET design, limited RF2(Cy5) binding 
to ECs and aECs were observed in up to 40nM of RF2(Cy5). This result suggests that 
much higher concentrations of RF2(Cy5) are needed to accurately characterize RF2 
binding in the context of the ECs and aECs. To overcome the concentration limit of the 
Cy3-Cy5 FRET pair in TIRF microscopy setup, the tRNA(Cy3) to RF2(QSY9) smFRET 
signal was developed for monitoring the weak RF2 binding micromolar concentration of 
RF2 (described in Section 2.2). The peptide release activity of the Cy3-QSY9 
experimental system was evaluated using the radioactive dipeptide release assay 
described previously for the Cy3-Cy5 system. Using high RF2(QSY9) concentration up 
to 2000nM, the binding and dissociation of RF2(QSY9) to ribosomal complexes were 
monitored as Cy3 fluorescence intensity versus time trajectories. As the lack of anti-
correlated Cy5 signal leads to difficulties in differentiating Cy3 photophysical noise, a 
data analysis scheme was developed with the help of Jason Hon (graduate research 
assistant, Gonzalez laboratory) to quantify RF2 binding kinetics and account for Cy3 
photoblinking.  
2.5.1 Evaluating peptide release activity of RF2(QSY9) on TCs using dipeptide 
release assay 
 
The peptide release rate of RF2(QSY9) was evaluated using the radioactive 
dipeptide release assay described in previous section (and Chapter 5). Since it has been 
demonstrated that RF2-mediated peptide release on the TC is completed by 10s (Figure 
2-7 A), the total peptide release at 1 minute is used to evaluate the peptide release activity 
of RF2 variants on the TC. The TC carrying radioactive dipeptide is incubated with 
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200nM of wtRF2 (aka, RF2T246A), unlabeled- RF2184, RF2(Cy5)-A and RF2(Cy5)-B at 
37ºC in Buffer M for 1 minute. The total amount of radioactive dipeptide released were 
quantified and normalized to wtRF2 as shown in (Figure 2-10 A). Little to no difference 
were observed for both unlabeled RF2 and RF2(Cy5), compared with wtRF2. 
 
Figure 2-10 Peptide hydrolysis of RF2(QSY9) on ribosomal complexes. 
(A) Top eTLC image shows the radioactive fMet-Lys dipeptide released after 1 minute 
incubation; bottom graph shows the quantification of the normalized fMet-Lys released 
by wtRF2, unlabeled-RF2184 and RF2(QSY9); error bars represent the error in eTLC 
quantification (extremely small); (B) rates of peptide release, khyd, of wtRF2 or 
RF2(QSY9) in Buffer A or Buffer M measured at room temperature on both ECs and 
aECs; time course is not shown; error bars represent the error of the exponential fits. 
 
2.5.2 RF2(QSY9) catalyze enhanced peptide release on aECs at room temperature 
 
The rates of peptide release catalyzed by wtRF2, unlabeled-RF2184 and 
RF2(QSY9) on both ECs and aECs were measured at conditions similar to single-
molecule experiments, in Buffer M and at room temperature, using the radioactive 
dipeptide release assay previously described for RF2(Cy5). A comparison of the peptide 
release rates between wtRF2 and RF2(QSY9) from the ECs and aECs is shown in Figure 
2-10 B and  Table 2-3. In both Buffer A and Buffer M, both wtRF2 and RF2(QSY9) 
catalyze peptide release on the aEC faster than the EC. Notably, comparing with the rates 
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measured at 37ºC (Table 2-3), the rates measured at room temperature were significantly 
reduced; however, the trend between complexes remains the same. This result is also 
consistent with the previous publication showing a faster peptide release rate on the aEC 
compared with the EC1. 
 








wtRF2 0.00016 +0.00005 
RF2(QSY9) 0.00013 +0.00004 
no RF2 0.0003 +0.0001 
aEC 
wtRF2 0.0005 +0.0002 
RF2(QSY9) 0.0009 +0.0003 
no RF2 0.0004 +0.0001 
 
 
2.5.3 RF2(QSY9) quenches Cy3-tRNA signal on TCs 
 
Having shown that RF2(QSY9) is biochemically active, RF2(QSY9) binding to 
the TC was investigated. Unlike the Cy3-Cy5 smFRET signal with two distinct, 
anticorrelated fluorescence readout, Cy3-QSY9 smFRET signal displays only changes in 
Cy3 fluorescence. Based on the stable RF2 binding to TC revealed by Cy3-Cy5 smFRET 
signal (Section 2.4.3) and a predicted EFRET of 0.99, stable RF2(QSY9) binding will lead 
to almost full quenching and disappearance of Cy3 fluorescence. Therefore, a Cy3 spot 
counting assay was used to assess RF2(QSY9) binding to surface-immobilized TCs 
carrying tRNALys(Cy3). In this assay, RF2(QSY9) binding is assessed by changes in the 
total number of Cy3 signal spots before and after incubation with 1µM unlabeled-RF2184 
or RF2(QSY9) (Figure 2-11A and B). The change in total number of observed Cy3 
fluorescence signals in absence and presence of unlabeled-RF2184 or RF2(QSY9) is 
reported as a percentage of Cy3 signal remained. In the presence of 1µM unlabeled-
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RF2184, 97% ±4% of the Cy3 signal were observed; whereas, in the presence of 1µM 
RF2(QSY9), only 34% ±2% of Cy3 signals remained unquenched (Figure 2-11C). This 
result shows that Cy3 quenching is dependent on the presence of QSY9 quencher. 
Furthermore, on the experimental timescale of up to 80s, the quenched Cy3 signals does 
not reappear, leading to a lower bound of RF2(QSY9) bound state lifetime on TCs to be 
~50s, which is the Cy3-photobleaching time. This lower bound is consistent with the 
previous result with RF1, which estimated an RF1:TC bound-state lifetime of much 
greater than ~20s78. Approximately 34% of the Cy3 signals were never quenched by 
RF2(QSY9), and the size of this population is similar to the ~20% biochemically inactive 
ribosomal complexes measured by Zavialov et. al 47. Thus, this result suggests the Cy3-
QSY9 smFRET signal reports on authentic RF2(QSY9) binding to the TC and the EFRET 
is in good agreement with the predicted EFRET of 0.99 based on RF2 conformation bound 
to TCs observed from X-ray crystallographic structures57,5.  
 
 
Figure 2-11 RF2(QSY9) binding to the TC. 
(A) Left: a cartoon representation of the TC carrying a P-site tRNALys(Cy3); right: a 
cartoon representation of the TC carrying a P-site tRNALys(Cy3) and a A-site 
RF2(QSY9); (B) left: an image of surface immobilized TCs in imaging buffer; right: 
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an image of surface immobilized TCs in imaging buffer containing 1μM RF2(QSY9) 
of the same microscope microfluidic channel; (C) A normalized bar graph showing the 
remaining Cy3 spots after 5 minutes incubation with either 1μM unlabeled-RF2184 or 
1μM RF2(QSY9) TCs in comparison to their corresponding buffer control prior to 
incubation; error bars represent 95% confidence interval of the Cy3 spot counts. 
 
2.5.4 RF2(QSY9) binding: presence of fluctuating and non-fluctuating time 
trajectories 
 
Next, RF2(QSY9) binding to both ECs and aECs were investigated using 1µM 
RF2(QSY9). Both complexes were independently immobilized on quartz slides for the 
collection of steady-state Cy3-intensity time trajectories using TIRF microscopy in the 
presence of 1µM RF2(QSY9). However, the use of a Cy3-QSY9 pair yields data from 
Cy3 alone, and therefore difference between RF2(QSY9) binding events and Cy3 
photophysical noise, or “blinking,” cannot be distinguished. To account for Cy3 
photophysical noise, control experiments were recorded for each complex in the presence 
of 1µM unlabeled-RF2184.  
The Cy3 fluorescence time trajectories showing one-step Cy3-photobleaching 
were collected in the presence of 1µM RF2(QSY9) on both ECs and aECs (Figure 2-12 A 
and B). In addition to Cy3-intensity versus time trajectories showing only one-step Cy3-
photobleaching without additional intensity fluctuation, a fraction of Cy3-intensity versus 
time trajectories was observed to fluctuate between two states: a high-intensity state and a 
low-intensity state in both ECs and aECs (Figure 2-12). The time trajectories were 
classified into two classes: (1) time trajectories showing only one-step Cy3 
photobleaching, called non-fluctuating time trajectories, and (2) time trajectories showing 
two-state Cy3 intensity fluctuation between high-intensity state and low-intensity state, 
called fluctuating time trajectories. In the presence of 1µM RF2(QSY9), 14% of the ECs, 
and 21% of the aECs exhibited fluctuations between these two states (Table 2-4). The 
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high-intensity state is interpreted as the RF2(QSY9)-unbound state. Based on the results 
with RF2(QSY9) binding to TCs (Figure 2-11) and the control experiments with 
unlabeled-RF2184, the low-intensity state is likely consisted of a mixture of RF2(QSY9)-
binding and Cy3-photoblinking events.  










1µM unlabeled 2040 1859 181 9 % 
1µM 
RF2(QSY9) 4688 4009 679 14 % 
aEC 
1µM unlabeled 3859 3379 480 12 % 
1µM 





Figure 2-12 Cy3-QSY9 smFRET signal and RF2(QSY9) binding. 
(A) Cartoon representation showing an EC with a Cy3-tRNA in the P-site and 
RF2(QSY9) in the A-site. (B) Cartoon representation showing an aEC with 
mismatched at the second position of the P-site codon AUA and positions of the 
smFRET signal. (C) An example of Cy3 fluorescence time trajectory of aECs 
incubating with 1µM RF2(QSY9). 




2.5.5 RF2(QSY9) binding and Cy3 photophysical noise on both ECs and aECs  
 
As a means of distinguishing between RF2(QSY9) binding and Cy3 
photophysical noise, both the number of fluctuating time trajectories and transition rates 
between the high-intensity and low-intensity states (klowhi and khilow) were quantified 
(Table 2-5). Compared with unlabeled-RF2184 control experiments, an increase in both 
the number of fluctuatingS time trajectories and transitions between the two intensity 
states would be a good indication of authentic RF2(QSY9) binding. Similar to the lack of 
observable RF2 binding to the EC at 10nM RF2(Cy5), the EC in the presence of 1µM 
RF2(QSY9) only had Cy3-intensity time trajectories with transition rates equivalent to 
those of the control, indicating that there was no significant binding (Table 2-5). On the 
other hand, the aEC had transition rates that were dramatically different from the control 
(Table 2-5), indicating that there are significant RF2(QSY9) the in the presence of 1µM 
RF2(QSY9). Therefore, while the EC dataset likely did not contain authentic RF2(QSY9) 
binding events, there was a significant number of aECs that appeared to transiently bind 
and release RF2. Furthermore, the 10-fold difference between the unlabeled-RF2184 and 
RF2(QSY9) klowhi and khilow to the aEC indicate the kinetics between authentic 
RF2(QSY9) binding and Cy3 photoblinking is likely to be distinguishable. 
 






EC 1µM unlabeled 0.0020 ±0.0001 0.082 ±0.003 
EC 1µM RF2(QSY9) 0.0032 ±0.0002 0.069 ±0.004 
aEC 1µM unlabeled 0.0020 ±0.0002 0.056 ±0.008 
aEC 1µM RF2(QSY9) 0.051 ±0.002 0.50 ±0.03 
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2.5.6 Estimation of Cy3-photoblinking by unlabeled-RF2184 and identification of 
kinetic subpopulations on the aEC 
 
The presence of Cy3 photoblinking hinders the ability to quantify RF2(QSY9) 
binding to ribosomal complexes, therefore, a procedure was devised with the help of 
Jason Hon (graduate research assistant, Gonzalez laboratory) to remove Cy3 
photoblinking from the single-molecule data based on the individual transition rates 
between the two intensity states and kinetically differentiate time trajectories resulting 
from Cy3 photoblinking from those resulting from authentic RF2(QSY9) binding. 
Because of the approximately 10-fold higher klowhi and khilow for aECs in the presence 
of RF2(QSY9) versus unlabeled-RF2184, a fraction of time trajectories is likely to have 
rate constants significantly faster than those measured for Cy3 photoblinking, and 
dividing the dataset into subpopulations by the kinetics of each Cy3 time trajectories 
could segregate time trajectories with significant Cy3 photoblinking from those recording 
primarily authentic binding events. The transition rates measured from the unlabeled-
RF2184 control experiments also serve as the basis for directly detecting the time 
trajectories with transition rates similar from those arise from Cy3 photophysics. 
Furthermore, authentic RF2(QSY9) binding is expected to exhibit an RF2(QSY9) 
concentration dependence; therefore, the steady-state measurements of aECs were 
repeated varying the concentration of RF2(QSY9) between 500nM and 2000nM. 
As the rate of authentic substrate binding is dependent on RF2(QSY9) 
concentration whereas the photoblinking transition rates are constant with respect to 
changes in RF2(QSY9) concentration were examined. The analysis revealed that, in 
addition to the photoblinking subpopulation, denoted Sub0 (colored green in Appendix 
D), aECs had two distinct, kinetic subpopulations, Sub1 and Sub2 (colored blue and red 
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in Appendix D, respectively, Table 2-6) that did not interconvert within the experimental 
observation, each with concentration-dependent transition rates. Representative Cy3 
intensity and Cy5 intensity versus time trajectories and EFRET versus time trajectories for 
Sub1 and Sub2 are shown in Figure 2-13 A, with the cartoon representation of the two 
states denoted. The low-intensity state in Sub1 and Sub2 was defined as the RF2 bound 
state (B) and the high-intensity state was defined as the RF2 unbound state (U). 
The post-synchronized two-dimensional surface contour plots of the time 
evolution of the population FRET, prepared by post-synchronizing each individual 
binding event based on U and normalized for each time bin, show that individual RF2 
binding events in Sub1 and Sub2 indeed differ dramatically. (Figure 2-13 B). In Sub1, 
RF2(QSY9) rapidly dissociate from aEC at a rate on the order of the camera acquisition 
rate, therefore leading to the “blurring” of EFRET value, where each binding event last for 
only a fraction of a frame (100ms) (Figure 2-13 B). The transition density plots of both 
Sub1 and Sub2 shows that the transition mainly occurs between the two states, B and U, 
as described earlier (Figure 2-13 C). The binding and dissociation rates of each 
individual time trajectory that was in Sub1 or Sub2 (kU→B
ind  and kB→U
ind  ) are calculated and 
plotted in a kU→B
ind  versus kB→U
ind  scatterplot (Figure 2-13 D). While the origin of the two 
kinetic subpopulations is unclear, lack of rapid and regular interconversion between the 
two subpopulations during our experimental timescale suggests that this heterogeneity 
arises from differences between ribosomal complexes and not in the heterogeneity of the 
RF2(QSY9). A potential difference in the ribosomal complexes could be the presence or 
absence of P-site peptide. The role of the P-site peptide on RF2 binding kinetics is further 
investigated in Section 3.4.  

















2000 5392 275 761 5 % 14 % 19 % 
1500 5501 144 807 3 % 15 % 17 % 
1250 5991 185 911 3 % 15 % 18 % 
1000 6092 216 903 4 % 15 % 18 % 
750 6018 206 853 3 % 14 % 18 % 








kUB (s-1) kBU (s-1) 
Sub1 
2000 2.0 ± 0.1 4.1 ± 0.3 
1500 1.75 ± 0.07 5.5 ± 0.3 
1250 1.53 ± 0.09 5.2 ± 0.3 
1000 1.29 ± 0.07 5.8 ± 0.4 
750 1.00 ± 0.06 6.4 ± 0.6 
500 0.56 ± 0.04 5.4 ± 0.7 
Sub2 
2000 0.124 ± 0.007 0.40 ± 0.03 
1500 0.095 ± 0.006 0.49 ± 0.02 
1250 0.093 ± 0.005 0.39 ± 0.02 
1000 0.063 ± 0.004 0.34 ± 0.02 
750 0.058 ± 0.008 0.34 ± 0.03 








Table 2-8 Transition rates between B and N of RF2 titration on aEC 
[RF2(QSY9)] 
(nM) 
kUB (s-1) kBU (s-1) 
2000 0.33 ± 0.08 0.9 ± 0.3 
1500 0.35 ± 0.02 1.49 ± 0.08 
1250 0.33 ± 0.02 1.22 ± 0.07 
1000 0.29 ± 0.02 1.30 ± 0.09 
750 0.27 ± 0.02 1.3 ± 0.1 
500 0.092 ± 0.009 0.82 ± 0.08 
 
 




Figure 2-13 smFRET measurements reveal two distinct RF2 binding 
subpopulations to mismatched complexes. 
(A) Representative examples of Cy3 intensity (green line) versus time trajectories and 
estimated EFRET (blue lines) versus time trajectories for the two kinetic subpopulations 
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in the aECs, the idealized trajectory of the Cy3 intensity versus time trajectories before 
photobleaching is shown in light green superimposed onto the intensity versus time 
trajectory. Red and green shadings on the estimated EFRET versus time trajectories 
correspond to the two estimated EFRET states, bound (B) and unbound (U), with their 
cartoon representations. (B) Two-dimensional surface contour plots of the time 
evolution of the population FRET for the two subpopulations generated as described 
Chapter 5. N represents the total number of estimated EFRET versus time trajectories 
that were used to construct the histograms and the n values represent the total number 
of transitions between estimated EFRET states. (C) Transition density plots of the two 
kinetic subpopulations. (D) A scatter plot showing the  kU→B
ind  versus kB→U
ind  of 1μM 
RF2(QSY9) binding for each individual smFRET trajectory. The two kinetic 
subpopulations, fast and stable, are colored as blue and red respectively. Each data 
point represents the average transition rate pair (kB→U
ind , kU→B
ind ) from an individual 
smFRET trajectory, where kU→B
ind  is the rate of RF2(QSY9) binding to the aEC and 
kB→U
ind  is the rate of RF2(QSY9) dissociation from the aEC. N represents the total 
number of smFRET trajectories in the scatter plot. The scatter plot including Cy3 
blinking subpopulation (Sub0) is shown in Appendix D. 
 
 
2.5.6 Calculation of RF2(QSY9) binding kinetics to the aEC 
 
The average equilibrium dissociation constant, KD, of RF2(QSY9) to aECs is 
estimated using the RF2(QSY9) binding kinetics measured. Normalizing each Cy3-
intensity versus time trajectory by defining the EFRET of U to be 0, the EFRET of B was 
measured as 0.882 ±0.001. From fitting a linear equation to the observed rate constants 
versus RF2(QSY9) concentration (Figure 2-14 A and B, Table 2-7), Sub1 had a kon
Sub1 of 
1.19 ±0.02 μM-1s-1 and koff
Sub1 of 5.2 ±0.2 s-1 (colored blue), and Sub2 had kon
Sub2 of 0.064 
±0.004 μM-1s-1 and koff
Sub2 of 0.345 ±0.009 s-1 (colored red). The overall rate of transition 
between B and U, kBU and kUB were calculated (Table 2-8). The kon,app of 0.25 ±0.02 
μM-1s-1 was obtained by taking the slope of a linear equation fit to the kUB versus RF2 
concentration plot (Figure 2-14, colored purple). Together with the koff,app of 1.20 ±0.04 
s-1, these average rates give a KD of 4.8 ±0.4 μM. 
 





Figure 2-14 RF2 binding and dissociation rates from aECs. 
(A) Calculated kUB (filled symbols) versus RF2(QSY9) concentration of the two 
kinetic subpopulations (blue/Sub1 and red/Sub2) and their aggregate rates (purple). 
The blue line is the unweighted linear fit with the form, y=mx with slope m = 
1.14(±0.05), R2 of 0.99. Red line is the unweighted linear fit with the form, y=mx with 
slope m = 0.064(±0.004)and R2 of 0.98. The purple line is the unweighted linear fit 
with the form, y=mx with slope m = 0.22(±0.03) and R2 of 0.92. The error bars 
represent 95% confidence intervals. (B) Calculated kBU (opened symbols) versus 
RF2(QSY9) concentration of the two kinetic subpopulations (blue/Sub1 and red/Sub2) 
and their aggregate rates (purple). The blue line is the unweighted linear fit with the 
form, y=mx+b with slope set at m = 0 and intercepts at b = 5.4(±0.3). Red is the 
unweighted linear fit with the form, y=mx+b with slope set at m = 0 and intercepts at b 
=0.36(±0.04). The purple line is the unweighted linear fit with the form, y=mx+b with 





A novel tRNA(Cy3) to RF2(Cy5) smFRET signal was developed for monitoring 
RF2 binding kinetics to ribosomal complexes. This smFRET signal is suitable for 
studying RF2(Cy5) binding to the TC, which demonstrated stable RF2 binding, but 
limited for investigating binding to the ECs and aECs due to the limitation of RF2(Cy5) 
concentration allowed on a TIRF microscopy setup. To overcome the concentration 
limitation of the Cy3-Cy5 FRET pair, the smFRET signal was redesigned with 
tRNA(Cy3) and RF2(QSY9) to extend the study of RF2 binding kinetics at micromolar 
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concentrations of RF2. Using this tRNALys-RF2 smFRET signal, RF2(QSY9) binding 
kinetics to the ECs and aECs were investigated. In contrast to the TC, RF2(QSY9) 
exhibited transient binding to the aEC with a KD of 4.8±0.4 μM, whereas no RF2(QSY9) 
binding was observed on the ECs to the limit of 2µM RF2(QSY9). In addition, two RF2 
binding subpopulations with distinct binding kinetics to the aEC were identified. The 
development of the tRNA-RF2 smFRET signals opens the door to investigate the RF2 
binding kinetics in the context of important translational processes such as translation 
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In post PT QC, RF3 enhances the rate of RF2-mediated peptide release 20- to 50-
fold on aECs, thus allowing post PT QC to compete with other translational processes 
during translation elongation 1. To elucidate the mechanistic role of RF3 in post PT QC, I 
investigated the effect of RF3 on the interaction of RF2 with ECs and aECs. The 
observed 20- to 50-fold enhancement has been shown at saturating concentrations of 
RF2, where RF2 is already bound as much as possible prior to addition of RF3 1. These 
results indicate that RF3 likely has additional mechanistic roles aside from increasing the 
affinity of RF2 to the ribosomal complexes, which I set out to investigate with the 
smFRET signals, tRNA(Cy3)-RF2(Cy5) or tRNA(Cy3)-RF2(QSY9), reporting on RF2 
binding to ribosomal complexes (Section 3.2 and Section 3.3, respectively). Finally, to 
address some experimental findings and provide justification of the steady-state RF2 
binding measurements from Cy3-QSY9 experiments, the role of the P-site peptide on 
RF2 binding kinetics was investigated and discussed (Section 3.4).  
3.2 Studying Effect of RF3 on RF2 Binding using Cy3-Cy5 smFRET 
signal 
 
3.2.1 RF3 enhancement of peptide release rate on wtRF2 
 
As reviewed in Chapter 1 and Chapter 2, the peptide release activity of RF2 is 
dependent on the amino acid identity at position 246 and the N5-methyl modification at 
                                                 
2 Bridget Huang performed all of the smFRET and biochemical experiments. Bridget Huang and Jason Hon 
performed the data analysis of the smFRET experiments. A manuscript detailing this material is currently 
in preparation. 
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Q235. To confirm that the RF3 enhancement on the rate of RF2-mediated peptide release 
is not dependent on these two factors, the peptide release rate of wtRF2, which has 
T246A mutation and prepared with co-overexpression of N5-glutamine methyltransferase 
as described in Chapter 2, was examined absence or presence of 10µM RF3 in a 
dipeptide release assay. Using the aEC prepared as described in Chapter 2, a 30-fold 
RF3-dependent enhancement on the rate of RF2-mediated peptide release from 0.007 
±0.004 s-1 to 0.20 ±0.09 s-1 was observed with conditions, at 37ºC in the presence of 
GTP, similar to that reported by Zaher et. al1 (Table 3-1). The hypo-methylated RF2T246A 
variant, prepared without co-overexpression of N5-glutamine methyltransferase, was 
prepared for comparison with the published literature value. Compared with the reported 
rates, the peptide release rates measured here are faster as a result of the more active RF2 
preparation and the hypo-methylated RF2(T246) rates of 0.005 +0.001s-1 and 0.048 
+0.003s-1 , in absence and presence of RF3 respectively, are almost in complete 
agreement with the reported rates of ~0.002s-1 and ~0.06s-1.1 This result indicates that 
RF3 enhances the rate of peptide release regardless of the RF2 variants and may play an 












Table 3-1 Rates of Peptide Release Measured at 37°C 
  
Buffers Complexes RF2 variants 
RF2 RF2+RF3 







0.005 +0.001 0.048 +0.003 
wtRF2 0.007 +0.004 0.20 ±0.09 
Buffer M 
EC  
wtRF2 0.0007 +0.0001 0.012 +0.001 
RF2184 0.0008 +0.0002 0.010 +0.001 
aEC 
wtRF2 0.008 +0.003 0.099 +0.007 
RF2184 0.006 +0.002 0.100 +0.009 
RF2(Cy5)-A 0.0030 +0.0007 0.035 +0.008 
RF2(Cy5)-B 0.005 +0.002 0.055 +0.008 
 
3.2.2 RF3 enhances RF2(Cy5) peptide release rate 
 
Using the same radioactive dipeptide release assay setup, the RF3-dependent 
enhancement on the rate of RF2-mediated peptide release were examined using both 
RF2(Cy5)-A and RF2(Cy5)-B, isolated as described in section 2.3.6.2. In the smFRET 
experimental buffer M and at 37°C, the rate of peptide release increases 12-fold from 
0.0030 +0.0007s-1 to 0.035 +0.008s-1 and 11-fold from 0.005 +0.002s-1 to 0.055 +0.008s-
1, for RF2(Cy5)-A and RF2(Cy5)-B respectively (Table 3-1). This RF3 enhancement is in 
good agreement with the 12-fold increase from 0.008 +0.003s-1 to 0.099 +0.007s-1 
observed using wtRF2 (Table 3-1). On the basis of this observation, I conclude that Cy5-
conjugation has insignificant effect on the RF3-dependent peptide release rate 
enhancement. In addition, the difference between RF2(Cy5)-A and RF2(Cy5)-B appears 
to be negligible, therefore, RF2(Cy5)-A will be used in all smFRET experiments and 
denoted as RF2(Cy5). 
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3.2.3 Effect of RF3 on RF2(Cy5) binding on ECs and aECs 
 
The effect of RF3 on RF2(Cy5) binding kinetics to ECs and aECs were examined 
using steady-state smFRET experiments using 10nM RF2(Cy5), 10µM RF3 and 1mM 
GTP. In contrast to the limited RF2(Cy5) binding observed in absence of RF3 discussed 
in Section 2.4.3, increased number of smFRET trajectories were observed on both EC 
and aECs, 313 and 285, respectively (Table 3-2). The time trajectories observed exhibited 
transient RF2(Cy5) binding and dissociation from the EC and aEC as shown by the 
representative Cy3 intensity and Cy5 intensity versus time trajectories and the EFRET 
versus time trajectories in Figure 3-1 A. The RF2-bound state is denoted as B state and 
the RF2-unbound state is denoted as U state as indicated by the cartoon representation in 
Figure 3-1 A. To visualize the time evolution of the population FRET, each individual 
binding event is post-synchronized based on U and normalized for each time bin (Figure 
3-1 B). The post-synchronized two-dimensional surface contour plots of both EC and 
aEC at 10nM RF2(Cy5) and 10μM RF3 show entry from U into B. The transition density 
plots shows that RF2(Cy5) transition between U and B, where blurring due to fast 
transition on both EC and aEC leads to lower EFRET of the B (Figure 3-1 C). The 
calculated kBU and kUB are shown in Table 3-3. 
 






EC RF2(Cy5) 1 1474 
EC RF2(Cy5) + RF3 313 786 
aEC RF2(Cy5) 32 1397 
aEC RF2(Cy5) + RF3 285 850 
 
 




Figure 3-1 Effect of RF3 on RF2(Cy5) binding kinetics 
(A) An representative example of Cy3 and Cy5 intensity (green and red lines) versus 
time trajectory and estimated EFRET (blue line) versus time trajectory in presence of 
10nM RF2(RF2), 10μM RF3 and 1mM GTP on EC (left column) and aEC (right 
column). The idealized trajectory of the EFRET versus time trajectories before 
photobleaching is shown in cyan superimposed onto the EFRET versus time trajectory. 
The cartoon representations the two RF2(Cy5) binding states are shown, the pink 
shading represents the RF2-bound states (B) and the light green shading represents the 
RF2-unbound state (U). (B) Post-synchronized two-dimensional surface contour plots 
of time evolution of the population FRET by individual binding event. The N values 
represent total number of estimated EFRET versus time trajectories that were used to 
Chapter 3 The role of RF3 in post PT QC pathway 
90 
 
construct the histograms and the n values represent total number of transitions between 
estimated EFRET states. (C) Transition density plots.  
 
Table 3-3 The rate of RF2(Cy5) binding and dissociation in presence of RF3 
 kUB (s-1) kBU (s-1) 
EC + RF2(Cy5) + RF3 1.0 +0.2 0.130 +0.007 




3.3 Studying Effect of RF3 on RF2 Binding at high concentration of 
RF2 
 
3.3.1 Measurement of RF3 enhancement of RF2(QSY9)-mediated peptide hydrolysis 
rate 
 
To demonstrate that RF3 enhances the rate of peptide release catalyzed by 
RF2(QSY9), the rates of peptide release were measured using a dipeptide release assay 
under conditions of the smFRET assays, with Buffer M at room temperature and 
supplemented with 1mM GTP. In the presence of 10μM RF3, the rate of peptide release 
using wtRF2 was 0.0034 ±0.0006 s-1, which is similar to the rate of peptide release using 
RF2(QSY9), 0.003 ±0.001 s-1 (Table 3-4). Both the wtRF2 and RF2(QSY9) showed a 
RF3-dependent enhancement of ~7-fold and ~3-fold on aECs respectively. While the 
RF3 enhancement effect is less than the ~20-50-fold reported1, the minor difference in 
the RF3 enhancement effect between wtRF2 and RF2(QSY9) suggests that changes in the 
experimental condition may have a larger effect than preparation of RF2(QSY9) (Figure 
3-2). 




Figure 3-2 RF3 enhancement of RF2-mediated peptide hydrolysis rates. 
Rates of peptide release (khyd) measured with biochemical dipeptide release assay for 
wtRF2 and RF2(QSY9) at room temperature in Buffer M. The error bars represent the 
error of the fit, analogous to previously reported1. 
 
 
Table 3-4: Rates of Peptide Release Measured at Room Temperature in Buffer M 
Complexes RF2 variants 
RF2 RF2+RF3 
khyd (s-1) khyd (s-1) 
EC 
wtRF2 0.00016 +0.00005 0.0007 +0.0001 
RF2(QSY9) 0.00013 +0.00004 0.00039 +0.00006 
no RF2 0.0003 +0.0001 0.0004 +0.0001 
aEC 
wtRF2 0.0005 +0.0002 0.0034 +0.0006 
RF2(QSY9) 0.0009 +0.0003 0.003 +0.001 
no RF2 0.0004 +0.0001 0.00090 +0.0002 
 
3.3.2 Characterization of RF3-dependent three-state time trajectories 
 
The binding kinetics of 1μM RF2(QSY9) with both ECs and aECs in the presence 
of increasing concentrations of RF3, in a range between 10nM to 10μM, were examined 
in steady-state smFRET experiments. Strikingly, unique to Cy3-intensity versus time 
trajectories recorded in the presence of RF2(QSY9) and RF3 on both ECs and aECs, a 
significant number of trajectories with fluctuations between three intensity states were 
observed and manually identified (Figure 3-3 A and Figure 3-4 A). The number of time 
trajectories showing three-state transitions increases with increasing concentration of RF3 
in both EC and aEC (Table 3-5). Consistent with the previous observation, no three-state 
time trajectories were identified in absence of RF3.  
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10 3793 262 101 
1 3010 272 19 
0.1 4026 202 37 
0.01 3990 380 11 
0 4285 1193 0 
aEC 
10 3568 434 238 
1 4450 437 115 
0.1 4491 440 201 
0.01 4075 380 94 
0 4236 564 0 
 
Similar to the previous chapter, the high-intensity state is considered as an 
unbound state (U), and the low-intensity state is considered as a bound state (B). To 
better characterize the intermediate-intensity state (I), the EFRET of these three-state time 
trajectories and in combination with two-state time trajectories were examined (Figure 
3-3 A and Figure 3-4 A). The Cy3-intensity versus time trajectories were normalized by 
defining the EFRET of U as 0 in both ECs and aECs. The mean EFRET of I is 0.612 ± 0.003 
on aECs and 0.580± 0.007 on ECs, and the mean EFRET of B is 0.927 ± 0.004 on aECs 
and 0.950± 0.006 on ECs (Table 3-6). Notably, the compiled histogram of the three-state 
Cy3-intensity versus time trajectories shows that I is well populated and separated from 
B and U, suggesting that I is a distinct state from both B and U observed in the absence 
of RF3 (Appendix E).  
To visualize the time evolution of the population FRET, each individual binding 
event is post-synchronized based on U and normalized for each time bin (Figure 3-3 B 
and Figure 3-4 B). The post-synchronized two-dimensional surface contour plots of both 
EC and aEC at 1μM RF2(QSY9) and 10μM RF3 show entry from U into I, followed by 
increased density into B. To further characterize I, the numbers of transitions between 
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each state were quantified. The result indicates that transitions from U into B almost 
always go through I and vice versa, as shown in the transition density plots Figure 3-3 C 
and Figure 3-4 C. This result is consistent with the idea that I is an RF3-stabilized RF2 
binding intermediate for both ECs and aECs.  
To exclude the possibility that I arose from Cy3 photophysical effects. It was 
further confirmed that N is both RF2(QSY9) and RF3-dependent by verifying that no 
three-state Cy3-intensity versus time trajectories were observed using 1μM unlabeled-
RF2 and 10μM RF3, as well as with 10μM RF3 and no RF2 (data not shown). Based on 
these controls, I is consistent with an RF2 binding intermediate which is stabilized in the 
presence of RF3. When processed with all the three-state trajectories, the apparent rates 
of transition between B, N, and I in individual Cy3-intensity versus time trajectories are 
identical for molecules identified at 10nM RF3 as for molecules identified at 10μM RF3, 
implying that there are two distinct and slowly interconverting populations of Cy3-
intensity versus time trajectories – those that apparently fluctuate between B, N, and U, 
and those that apparently fluctuate between only B and U. The fraction of the three-state 
trajectories increases as a function of RF3 concentration (Table 3-5).  
 












10μM 2-state 0 - - - 0.97 ± 0.02 
10μM 3-state 0 - 0.580 ± 0.007 0.950 ± 0.006 
aEC 
0nM 2-state 0 - - - 0.88 ± 0.001 
10μM 3-state 0 - 0.612 ± 0.003 0.927 ± 0.004 








Figure 3-3 RF3 stabilizes an RF2 binding intermediate on ECs 
(A) An representative example of three-state Cy3 intensity (green line) versus time 
trajectory and estimated EFRET (blue line) versus time trajectory in presence of 1μM 
RF2(QSY9), 10μM RF3 and 1mM GTP on EC. The idealized trajectory of the Cy3 
intensity versus time trajectories before photobleaching is shown in light green 
superimposed onto the intensity versus time trajectory. The cartoon representations of 
each state and their estimated EFRET efficiency are shown, the pink shading represents 
the RF2-bound states (B and I) and the light green shading represents the RF2-unbound 
state (U). (B) Post-synchronized two-dimensional surface contour plots of time 
evolution of the population FRET by individual binding event. The N values represent 
total number of estimated EFRET versus time trajectories that were used to construct the 
histograms and the n values represent total number of transitions between estimated 
EFRET states. (C) Transition density plot. (D) A scatter plot showing the kU→(B+N)
ind
 





 at 1μM RF2(QSY9), 10μM RF3 and 1mM GTP. N represents total 
number of smFRET trajectories in the scatter plot.  
 
 
Figure 3-4 RF3 stabilizes an RF2 binding intermediate on aECs 
(A) An representative example of three-state Cy3 intensity (green line) versus time 
trajectory and estimated EFRET (blue line) versus time trajectory in presence of 1μM 
RF2(QSY9), 10μM RF3 and 1mM GTP on aEC. The idealized trajectory of the Cy3 
intensity versus time trajectories before photobleaching is shown in light green 
superimposed onto the intensity versus time trajectory. The cartoon representations of 
each state and their estimated EFRET efficiency are shown, the pink shading represents 
the RF2-bound states (B and I) and the light green shading represents the RF2-unbound 
state (U). (B) Post-synchronized two-dimensional surface contour plots of time 
evolution of the population FRET by individual binding event. The N values represent 
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total number of estimated EFRET versus time trajectories that were used to construct the 
histograms and the n values represent total number of transitions between estimated 





 at 1μM RF2(QSY9), 10μM RF3 and 1mM GTP. N represents total 
number of smFRET trajectories in the scatter plot. 
 
3.3.3 RF3 affects RF2 affinity for both ECs and aECs 
 
The effect of RF3 on RF2(QSY9) binding to both ECs and aECs is investigated 
by considering B and I as a single bound state (B+I) and measuring the rate constants 
kU(B+I), which is the overall flux of RF2(QSY9) onto the ribosomal complex, and 
k(B+I)U, which is the overall flux of RF2(QSY9) out of the ribosomal complex. In 
contrast to the lack of observable RF2(QSY9) binding in the absence of RF3, 
RF2(QSY9) binding to ECs in the presence of 10μM RF3 was observed. Due to the lack 
of quantifiable binding in the absence of RF3, it is difficult to systematically characterize 
changes in RF2 binding to ECs a function of RF3 concentration. Therefore, ECs and 
aECs are compared only in the presence and absence of 10μM RF3. The non-
photoblinking (non-Sub0) population at 10μM RF3, including both apparent two-state 
and three-state Cy3-intensity versus time trajectories, were roughly equivalent for both 
ECs and aECs (Table 3-7). RF3 systematically enhances kU(B+I) to aECs by 
approximately 10-fold, from 0.13 ±0.02s-1 to 1.31 ±0.07s-1 in the presence of 10μM RF3 
(Figure 3-5 A and Table 3-7). On the other hand, the k(B+I)U to aECs in the absence of 
RF3, 0.38 ±0.04s-1, was comparable for all additions of RF3, for example, 0.37 ±0.03s-1 
in the presence of 10μM RF3 (Figure 3-5 B and Table 3-7).  
The kU(B+I) and k(B+I)U of RF2(QSY9) binding are plotted as against RF3 
concentration (Figure 3-5). The kU(B+I) accelerates up to 10-fold as increasing RF3 
concentration, whereas k(B+I)U remains independent of RF3 concentration. While the 
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binding and dissociation of RF3 cannot be monitor using the tRNA-RF2 smFRET signal 
and the sequence of RF2 and RF3 binding remain unclear, a simple kinetic scheme is 
proposed as shown in Figure 3-5 C, where both RF2 and RF3 can independently bind to 
the aEC. Notably, based on the slow interconversion of three-state trajectories, kU(B+I) 
can be fitted with this kinetic scheme, as reviewed by Weikl and Paul, to extract 
information such as KM
115. The equation, 𝑘𝑜𝑏𝑠 =
𝑘1𝐾𝑀+𝑘2[𝑅𝐹3]
𝐾𝑀+[𝑅𝐹3]
, where k1 of 0.14 ±0.02s
-1 
is equivalent to the kU(B+I) in absence of RF3, k2 of 1.5 ±0.1s
-1 is equivalent to the 
kU(B+I) in presence of saturating RF3 and KM of 0.05 ±0.02μM is the RF3 concentration 
when the effect of RF3 on kU(B+I) is half of the maximum (Figure 3-5 A). 
 
 
Table 3-7 Transition Rates and Calculated RF2 Fractional Occupancy of 1μM 








EC 10 1.31 ± 0.07 0.72 ± 0.05 0.64 ± 0.05 
aEC 
10 1.1 ± 0.3 0.37  ± 0.03 0.8 ± 0.2 
1 1.56 ± 0.09 0.305 ± 0.008 0.84 ± 0.06 
0.1 0.99 ± 0.09 0.38 ± 0.01 0.72 ± 0.07 
0.01 0.39 ± 0.04 0.36 ± 0.03 0.52 ± 0.07 
0 0.13 ± 0.02 0.38 ± 0.04 0.26 ± 0.04 
*Calculated by kU(B+I) /( kU(B+I) + kU(B+I)). 
 




Figure 3-5 RF3 titration on aECs 
(A) kU(B+I) (filled symbols) versus RF3 concentration of the aEC with x-axis break 
between 0.0002 to 0.0005 to show the data point at 0μM RF3 on a log-scale. Black line 
is a Hill fit of with the form 𝑘𝑜𝑏𝑠 =
𝑘1𝐾𝑀+𝑘2[𝑅𝐹3]
𝐾𝑀+[𝑅𝐹3]
, where k1=0.14 ±0.02s
-1, k2=1.5 
±0.1s-1, KM=0.05 ±0.02μM and R
2=0.98 115. The error bars represent 95% confidence 
intervals. (B) k(B+I)U (opened symbols) versus RF3 concentration of the aEC with x-
axis break between 0.0002 to 0.0005 to show the data point at 0μM RF3 on a log-scale. 
Black line is a linear fit with the form y=mx+b where m is set to 0 and b = 0.36±1.5E-
9. The error bars represent 95% confidence intervals. (C) Cartoon scheme of the model 
used to fit kU(B+I) (filled symbols) versus RF3 concentration. 
 





 scatterplot of aEC (Figure 3-4 D). There is a dramatic change in the RF2 
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binding subpopulations to aECs, described in the previous section, in presence of 10μM 
RF3. The two binding subpopulations to aECs observed in the absence of RF3 (Figure 





 scatterplots of ECs and aECs at 10μM RF3 suggest that 
the RF2(QSY9) binding kinetics in presence of RF3 are similar (Figure 3-3 D and Figure 
3-4 D). Indeed, the kU(B+I) of the EC and aEC are within error, while the k(B+I)U  of the 
EC was slightly faster than for the aECs (Table 3-7); therefore, the overall RF2(QSY9) 
affinity of both complexes, in the presence of 10μM RF3, is essentially equivalent, and 
significantly higher than in the absence of RF3. 
Equivalent RF2 affinities for ECs and aECs in the presence of RF3 are in striking 
contrast to biochemical data, which showed no appreciable peptide release on the EC 
versus 0.003 ±0.001s-1 from the aEC (Figure 3-2 and Table 3-4). Reasoning that 
occupancy of B is necessary, but perhaps not sufficient for peptide release, and that based 
on its transition pattern and EFRET, I is unlikely to be catalytic, the apparent occupancy of 
B is further examined to see if the occupancy could account for the difference in peptide 
release rate between the two ribosomal complexes. Because the number of trajectories in 
the non-photoblinking trajectories of both ribosomal complexes were roughly equivalent, 
the apparent B occupancy of the non-photoblinking trajectories of EC and aEC were 
compared by counting each time point spent in B versus the total observation time. The 
result indicates that the apparent B occupancy of the EC, 0.483 ±0.002, was slightly 
higher than that of the aEC, 0.401 ±0.001, however, this difference is insufficient to 
account for the difference in bulk biochemistry between the two complexes. Therefore 
these data are consistent with a model wherein occupancy of B, observed within the 
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context of aECs, is necessary but not sufficient for peptide release, whereas neither 
occupancy of I nor of B, within the context of an EC, is sufficient for peptide release. 
3.3.4 Investigating the lack of three-state time trajectories in Cy3-Cy5 smFRET 
signal 
 
The kU(B+I) and k(B+I)U calculated by aggregating the B and I as the bound state 
showed that kU(B+I) is dependent on RF3 concentration, whereas k(B+I)U is independent 
of RF3 concentration even with the presence of a new state I observed in the presence of 
RF3. This observation is likely related to the artificial aggregation of the B and I in the 
calculation. Therefore, to investigate the role of RF3 on the transition in and out of B, 
kB(I+U) and k(I+U)B were calculated by combining U and I as an aggregated unbound 
state (Table 3-8). The result shows that both kB(I+U) and k(I+U)B increases as a function 
of RF3 concentration, suggesting that RF3 affects the occupancy of B.  
 
 








EC 10 0.768 ± 0.058 0.741 ± 0.077 0.51 ± 0.06 
aEC 
10 0.905 ± 0.034 1.299 ± 0.044 0.41 ± 0.02 
1 0.943 ± 0.04 0.569 ± 0.026 0.62 ± 0.04 
0.1 0.859 ± 0.058 1.268 ± 0.088 0.40 ± 0.04 
0.01 0.442 ± 0.027 0.850 ± 0.064 0.34 ± 0.03 
0 0.135 ± 0.008 0.370 ± 0.033 0.27 ± 0.03 
*Calculated by kU(B+I) /( kU(B+I) + kU(B+I)). 
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In contrast to I detected using Cy3-QSY9 smFRET signal, three-state time 
trajectories were not observed using Cy3-Cy5 smFRET signal. As a means of further 
supporting the observation of I, the concentration of RF2(QSY9) was lower from 1μM to 
10nM with 10μM RF3, a condition analogous to the Cy3-Cy5 smFRET experiments. The 
total number of observed three-state trajectories decreased dramatically as a function of 
RF2(QSY9) concentration. At 10nM RF2(QSY9), only 7 three-state trajectories were 
observed (Table 3-9), whereas no three-state time trajectories were observed using Cy3-
Cy5 smFRET signal. The kU(B+I) and k(B+I)U of the Cy3-QSY9 smFRET signal are 
compared with the kUB and kBU of the Cy3-Cy5 smFRET signal. The kBU of 0.61 
±0.05s-1 measured using RF2(Cy5) is in the same order of magnitude with the k(B+I)U of 
0.22 ±0.07s-1 measured using RF2(QSY9) on the aECs, suggesting that the B of the 
RF2(Cy5) is B+I of the RF2(QSY9). Since the energy transfer efficiency between the 
two chromophores can be affected by changes in parameters such as changes in the Cy3 
quantum yield or rotational anisotropy of either chromophore, the Ro of the Cy3-Cy5 and 
Cy3-QSY9 smFRET signals were estimated based on the overlap integral of the two 
spectral overlaps using a previously described method for fluorescence quencher 
chromophores97,99. The Ro of Cy3-Cy5 is estimated as 67Å and the Ro of Cy3-QSY9 is 
estimated as 56Å in the experimental Buffer M. Based on the EFRET of ~0.6 in I using 
Cy3-QSY9 smFRET signal, the estimated distance between Cy3 and QSY9 is ~52Å. 
Using this distance, the expect EFRET of I using Cy3-Cy5 smFRET signal is calculated as 
~0.82, which would be masked by the B with experimentally measured EFRET of ~0.84 
(Figure 2-8 D). This estimation provides a potential explanation of the lack of three-state 
trajectories in the Cy3-Cy5 smFRET data set. 









kU(B+I) (s-1) k(B+I)U (s-1) 
 3-state 
trajectories # 
1000 10 1.1 ±0.3 0.37 ±0.02  238 
100 10 0.35 ±0.10 0.27 ±0.04  40 
10 10 0.015 ±0.008 0.22 ±0.07  7 
 
 
3.4 Investigating the role of nascent polypeptide on the P-site tRNA on 
RF2 binding 
 
The polypeptide chain (PPC) attached to the P-site tRNA has been shown to play 
a role in enabling large-scale ribosomal conformational changes of TCs, involving a 
transition between a non-rotated and a rotated conformation of the large subunit relative 
to the small subunit 78.  By comparing the structure of an RF2-bound TC, which is in the 
non-rotated state, to the structure of the ribosomal complex in the rotated state, Jin et al 
showed that there are numerous steric clashes that would potentially interfere with RF2 
binding into the A site in the rotated state 90. Based on the measured peptide release rates, 
aECs in the steady-state smFRET assay likely consisted of a mixture of complexes with 
and without PPC attached to the P-site tRNA, whereas ECs consisted of almost 
exclusively complexes with PPC attached to the P site (Figure 3-2 and Table 3-4). 
Reasoning that peptide-dependent ribosomal conformational changes could possibly be 
relevant to the mechanism of post PT QC for aECs, the RF3-dependent and independent 
RF2 binding kinetics were evaluated by using conditions that allow direct comparison 
between ribosomal complexes that have PPC attached to the P-site tRNA and those that 
have released it. To do this, the PPC were artificially released using an antibiotic called 
puromycin, which mimics an aa-tRNA to catalyze peptidyl transfer and rapid dissociation 
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of newly form polypeptide, prior to the experiments and conversely prevented peptide 
release using a catalytically inactivated RF2 mutant with the GGQ motif mutated to GAQ 
64, RF2GAQ, during RF2 binding measurement experiments both in the absence or 
presence of RF3.  
3.4.1 RF2(QSY9) binding to puromycin-treated aECs 
 
The RF2 binding to aECs in the absence of PPC attached to the P-site tRNA were 
measured by pre-treating aECs with puromycin to release PCC prior to adding 1µM 
RF2(QSY9) and carrying out steady-state smFRET experiments analogous to other 
smFRET experiments. RF2(QSY9) binding to puromycin-treated aECs demonstrated a 
relatively similar kBU and kUB compared with the untreated aEC (Figure 3-6 and Table 
3-10), suggesting that presence or absence of PPC attached to P-site tRNA, with kBU of 
1.6 ±0.1s-1 and kUB of 0.31 ±0.04s
-1 versus kBU of 1.2 ±0.1s
-1 and kUB of 0.22 ±0.02s
-1 
respectively, has little to no effect on RF2 binding kinetics. Additionally, in the absence 
of RF3, the relative size of the two static binding subpopulations was unchanged (data 
not shown), suggesting that the heterogeneity did not arise from the presence or absence 
of PCC.  
The same experiment was repeated in the presence of 10µM RF3, no significant 
changes in the kU(B+I) and k(B+I)U, 2 ±1s
-1 and 0.17 ±0.04s-1 respectively, as well as no 
significant changes in the fraction of three-state time trajectories were observed (Figure 
3-7 and Table 3-10). These results indicate that, to the limits of the smFRET assay, RF2 
binding kinetics are insensitive to the absence of PPC attached to P-site tRNA. 
 





Figure 3-6 RF2 binding kinetics using inactive RF2GAQ(QSY9) and puromycin 
treatment. 
(A) Calculated aggregated on rates of 1μM RF2(QSY9) or 1μM RF2GAQ(QSY9)on 
puromycin-treated or untreated aECs in absence of RF3, the error bars represent 95% 
confidence interval; (B) Calculated aggregated off rates of 1μM RF2(QSY9) or 1μM 
RF2GAQ(QSY9) on puromycin-treated or untreated aECs in absence of RF3, the error 
bars represent 95% confidence interval. 
 
 
Table 3-10 Rates of Puromycin-Treatment and RF2GAQ(QSY9) on aECs  





RF2(QSY9) - - 1.6 ± 0.1 0.31 ± 0.04 
RF2(QSY9) - + 1.2 ± 0.1 0.22 ± 0.02 
RF2GAQ(QSY9) - - 2.5 ± 0.5 0.18 ± 0.02 
RF2GAQ(QSY9) - + 1.4 ± 0.2 0.17 ± 0.02 
RF2(QSY9) + - 0.17 ± 0.08 1.2 ± 0.4 
RF2(QSY9) + + 0.17 ± 0.04 2 ± 1 
RF2GAQ(QSY9) + - 0.29 ± 0.07 2 ± 1 
RF2GAQ(QSY9) + + 0.30 ± 0.06 2.1 ± 0.7 
 
3.4.2 RF2GAQ(QSY9) binding to ribosomal complexes is similar to RF2(QSY9) 
 
3.4.2.1 RF2GAQ(QSY9) mutant is defective in peptide hydrolysis but not binding to 
the TCs  
 
To further demonstrate that RF2(QSY9) binding in the A site is not dependent on 
the PPC-tRNA in the P site, a catalytically-inactive RF2GAQ mutant was conjugated with 
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QSY9, RF2GAQ(QSY9) 64. As previously reported, while this RF2GAQ mutant has 
insignificant peptide release activity, its ribosome binding activity does not appear to be 
greatly hindered based on a similar peptide release assay 64, thereby allowing us to 
observe RF2 binding in the presence of PPC attached to P-site tRNA. To confirm that the 
RF2GAQ preparation is indeed biochemically inactive, both RF2GAQ and RF2GAQ(QSY9) 
were tested with a radioactive dipeptide release assay as described in earlier section. Both 
RF2(GAQ) and RF2GAQ(QSY9) do not release peptide from TCs (data not shown). To 
demonstrate that RF2GAQ(QSY9) construct is not defective in binding TCs, its binding 
was characterized using the Cy3 spot counting assay as described above for RF2(QSY9). 
The result shows that 24%±0.5% of Cy3 signal was observed in the presence of 1μM 
RF2GAQ(QSY9), which is nearly identical to the ~34% observed with 1µM RF2(QSY9).  
3.4.2.2 Binding of RF2GAQ(QSY9) to the ECs and aECs 
 
The binding and dissociation of 1μM RF2GAQ(QSY9) were examined under 
steady-state smFRET experiments. In the absence of RF3, RF2GAQ(QSY9) showed 
negligible differences of both kBU and kUB, 2.5 ±0.5s
-1 and 0.18 ±0.02s-1 respectively, 
compared with RF2(QSY9) after release of PPC from the P-site tRNA by puromycin 
treatment as well as negligible differences in the overall fractional composition of the 
binding subpopulations (Figure 3-7 and Table 3-10). I am especially interested in 
showing the RF3-dependent effects on RF2 binding  prior to the release of PPC from the 
P-site tRNA, as if they do, then this would further support the proposal that the RF3 
effects, in particular, those associated with the binding intermediate, are likely on the 
pathway to peptide release. In the presence of 1μM RF2GAQ(QSY9) and 10μM RF3, 
minor differences in RF2 binding kinetics were observed with kU(B+N) and k(B+N)U of 2 
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±1 s-1 and 0.29 ±0.07 s-1 respectively, which is consistent with the idea that the RF3 
stabilizes an RF2 binding intermediate on pathway to peptide release and the PPC 
attached to the P-site tRNA has a minimal effect on RF2 binding kinetics even in the 
presence of RF3 (Figure 3-7 and Table 3-10). This result is further validated by 
examining the effect of RF3 on RF2GAQ(QSY9) binding to puromycin-treated aECs. As 
anticipated, the kU(B+N) and k(B+N)U of RF2
GAQ(QSY9) binding to puromycin-treated, 
2.1 ±0.7s-1 and 0.30 ±0.06s-1 respectively, and untreated aECs are again nearly identical 
(Figure 3-7 and Table 3-10).  
 
 
Figure 3-7 RF2 binding kinetics using inactive RF2GAQ(QSY9) and puromycin 
treatment in presence of RF3. 
(A) kU(B+I) (dark grey) of 1μM RF2(QSY9) or 1μM RF2
GAQ(QSY9) on puromycin-
treated or untreated mismatched complexes in presence of 10μM RF3 and 1 mM GTP, 
the error bars represent 95% confidence interval. (B) k(B+I)U (light grey) of 1μM 
RF2(QSY9) or 1μM RF2GAQ(QSY9) on puromycin-treated or untreated mismatched 
complexes in presence of 10μM RF3 and 1mM GTP, the error bars represent 95% 
confidence intervals. 
 
Based on these experiments, RF2 binding is insensitive to the absence or presence 
of the PPC attached to the P-site tRNA. The presence of the RF3-stabilized RF2 binding 
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intermediate is independent of PPC attached to the P-site tRNA, which also justify the 
RF2 binding kinetics measured in the previous steady-state experiments. Importantly, all 
these results are consistent with the idea that occupancy of B is necessary, but not 
sufficient, for catalyzing peptide release.  
3.5 Discussion 
 
3.5.1 Mechanistic role of RF3 in post PT QC pathway 
 
As a step toward understanding the post PT QC mechanism, especially the critical 
mechanistic role of RF3 in enhancing the RF2-mediated peptide release rate, the RF2 
binding to different ribosomal complexes were systematically characterized using both  
fMet-Lys-tRNALys(Cy3) to RF2(Cy5) and fMet-Lys-tRNALys(Cy3) to RF2(QSY9) 
smFRET signals. The RF2 binding kinetics to ECs and aECs, both in the absence and the 
presence of RF3, were directly measured. The lack of quantifiable RF2 binding to the 
EC, even at 2000 nM of excess RF2(QSY9), is consistent with previous biochemical 
experiments where peptide release on near-stop and sense codons were observed only at 
concentrations up to order of 100µM of RF1/294. On the other hand, the transient RF2 
binding to the aEC with a KD of ~5µM. Increased affinity for the A site of the aEC 
relative to the EC points toward differences of the A-site specificity of the two 
complexes. 
Using the tRNA-RF2 signal, I evaluated the effect of RF3 on RF2 binding to both 
ECs and aECs. A subset of Cy3-intensity versus time trajectories showing three states: B 
which is the bound state of RF2 to ribosomal complexes and is likely similar to that 
observed in RF2-bound TCs, U which is the unbound state, and I which is an RF3-
stabilized RF2 binding intermediate. The transitions into I precede both binding and 
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dissociation of RF2 as supported by quantifying the transition counts between B, U and I. 
Based on this kinetic pattern and the well-resolved EFRET of the three states, I is likely an 
RF2 binding intermediate that is on pathway from U to B and vice versa, but stabilized 
only in presence of RF3. Though the structure of this RF3-stablized RF2 binding 
intermediate cannot be directly deduced from the smFRET measurement, I could 
possibly be further characterized by structural techniques. 
Based on quantifying the occupancies and the rates of transitions of B, U and I, 
RF3 may play a role in both increasing RF2 affinity to ECs and aECs and in a post-
binding regulatory step for the aEC (Figure 3-8). To calculate the binding and 
dissociation of RF2(QSY9), B and I were combined as the RF2-bound state, B+I, and U 
as the unbound-state to calculate kU(B+I) and k(B+I)U. The overall effect of I results in 
observable RF2 binding to ECs and a 10-fold increase of kU(B+I) to aECs from 0.13 
±0.02s-1 in the absence of RF3 to 1.31 ±0.07s-1 in the presence of 10μM RF3. A potential 
interpretation of the role of RF3 in increasing the affinity of RF2 to ribosomal complexes 
is that there is a lower free energy barrier between U and the RF3-stablized RF2 
intermediate, I, than the free energy barrier between U and B. Therefore RF2 binding 
appears accelerated because it is easier for RF2 to directly enter I, which is a bound state, 
than it is for RF2 to directly enter B. RF3 also increases the occupancy of B in both ECs 
and aECs, which is a mechanistic role distinct from the effect of RF3 on RF2 affinity to 
ribosomal complexes. Based on comparison between the peptide release activity and the 
occupancy of B, there are at least three distinct conformations that are indistinguishable 
in B on both ECs and aECs (Figure 3-8): (i) a catalytically inactive state, which could be 
a result of either an unproductive ribosomal or an unproductive RF2 conformation, (ii) a 
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catalytically competent state, which is on pathway to peptide release, and (iii) a post-
peptide release ribosome with a deacylated P-site tRNA. While the A-site codon of the 
ECs and aECs both differ from the stop codons of the TC and the P-site codon-anticodon 
interaction is perturbed in the aEC, the X-ray crystallographic structures of RF2-bound 
TCs following peptide release5,57 are likely to have similar contacts and overall ribosomal 
and RF2 conformations to the post-peptide release state ECs and aECs, described as (iii). 
In the catalytically competent state (ii), RF2 is bound in the A site and likely has the 
domain 3 carrying the GGQ motif extended into the PTC. Furthermore, the 
conformations of both the PTC and RF2 are likely packed for optimal peptide release. In 
contrast to the conformation of (ii) and (iii), the catalytically inactive state, (i), could have 
a suboptimal RF2 conformation, such as incomplete extension of the domain 3 carrying 
GGQ motif toward the PTC, and/or an altered PTC conformation, such as improper 
packing of the P-site tRNA, either of which could make the conformation unable to 
hydrolyze peptide without altering the EFRET of B in the smFRET signals.  




Figure 3-8 Mechanistic model of the role of RF3 in post PT QC pathway 
(A) Cartoon showing proposed mechanistic model of RF2(QSY9) binding to EC in 
presence of RF3. (B) Cartoon showing proposed mechanistic model of RF2(QSY9) 
binding to aEC in presence of RF3. Asterisk represents catalytically competent 
complex. Dashed-line box includes indistinguishable structure with EFRET = 0.99. 
 
The entry into the catalytically inactive and catalytically competent states is likely 
regulated between ECs and aECs. On the aEC, transition into the catalytically competent 
state is favored over the catalytically inactive state (as indicated by the enlarged arrows in 
Figure 3-8 B). This preference is reversed on the EC (as indicated by the small arrows in 
Figure 3-8 A). A plausible explanation for this difference is that the perturbed codon-
anticodon interaction in the aEC may disrupt the ribosomal conformation or 
conformational dynamics in the PTC that normally prevents the release of the nascent 
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polypeptide chain from the P-site tRNA, whereas this barrier to peptide release remains 
intact with an undisrupted codon-anticodon interaction in the EC. Using the tRNA-RF2 
smFRET signal, I cannot distinguish if transition into the catalytically competent state 
can occur directly or if the transition into the catalytically competent state requires first 
transitioning into the catalytically inactive state (represented by the question mark in 
Figure 3-8). The RF3-stablized RF2 binding intermediate I could act as a regulatory 
point, facilitating more efficient sampling of B, thus leading to preferential sampling into 
the catalytically competent state on the aEC (Figure 3-8 B) and preferential sampling into 
the catalytically inactive state on the EC (Figure 3-8 A). Importantly, because RF3 effects 
on RF2 binding are insensitive to the presence or absence of a nascent polypeptide on the 
P-site tRNA, both the affinity and regulatory effects observed can occur on pathway to 
peptide release. 
3.5.2 Implication and future direction 
 
To further understand the post-binding regulatory steps, a new smFRET signal 
can be designed for detecting the differences between the catalytically competent and 
catalytically inactive states proposed in the models (Figure 3-8). I suspect these two states 
likely have both ribosomal conformational, especially P-site fMet-Lys-tRNALys, and RF2 
conformational differences. While the smFRET signal for detecting the ribosomal 
conformational change might be more convoluted and difficult to design, many studies 
have pointed to the possibility of a class 1 RF conformational change of the domain 
bearing the GGQ motif extending toward the PTC upon binding to a TC 62,82,84,85,116. The 
most notable study is the recent report of direct observation of this conformational 
change with free RF1 and RF1-bound to a TC85. Therefore, a potential design for such a 
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smFRET signal would be a signal between the P-site peptidyl-tRNA and a location in 
proximity of the GGQ motif, where the class 1 RFs are thought to have the largest protein 
conformational change relative to the core of class 1 RFs. 
In addition to enhancing RF2-mediated peptide release in post PT QC, RF3 also 
promotes dissociation of class 1 RFs from TCs in canonical translation termination. The 
RF2 binding intermediate identified in the presence of RF3 on both ECs and aECs, I, 
may play a functional role during recycling of class 1 RFs. Two mechanisms for how 
RF3 recycle the class 1 RFs have been proposed, where 1) recycling of class 1 RFs is 
achieved by transition from a non-rotate ribosome state to a rotated state, creating steric 
clashes with class 1 RFs, thus leading to their dissociation, or 2) recycling of class 1 RFs 
occurs by inducing dissociation of RFs, which then permit transition from the non-rotated 
ribosome state to a rotated state 50,78,86. If I can form on TCs, a reduced free energy 
barrier between the highly stable RF2-bound state on the TC and the RF binding 
intermediate state could promote the class 1 RF dissociation by providing a kinetic 
stepping stone for releasing the class 1 RFs. This hypothesis can be directly tested by 
demonstrating the existence of an RF3-dependent intermediate in context of RF2 
recycling using a setup similar to our smFRET signal in the future work.  
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In the ArfA-RF2 ribosome rescue pathway, the presence of both ArfA and RF2 
are required to catalyze peptide release from nTCs, which rescues the tightly associated 
nTCs allowing them to be recycled into the constitutive ribosomal subunits. It has been 
proposed that ArfA likely directly recruits RF2 to the A site of nTCs. However, the 
precise effect of ArfA on RF2 affinity to ribosomal complexes has not been directly 
demonstrated. In addition, the ArfA-RF2 pathway selectively catalyzes peptide release 
from nTCs with truncated mRNAs, in particular with an empty or partially empty A site, 
but not from ECs with full-length mRNA. I propose that ArfA stabilizes RF2 on nTCs, 
but not ECs, thereby promoting RF2-mediated peptide release on nTCs. To investigate 
the role of ArfA on RF2 binding, a P-site fMet-Phe-tRNAPhe(Cy3) to RF2(Cy5) smFRET 
signal is used to directly monitor RF2 affinity for nTCs and ECs in absence and presence 
of ArfA. 
4.2 Monitoring the effect of ArfA on RF2(Cy5) binding 
4.2.1 ArfA enhances RF2-mediated peptide release on nTCs 
 
As demonstrated in Chapter 2, RF2 alone does not catalyze peptide release on 
nTCs or ECs based on a dipeptide release assay. Using the same experimental condition, 
1 minutes incubation and 37°C, in the presence of 1µM ArfA, the total amount of fMet-
Phe dipeptide released of 54.84±0.02% is higher than nTC with RF2 alone, EC with RF2 
                                                 
3 Bridget Huang performed all of the smFRET and biochemical experiments. Bridget Huang and Jason Hon 
performed the data analysis of the smFRET experiments. 
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alone and EC with both RF2 and ArfA (Figure 4-1 A and B). This result suggests that 
ArfA leads to RF2-mediated peptide release on nTCs, similar to the results reported by 
Kurita et. al and Zeng and Jin42,44. The maximum fMet-Phe dipeptide released is in good 
agreement with the reported ~7pmol out of 13pmol (~54%)42. Notably, this experimental 
condition is similar to the dipeptide release assay performed on TCs described in Chapter 
2, and the result indicates that, in the presence of both RF2 and ArfA, the rate of peptide 
release from nTCs might be comparable to that observed from TCs. Using condition 
analogous to the smFRET experiment, the peptide release activity of 10nM RF2(Cy5) in 
absence or presence of 1μM ArfA at room temperature after five minutes incubation was 
examined. The total fMet-Phe dipeptide released in the presence of ArfA is 44.49±0.02%, 
which is similar to the result obtained using wtRF2 (Figure 4-1 C). 




Figure 4-1 fMet-Phe dipeptide release catalyzed by RF2 and ArfA. 
(A) an eTLC image showing separation of fMet and fMet-Phe of fMet-Phe dipeptide 
release catalyzed by wtRF2 at one minute and 37°C. (B) Quantification of the 
percentage of total radioactive fMet-Phe released, the error bars represent the 
uncertainly of eTLC quantification. (C) Quantification of the percentage of total 
radioactive fMet-Phe released by 10nM RF2(Cy5) or 10nM RF2(Cy5) and 1μM ArfA 
at 5 minutes and room temperature, the error bars represent the uncertainly of eTLC 
quantification. 
 
4.2.2 ArfA stabilizes RF2(Cy5) on nTCs 
 
The binding and dissociation of RF2(Cy5) were monitored using the fMet-Phe-
tRNAPhe(Cy3) to RF2(Cy5) smFRET signal. Three ribosomal complexes were prepared: 
1) a TC with P-site fMet-Phe-tRNAPhe(Cy3) and A-site UAA stop codon (Figure 4-2 A), 
2) an nTC with P-site fMet-Phe-tRNAPhe(Cy3) and a vacant A site (Figure 4-2 B), 3) an 
EC with P-site fMet-Phe-tRNAPhe(Cy3) and A-site AAA sense codon (not shown). 
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Steady-state smFRET experiments were performed using surface-immobilized ribosomal 
complexes with 10nM RF2(Cy5) without ArfA (described in Chapter 2) and with 1µM 
ArfA for nTC and EC. 
As expected, RF2(Cy5) binds stably to TCs, and remains associated with TC to 
the limit of the smFRET experimental setup. This result is consistent with previously 
reported RF1(Cy5) binding to TC carrying fMet-Phe-tRNAPhe(Cy3), where the 
measurement of the lifetime of RF1(Cy5) on TC is limited by photobleaching of Cy5 
fluorophore78. A representative Cy3/Cy5 intensity versus time trajectory and the 
calculated EFRET versus time trajectory are shown in Figure 4-2 A.  
To visualize the time evolution of the population FRET, two-dimensional surface 
contour plots of both RF2(Cy5)-bound TC and RF2(Cy5) and ArfA- bound nTC were 
prepared using smFRET data set collected in presence of 10nM RF2(Cy5) (Figure 4-2 C). 
A small fraction of time trajectories demonstrated transient binding and dissociation of 
RF2(Cy5), which is suspected to originate from heterogeneous preparation of the TCs 
(Figure 4-2 C, left). This was confirmed to be distinct from Cy5 photoblinking by 
imaging TCs following washing out the RF2(Cy5), after which this population was not 
observed (Figure 4-2 D, left). Under steady-state conditions, RF2(Cy5) is already bound 
to TCs at the beginning of data collection and remain stably-bound to TCs until 
photobleaching of the Cy5 fluorophore; therefore, the TDP reports on nearly no transition 
in this data set.  




Figure 4-2 the role of ArfA on RF2(Cy5) binding 
(A) Cartoon representation of RF2(Cy5) bound to TC with a representative example of 
Cy3 and Cy5 intensity (green and red lines) versus time trajectory and estimated EFRET 
(blue line) versus time trajectory in the presence of 10nM RF2(RF2) on TC. (B) 
Cartoon representation of RF2(Cy5) and ArfA bound to nTC with a representative 
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example of Cy3 and Cy5 intensity (green and red lines) versus time trajectory and 
estimated EFRET (blue line) versus time trajectory in the presence of 10nM RF2(RF2) 
and 1µM ArfA on nTC. (C) Post-synchronized two-dimensional surface contour plots 
of the time evolution of the population FRET by the individual binding event, collected 
in the presence of 10nM RF2(Cy5) on TC, or 10nM RF2(Cy5) and 1µM ArfA on nTC. 
The N values represent the total number of calculated EFRET versus time trajectories 
that were used to construct the histograms. (D) Post-synchronized two-dimensional 
surface contour plots of the time evolution of the population FRET by the individual 
binding event, collected after washing out 10nM RF2(Cy5) on TC, or 10nM RF2(Cy5) 
and 1µM ArfA on nTC. The N values represent the total number of calcualted EFRET 
versus time trajectories that were used to construct the histograms. 
 
As described in Chapter 2, RF2(Cy5) affinity for both nTCs and ECs is extremely 
limited with 10nM RF2(Cy5). Out of 12714 Cy3 signals, only 4 FRET trajectories were 
observed on nTCs, and no FRET trajectory was observed between fMet-Phe-
tRNAPhe(Cy3) and RF2(Cy5) on ECs. This observation is consistent with the lack of 
RF2-mediated peptide release observed in the dipeptide release assay. In the presence of 
10nM RF2(Cy5) and 1µM ArfA on ECs, 3 out of 12482 Cy3 signals showed FRET, 
suggesting that ArfA does not affect RF2(Cy5) binding to ECs. Intriguingly, under the 
same condition with 10nM RF2(Cy5) and 1µM ArfA on nTCs, the RF2(Cy5) affinity 
differs dramatically from ECs. The number of observed FRET trajectories observed from 
nTCs in the presence ArfA was significant, 105 out of 13039 Cy3 signals showed FRET 
with no fluctuations between FRET states. More importantly, RF2(Cy5) is stabilized on 
nTCs in the presence of 1µM ArfA, as shown by the representative Cy3/Cy5 intensity 
versus time trajectory and the corresponding EFRET versus time trajectory in Figure 4-2 B. 
The time evolution of the population FRET surface contour plot of nTC in the presence 
of RF2(Cy5) and ArfA (Figure 4-2 C, right) appear similar to the plot of TC in the 
presence of RF2(Cy5) (Figure 4-2 C, left). While the photobleaching time of the 
RF2(Cy5) on TCs and RF2(Cy5), ArfA on nTCs are different, the data likely reflect 
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stably bound RF2(Cy5) in both contexts. Therefore, in the presence of ArfA, RF2 binds 
to nTCs as though they contained a stop codon, showing binding events which, to the 
limits of my assay, were indistinguishable from those observed on TCs under similar 
conditions. 
To demonstrate that RF2(Cy5) is indeed stably associated to both TCs and nTCs, 
the excess RF2(Cy5) and/or ArfA were washed out the with imaging buffer (Figure 4-2 
D, right). With no excess RF2(Cy5), both TCs pre-exposed to RF2(Cy5) and nTCs pre-
exposed to both RF2(Cy5) and ArfA demonstrated stable RF2(Cy5) binding, similar to 
the population observed in the presence of excess labeled RF2(Cy5) (Figure 4-2 D). This 
result suggests that not only that RF2(Cy5) is stably bound to TCs and nTCs, but 
additionally that the two complexes are stable enough to resist washing with buffer. The 
stabilization of RF2(Cy5) on nTCs, but not ECs, confirms the hypothesis on the 
mechanistic role of ArfA in the ribosome rescue pathway.  
4.3 Discussion 
 
4.3.1 Mechanistic role of ArfA in ribosome rescue pathway 
 
As a step toward understanding the mechanistic role of ArfA in ArfA-RF2 
ribosome rescue pathway, the effect of ArfA on the RF2 binding to nTCs and ECs were 
examined using fMet-Phe-tRNAPhe(Cy3) to RF2(Cy5) smFRET signal. Under steady-
state experimental condition with 10nM RF2(Cy5), limited RF2(Cy5) binding to nTCs 
and ECs were observed. Presence of both 10nM RF2(Cy5) and 1µM ArfA did not 
significantly improve the RF2(Cy5) binding to ECs. In contrast, ArfA dramatically 
stabilizes RF2(Cy5) binding to nTCs. The observed time trajectories were comparable to 
those observed on RF2(Cy5) binding to TCs. 




Figure 4-3 Mechanistic model of the role of ArfA in ribosome rescue pathway 
(A) Cartoon showing proposed mechanistic model of RF2(Cy5) binding to EC in 
presence of ArfA. (B) Cartoon showing proposed mechanistic model of RF2(Cy5) 
binding to nTC in presence of ArfA. Asterisk represents catalytically competent 
complex. Dashed-line box includes indistinguishable structure with EFRET = 0.99. 
 
On the basis of the smFRET results and previous biochemical studies, the 
mechanistic models of the role of ArfA on RF2 binding to nTCs and ECs are proposed 
(Figure 4-3). Based on the binding site of ArfA near the mRNA channel and the tight 
dissociation constant of ~30nM42, ArfA likely associates with both nTCs and ECs prior to 
RF2 binding. However, the effect of ArfA on nTCs and ECs differs dramatically. To the 
limits of the smFRET experiments, ArfA does not stabilize RF2 on ECs (Figure 4-3 A). 
Based on the mechanism of canonical termination, a post-binding regulatory step likely 
exists in the ArfA-RF2 mechanism, thereby preventing promiscuous peptide release even 
if RF2 transiently associates with ECs (as indicated by the dotted box in Figure 4-3). In 
contrast, ArfA greatly stabilizes RF2 binding to nTCs (as indicated by the small arrow of 
RF2 dissociation in Figure 4-3 B). This stabilization effect on RF2 leads to smFRET 
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trajectories that resemble RF2 binding to canonical TCs. I suspect that ArfA may also 
accelerate the post-binding regulatory step, leading to efficient RF2-mediated peptide 
release (as indicated by the enlarged arrow with a question mark in Figure 4-3 B). 
Therefore, similar to the models proposed in Chapter 3, the RF2(Cy5)-bound state is 
consisted of at least three indistinguishable conformations in the fMet-Phe-tRNAPhe(Cy3) 
to RF2(Cy5) smFRET signal: (i) a catalytically inactive state, which could be a result of 
either an unproductive ribosomal or an unproductive RF2 conformation, (ii) a 
catalytically competent state, which is on pathway to peptide release, and (iii) a post-
peptide release ribosome with a deacylated P-site tRNA. Taken together, ArfA plays a 
role in stabilizing RF2 on nTC, which simulate RF2 binding to TCs, and may also 
contribute to a post-binding regulatory step in ribosome rescue pathway in bacteria.  
4.3.2 Future direction 
 
It remains elusive on what conformational changes in the structure of ArfA 
regulate RF2 binding to nTCs and ECs, but such changes must be required because 
sedimentation experiments revealed that ArfA binds to both nTCs and ECs42. As 
previously proposed by both Kurita et. al and Zeng and Jin42,44, selection of a specific 
ArfA conformation might be responsible for the recruitment of RF2 on nTCs. However, 
it is unclear if ArfA conformation is directly responsible for the effect on RF2 affinity, or 
other factors, such as the presence of full-length mRNA in the A site, may play a role as 
well. Specifically, ArfA may have two conformations on ribosomal complexes, one 
conformation responsible for stabilizing RF2, such as the one on nTCs and likely mimics 
the effect of a stop codon, and the another conformation which does not promote RF2 
binding, such as the one on ECs. In an alternative mechanism, ArfA could have the same 
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conformation regardless of the ribosomal complexes, but the truncated or full-length 
mRNA in the A site directly influences RF2 binding. A potential design to distinguish the 
two mechanisms is the use of dual-fluorescently labeled ArfA for direct detection of 
ArfA conformation on nTCs and ECs. Based on the dissociation constant of ~30nM, 
ArfA has a high probability of stably associate with both nTCs and ECs in the designed 
smFRET experiment. An atomic-resolution structure of an ArfA-bound ribosomal 
complex would provide further insight on the smFRET signal design for detecting ArfA 
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Chapter 5  Materials and methods 
 
5.1 Preparation and Assessment of Reagents 
 
5.1.1 Preparation of Ribosome 
The tightly-coupled 70S ribosomes used in the studies were purified using a standardized 
protocol in the Gonzalez lab. The purified 70S is then tested using a radioactive tripeptide 
formation assay to access the quality. 
 
5.1.1.1 Purification of MRE600 Ribosomes 
The wild-type E. coli ribosome from MRE600 strain were purified using the standard 
protocol in the Gonzalez lab based on previously published procedure117,118,119. The 
following is a copy of the standardized protocol in the lab, originally prepared by 
Professor Ruben Gonzalez 2006. 
 
Materials 
MRE600 bacterial strain: original stock is RG70 from Profesor Ruben Gonzalez, no 
antibiotic resistance 
Buffer A (for cell harvest and lysis): 20 mM Tris-HCl (pH4°C =7.2), 100 mM NH4Cl, 10 
mM MgCl2, 0.5 mM EDTA and 6 mM BME 
Buffer B (for sucrose cushion): 20 mM Tris-HCl (pH4°C =7.2), 500 mM NH4Cl, 10 mM 
MgCl2, 0.5 mM EDTA, 37.7% sucrose and 6 mM BME 
Buffer C (for 70S resuspension): 20 mM Tris-OAc (pH4°C =7.5), 60 mM NH4Cl, 7.5 mM 
Mg(OAc)2, 0.5 mM EDTA and 6 mM BME 
SW28 Gradients 10%-40%: 
 1. All solutions must be at room temperature. 
 2. Add 52.5 L BME to 125 ml 10% sucrose solution. 
 3. Add 52.5 L BME to 125 ml 40% sucrose solution. 
 4. Prepare six SW28 tubes by marking using the aluminum holder. 
 5. Pipet 20 ml 10% sucrose solution into each tube. 
6. Using syringe with needle, place 40% sucrose solution underneath 10% 
sucrose solution until the interface between solutions reaches the mark line 
(~19 ml). 
 7. Close tubes with rubber caps carefμlly to expel all air. 
 8. Level Biocomp Gradient Master. 
 9. Set Gradient Master: 
  SW28 short sucrose 10-40% wv 
  step 1 of 2 6:00/52.0°/25 rpm 
  step 2 of 2 0.07/76.0°/25 rpm 
 10. Chill gradients to 4°C in cold room for at least 3 hours. 
10X AEBSF: (Sigma A-8456) 180mM AEBSF aqueous solution (MW=239.7g/mol) 
10X Bestatin: (Sigma B-8385) 17mM bestatin in 50% DMSO 
10X Pepstatin A: (Sigma P-4265) 2.9mM pepstatin A in 100% DMSO 
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10X E-64: (Sigma E-3132) 2.2mM E-64 in 50% DMSO 
RNase inhibitor: (NEB M0307L) 
60% Surcorse Solution: w/v, 600g sucrose in final of 1L water, filtered 
 
Protocol 
1) Grow 5 mL MRE600 culture in LB medium without antibiotic at 37 °C for overnight  
2) Inoculate 3 mL of overnight culture to each liter of 2 L fresh TB medium grow at 
37 °C until the OD600nm gets to 0.5 
3) Rapidly cool the cells down to 4 °C on ice in cold room (~1 hour) 
4) Spin down in JA-10 rotor at 5500g for 10 min at 4°C, repeat to spin down all culture 
5) If necessary, freeze pellets in liquid nitrogen and store at -80°C 
6) Add 20 mL Buffer A to frozen pellet     
7) Thaw and resuspend cells with 25 mL pipette 
8) Add 100 μL of each protease inhibitor (10X AEBSF, 10X Bestatin, 10X Pepstatin A, 
10X E-64) and 1000U of RNase inhibitor 
9) Rinse French press with NanoPure H2O 
10) Lyse cells with pressure 1100 psi twice 
11) Collect lysate into JA-17 tube with another 1000U RNase inhibitor added 
12) Spin in JA-17 rotor at 12800 RPM for 15 min at 4°C 
13) Load 8-9 mL of clear supernatant onto each 15 mL Buffer B sucrose cushion. 
14) Spin the sucrose cushion in Ti 70 fixed-angle rotor, centrifuge at 33000 RPM for 22h 
at 4 °C, using maximum acceleration and deceleration. 
15) Discard supernatant, circle ribosome pellets with a marker on the tubes, invert Ti70 
tubes on clean paper towel in cold room, allow to drain for 10 min 
16) Add ~ 1 mL Buffer C to pellet (may adjust depending on the pellet size), place tube at 
an angle on the rotary shaker in cold room, rotate for 2-6 h until resuspended or 
simply leave them in the cold room for overnight. 
17) Measure the ribosome concentration at A260 with 1:1000 fold dilution in H2O (1 
A260 unit = 1/15 mg/mL or 1 A260 unit = 20 nM) 
18) Making SW28 Gradients with Buffer C (see Materials) 
19) Apply ~ 15 mg resuspended ribosomes per gradient, and carefμlly balance the 
centrifuge tubes with swing buckets SW28 rotor to the same weight (with ± 0.01 g 
accuracy), use all six buckets 
20) Spin in SW28 rotor at 22000 rpm for 17 h at 4°C, with minimum acceleration and no 
break for deceleration.     
21) Analyze gradients using the following parameters: 
 wavelength = 260 nm 
 pathlength = 5 mm 
 sensitivity = 2.0 
 flow rate = 3.0 mL/min 
 chart speed = 30 cm/h 
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 reference cell = H2O 
 min open 
 
22) Collect 70S peak from each gradient (volume collected ~8 mL per gradient) 
23) Place the collected 70S in Ti70 tubes, fill tubes with Buffer C (-sucrose) 
24) Spin in Ti70 rotor at 45000 rpm for 20 h 
25) Discard supernatant, circle ribosome pellets with a marker on the tubes, invert Ti70 
tubes on clean paper towel in cold room, allow to drain for 10 min 
26) Add ~500μl-1000μl Buffer C to each pellet (may adjust depending on the pellet size), 
place tube at an angle on the rotary shaker in cold room, rotate for 2-3 h until 
resuspended  
27) Measure the ribosome concentration at A260 with 1:1000 fold dilution in H2O (1 A260 
unit = 1/15 mg/mL or 1 A260 unit = 20 nM) 
28) Making SW28 Gradients with Buffer C (see Materials) 
29) Apply ~ 7-8 mg resuspended ribosomes per gradient, and carefμlly balance the 
centrifuge tubes with swing buckets SW28 rotor to the same weight (with ± 0.01 g 
accuracy), use all six buckets 
30) Spin in SW28 rotor at 22000 rpm for 17 h at 4°C, with minimum acceleration and no 
break for deceleration.     
31) Analyze gradients using the following parameters: 
 wavelength = 260 nm 
 pathlength = 5 mm 
 sensitivity = 2.0 
 flow rate = 3.0 mL/min 
 chart speed = 30 cm/h 
 reference cell = H2O 
 min open 
 
32) Purified 70S ribosomes can be flash frozen in liquid nitrogen and stored in -80 °C. 
5.1.1.2 Assessment of Ribosome by tripeptide formation Assay 
The quality of purified wild-type ribosome is assessed by a radioactive tripeptide 
formation assay. A common number is the lab is ~60-70% tripeptide formation at 10s. 
The endpoint of the reaction is typically ~70% in a fully optimized system. The size of 
the tripeptide formation reaction can be adjusted as needed.  
 
Materials 
5X initiation polymix: 250mM Tris-OAc, pHRT=7.0, 500mM KCl,  
25mM NH4OAc, 2.5mM Ca(OAc)2, 25mM Mg(OAc)2, 0.5 mM  EDTA, 25mM 
Putresciene-HCl, 5mM Spermidine (Free Base) and 30mM BME 
1X initiation polymix buffer: 50mM Tris-OAc, pHRT=7.0, 100mM KCl,  
5mM NH4OAc, 0.5mM Ca(OAc)2, 5mM Mg(OAc)2, 0.1 mM  EDTA, 5mM Putresciene-
HCl, 1mM Spermidine (Free Base) and 6mM BME 
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1X Buffer 6: 50mM Tris-OAc, pHRT=7, 100mM KCl, 50mM NH4OAc, 0.5mM 
Ca(OAc)2, 0.1mM EDTA, 5mM Mg(OAc)2 and 6mM BME 
1X translocation polymix: 50mM Tris-OAc, pHRT=7.0, 100mM KCl,  
5mM NH4OAc, 0.5mM Ca(OAc)2, 10mM Mg(OAc)2, 0.1 mM  EDTA, 5mM 
Putresciene-HCl, 1mM Spermidine (Free Base) and 6mM BME 
GTP solution: (Sigma G8877) prepared as 50mM solution in water, adjust to pHRT~7 
with 1M KOH, filtered  
Cellulose TLC plates: (EMD Millipore 1055770001)  
Stoddard Solvent: (VWR EM-SX0995-1) 




Making Ribosomal Complex: 
1) Tight-coupled 70S pre-initiation mix 
vol (μl)     cocn(uM) 
amt 
(pmol) 
9.00  70S 3 27 
0.32   IF1 110 35 
0.27  IF2 99 27 
0.17   IF3 206 35 
0.40  GTP 50mM  
5.00   
5X initiation 
polymix     
0.84   H2O     
16.00     
10min 37°C, then keep at RT 
 
2) 70S Complex Formation 
vol 





70S   
0.49   mRNA  110 54 
0.51  S35 fMet-tRNA 28.5 14.5 
8.00   H2O     
25.00     
20min 37°C, then keep on ice 
 
3) 10mM GTP Charging Mix 
vol 
(μl)     cocn(uM) 
amt 
(pmol) 
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3  1x Buffer 6   
1   GTP 50mM   
0.5  Phosphoenolpyruvate 0.3M  
0.5   pyruvate kinase     
5     
 
4) EF-Tu/EF-Ts Mix 
vol 
(μl)     cocn(uM) 
amt 
(pmol) 
2.62  Ef-Tu 110 288 
2.12   EF-Ts 101 214 
5.26   1X Buffer 6     










mix   
2  
GTP charing 
mix    
6   1X Buffer 6     
18     
 









Tu(GTP)/EF-Ts   
1.81   Lys-tRNALys 19.9 36 
1.53   Phe-tRNAPhe 23.5 36 
2.66   1X Buffer 6     
24.00     
 
1min 37°C, then 1min on ice 
 
7) EF-G Mix 




(μl)     cocn(uM) 
amt 
(pmol) 
0.40  EF-G 136 54 
0.41  
GTP Charing 
mix     
3.19   1X translocation polymix   
4.00     
 
8) PheT3/LysT3 Delivery and EF-G Translocation 
vol 
(μl)     cocn(uM) 
amt 
(pmol) 
25.00  70S Complex   
4.00  EF-G    
24.00  PheT3/EF-Ts    
53     
Taking time points quenched with 1M KOH at 0s, 15s, 30s, 60s, 5min 
9) Store the sample in -80 or proceed to the next section 
Visualization and quantitation of tripeptide with eTLC: 
1) Trim one side of the eTLC plates off by ~1.5cm to allow the plate to fit inside the 
eTLC running tanks 
2) Mark the center of the eTLC plate with a pencil  
3) Using a pipette, spot ~0.4μl-1μl of the time course samples alone the center of the 
eTLC plates, leaving at least 0.5cm space between each spot 
4) Allow the spots to air dry until invisible (~5min) 
5) Place a plastic serological pipet at the top edge of the eTLC, parallel to the spots, use 
a p1000 pipette, drip 1ml-2ml eTLC running buffer near the serological pipet 
6) Slowly roll the running buffer down using the serological pipet until buffer is near the 
sample spots, but not touching 
7) Allow running buffer to slowly diffuse to the sample spots 
8) Repeat step 5-7 for the bottom edge of the eTLC plate 
9) Allow the running buffer to diffuse and cover the entire eTLC plate 
10) Insert the eTLC plate into the eTLC running tank, containing eTLC running buffer at 
the bottom layer and Stoddard Solvent on the top layer. Note down the direction of 
electric flow. 
11) Run the eTLC at constant voltage of 1200V for 30min 
12) After turning off the power and unplug the wire, remove the eTLC plate and allow the 
plate to air dry completely in a fume hood 
13) Wrapped the dried eTLC plate with plastic wraps completely and expose to a 
phosphorimaging screen overnight 
14) Scan the phosphorimaging screen with Typhoon scanner 
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15) Analyze the production of tripeptide over time with ImageQuant software. 
5.1.2 Preparation of tRNAs 
The uncharged tRNAs are typically purchased from commercial sources with the 
exception of tRNALys due to the need of large quantity and high purity. The tRNAs are 
aminoacylated or fluorescently labeled, then aminoacylated.  
 
5.1.2.1 Preparation of fMet-tRNAfMet 
The protocol for aminoacylation and formylation of tRNAfMet is originated from 
Professor Ruben Gonzalez’s postdoctoral work and Dr. Margaret Elvekrog’s protocol. 
The procedure incudes preparation of 5:10-methenyltetrahydrofolate (5:10 MTHF), 
which can be stored at -20/-80°C. 10N-formyltetrahydrofolate (THF) is prepared fresh 
prior to each aminoacylation reaction. 
 
Materials 
N-Formylmethionine-specific transfer ribonucleic acid from E. coli MRE600: (MP 
Biomedical, cat #: 0219915450)  
5X AF buffer: 250 mM Tris-HCl (pH37°C=7.5), 35 mM MgCl2, 750 mM KCl, 0.5 mM 
EDTA, 5 mM DTT and 12.5 mM ATP 
Methionyl tRNA synthetase (MetRS): overexpression vector provided by Prof. Sylvain 
Blanquet (CNRS-Ecole Polytechnique, Palaiseau Cedex, France), preparation outlined in 
reference108. 
formylmethionyl-tRNA formyltransferase (transformylase): overexpression vector 
provided by Prof. Sylvain Blanquet (CNRS-Ecole Polytechnique, Palaiseau Cedex, 
France), preparation outlined in reference108. 
 
Protocol 
Preparation of 5:10-methenyltetrahydrofolate (5:10 MTHF) 
1) Dissolve folinic acid in 50mM BME to make ~24mM solution (example: 25mg of 
folinic acid in 2ml of 50mM BME, 6.99μl BME+ 1993.01μl nanopure water) in a 
15ml Falcon tube 
2) Treat the solution with 220μl 1M HCl 
3) Incubate at 37°C for 3 hours (make sure to resuspend precipitants) 
4) Check the formation of 5:10-methenyltetrahydrofolate (MTHF) by A355nm UV-Vis 
reading by dilution 1:1000 in water (355 nm = 25 x 10
3 M-1cm-1 for 5:10-MTHF) 
5) Dilute with 0.1M HCl until ~15mM final concentration of 5:10-MTHF 
6) Aliquots and store at -20/-80C. 
Aminoacylation and formylation of tRNAfMet 
1) Before use, warm aliquot to room temperature, neutralize with 20 mol KOH and 
10 mol Tris-HCl, pHrt=7.8 (10 L 5:10 MTHF + 1 L 1 M KOH + 0.5 L Tris-
HCl) and incubate at room temperature for 15 minutes to generate 10N-
formyltetrahydrofolate. 
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43.5 mM Tris-HCl, pH 7.6 1000 mM 0.50 
86.9 mM KOH  1000 mM 1.00 
13 mM 5:10 MTHF  15 mM 10.00 
      11.50 
Incubate at room temperature for 15 minutes. The final reagent should be 
transparent/clear and not yellow. 
2) Reaction chemistry: 
conc. unit chemical   
stock 
conc. unit volume (µl) 
1 X 1X AF buffer 5 X 10.00 




(Met)   1000 µM (1mM) 4 
300 µM THF  12000 µM  1.25 
    H2O       25.84 
0.02 µM MetRS  6.9 µM 0.14 
0.2 µM Transformylase 6.6 µM 1.52 
      50.00 
Incubate at 37°C for 10 minutes. 
 
3) Quench the reaction with 0.1X total volume of 3M NaOAc, pHRT=5 
4) Extract the reaction mixture with equal volume of cold phenol (pH=6.7), keep the 
upper aqueous layer 
5) extract the aqueous layer with equal volume of chloroform, keep the upper aqueous 
layer 
6) add 4X volume of 100% ethanol, mix well and precipitate for 1 hour at -80°C 
7) spin down the precipitation at 18,000g at 4°C for 30min 
8) remove the supernatant carefully and keep the white precipitant 
9) resuspend the pellet in 30-70µl of 10mM KOAc (pH 5) 
10) buffer exchange a Micro Bio-Spin 6 column with 10mM KOAc (pH 5) 
11) buffer exchange the suspension by applying to the Bio-Spin 6 column  
12) aliquot and flash freeze the final product in liquid nitrogen and store at -80°C 
Assessing the aminoacylation and formylation yield 
1) Determine the concentration of the tRNAfMet by UV-Vis absorbance at 260nM. The 
extinction coefficient for tRNAfMet is 726,700 M-1cm-1 at 260 nm. 
2) The yield is determined by separation of each species by hydrophobic interaction 
chromatography (HIC) with the following buffers: 
tRNA HIC Buffer A:  1.7 M NH4SO4 
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    10 mM NH4OAc, pH 6.3* 
tRNA HIC Buffer B: 10% Methanol 
    10 mM NH4OAc, pH 6.3* 
 
*Note that this is the pH of the 1 M NH4OAc stock solution, not the final HIC 
Buffer pH. The final solution does not need to be pH adjusted. The tRNA HIC 
buffers should be filtered and chilled prior to use. 
3) Dilute 0.1nmoles of fMet-tRNAfMet (minimal quantity needed, load larger quantity 
for more sensitive detection) with 60-70 µL of tRNA HIC Buffer A 
4) The chromatograph should show peaks at: 
Elution volume % Buffer B Identity 
~12mL ~12% tRNAfMet 
~15mL ~15% Met-tRNAfMet 
~22mL ~25% fMet-tRNAfMet 
  
5.1.2.2 Preparation of Phe-tRNAPhe 
 
Materials 
5X charging buffer: 500 mM Tris-HCl (pH37°C=7.5), 25 mM MgCl2, 750 mM KCl, 2.5 
mM EDTA, 5 mM DTT and 12.5 mM ATP  
Ribonucleic acid, transfer, phenylalanine specific from E. coli MRE 600: (Sigma-
Aldrich, R3143) 
Phenylalanyl tRNA synthetase (PheRS): overexpression vector provided by Prof. David 




Aminoacylation of tRNAPhe 
1) Reaction: 





200 mM Tris-HCl, pH=7.5 1 M 20.00 
25 mM KCl   2 M 1.25 
15 mM MgCl2  1 M 1.50 
2 mM BME   1 M 0.20 
5 mM ATP  0.1 M 5.00 
10 mM PEP   0.3 M 3.33 
12 µg  pyruvate kinase 25 mg/ml 0.48 
15 µM tRNAPhe   84.3 µM 17.79 
56 µM L-phenylalanine 2 mM 2.80 
    H2O       42.43 
0.75 µM PheRS   14.4 µM 5.21 
            100 




 Incubate at 37°C for 10min. 
2) Quench the reaction with 0.1X total volume of 3M NaOAc, pHRT=5 
3) Extract the reaction mixture with equal volume of cold phenol (pH=6.7), keep the 
upper aqueous layer 
4) extract the aqueous layer with an equal volume of chloroform, keep the upper 
aqueous layer 
5) add 4X volume of 100% ethanol, mix well and precipitate for 1 hour at -80°C 
6) spin down the precipitation at 18,000g at 4°C for 30min 
7) remove the supernatant carefully and keep the white precipitant 
8) resuspend the pellet in 30-70µl of 10mM KOAc (pH 5) 
9) buffer exchange a Micro Bio-Spin 6 column with 10mM KOAc (pH 5) 
10) buffer exchange the suspension by applying to the Bio-Spin 6 column  
11) aliquot and flash freeze the final product in liquid nitrogen and store at -80°C 
Assessing the aminoacylation yield using FPLC 
1) Determine the concentration of the tRNAPhe by UV-Vis absorbance at 260nm. The 
extinction coefficient for tRNAPhe is 260nm = 760000 M-1cm-1 
2) The yield is determined by separation of each species by hydrophobic interaction 
chromatography (HIC) with the following buffers: 
tRNA HIC Buffer A:  1.7 M NH4SO4 
    10 mM NH4OAc, pH 6.3* 
tRNA HIC Buffer B: 10% Methanol 
    10 mM NH4OAc, pH 6.3* 
 
*Note that this is the pH of the 1 M NH4OAc stock solution, not the final HIC 
Buffer pH. The final solution does not need to be pH adjusted. The tRNA HIC 
buffers should be filtered and chilled prior to use. 
3) Dilute 0.1nmoles of fMet-tRNAfMet (minimal quantity needed, load larger quantity 
for more sensitive detection) with 60-70 µL of tRNA HIC Buffer A 
4) The chromatograph should show peaks at: 
Elution volume % Buffer B Identity 
~25mL ~25% tRNAPhe 
~31mL ~30% Phe-tRNAPhe 
 
 
5.1.2.3 Purification of tRNALys 
This method is modified based on previously published protocol by Yokogawa et al109. 
The protocol provided is for small scale preparation. To purify a large quantity of 
tRNALys, the scale is increased by approximately 6-8 times (6-8 tubes of 200μl of beads) 
and repeating the binding and elution step for 4-5 times using the same tRNA 
flowthrough pool. 





tRNA from E. coli MRE 600 (Roche,  10109541001): prepare in water as ~1700 A260/ul 
solution 
Briefly, suspend the solid in 0.8ml of water, vortex and transfer to an eppendorf 
tube. Wash the glass container with additional small volume of water to get as 
much sample out as possible. 
Agarose resin, High capacity; 5mL (Fisher, PI-20359) 
Ultrafree-MC (Millipore, through Fisher UFC3 0GV 25): filter devices cannot exceed 
12,000g centrifugation (this is 11,500 rpm on our microcentrifuge) 
Amicon Ultra centrifugal filters: 0.5ml 10K MWCO (through Fisher, UFC501096) 
Tetramethylammonium chloride (Sigma, 87718-50G): Molecular Biology grade 
Biotinylated DNA oligo against tRNAlys (30nt), first order Sept 14, 2012 through IDT 
5- ATT GAT TAA AAG TCA ACT GCT CTA CCA ACT /3Bio/ -3 
2X TEA buffer: 10mM Tris-HCl (pH=7.6) , 1.8M TEA-Cl, 0.2mM EDTA 
10mM Tris-HCl (pH=7.6) solution 
10mM Tris-HCl (pH=7.6), 0.5M NaCl solution 
10mM Tris-HCl (pH=7.6), 15mM MgCl2 solution 
 
Protocol 
Primer Design (Suggested design requirements from the publication109) 
1.) 3’ biotin 
2.) no strong secondary structure 
3.) between 25-30nt 
4.) region around the anticodon loop and the D-arm is recommended 
 






Preparation of the resin: 200μl of beads 
1) 400μl of Streptavidin agrose resin (50% slurry) is pipetted into the upper cup of an 
Μltrafree-MC (0.22um) column 
2) equilibrate with 10mM Tris-HCl (pH=7.6)  
3) remove the buffer by centrifugation at 10,000 rpm for 10s 
4) mix in 800μl of 7.5uM biotinylated oligoDNA 
5) incubate at RT for 10min 
6) remove the excess solution by centrifugation at 10,000 rpm for 10s 
7) collect the flow-through and quantify the unbound oligoDNA by UV-Vis 
8) wash the resin with 10mM Tris-HCl (pH=7.6) 
9) suspend the resin with 10mM Tris-HCl (pH=7.6) to total of 250μl 
 
Binding tRNA: for every 200μl of beads 
1) transfer the suspended resin to a new Μltrafree-MC (0.22um) column 
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2) remove the buffer by centrifugation at 10,000 rpm for 10s 
3) mix 50μl of unfractionated tRNA mixture solution ( A260 total) with 50μl of water 
and 100μl of 2X hybridization buffer TAE 
4) load the 200μl mixture to the 200μl resin  
5) incubate the mixture at 65°C for 10 min 
6) remove unbound tRNA by centrifugation at 10,000 rpm for 10s 
7) collect the flowthrough unbound tRNA for future use 
8) Wash with 400μl of 10mM Tris-HCl (pH=7.6) containing 0.5M NaCl for total of 3 
times 
Elution 
1) elute the tRNA by heating at 65°C for 5min in 200μl 1X TEA buffer 
2) quickly centrifugate for 10s 
3) repeat step 1-2 again with another 200μl of 1X TEA buffer (optional?) 
 
Concentrate and buffer exchange 
1) use a 500μl Amicon filtration system to concentrate the eluted tRNAs 
2) buffer exchange with ~400μl of 10mM Tris-HCl (pH=7.6) buffer containing 15mM 
MgCl2 (Mg
+2 helps refold tRNAs) for a total of 2-3 times 
 
FPLC of the purified product 
1) run ~100pmole of purified tRNA in FPLC HIC column to confirm purification of the 
tRNA 
tRNA HIC Buffer A:  1.7 M NH4SO4 
   10 mM NH4OAc, pH 6.3* 
tRNA HIC Buffer B: 10% Methanol 
   10 mM NH4OAc, pH 6.3* 
 
5.1.2.4 Preparation of Lys-tRNALys 
The Lys-tRNALys used in the studies were all purified from the protocol described in the 
previous section. The commercial tRNALys from MP BioMedical were used as a 
comparison. To determine the aminoacylation efficiency of Lys-tRNALys, a radioactive, 
TLC-based method was used due to poor separation of tRNALys and Lys-tRNALys on 
HIC. The protocol is modified from previous work by Ledoux et. al and Wolfson et. 
al110,120, and described in the dissertation work by Dr. Philip Effraim and Dr. Mike 
Englander. An alternative approach for quantifying aminoacylation efficiency by using 
acid PAGE gel is also described.  
 
Materials 
Nuclease P1 from Penicillium citrinum: (Sigma, N8630-1VL) resuspend as 1U/μl in 
200mM NaOAc, pH5 containing 50% glycerol  
eTLC plate: TLC Cellμlose (plastic sheets of 20 x 20 cm) CCM Cellμlose from EMD 
#5577-7 
Lysine Specific Transfer Ribonucleic Acid from Escherichia Coli MRE 600, 10 units 
(MP Biomedical #199156)  
TLC buffer: Glacial AcOH: 5%, 1M NH4Cl: 10%, ddH2O: 85% 
Acid PAGE Running buffer: 33.34mL 3M NaOAc pH 5, fill to 1L with H2O 
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2X XC/Urea/EDTA acid PAGE loading buffer recipe: 
 Add 24g Urea to 15mL ddH2O 
 Stir at 37°C for 45 min until dissolved 
 Add 3.2mL of 0.5M EDTA 
 Add 800μl of 1% XC 
 Fill volume to 40mL with H2O (Filter) 
Lysyl tRNA synthetase (LysRS): the overexpression vector is provided by by Prof. 




Aminoacylation of tRNALys 
1) Reaction: 





200 mM Tris-HCl, pH=7.5 1 M 40.00 
25 mM KCl   2 M 2.50 
15 mM MgCl2  1 M 3.00 
2 mM BME   1 M 0.40 
5 mM ATP  0.1 M 10.00 
10 mM PEP   0.3 M 6.67 
0.12 µg/ul pyruvate kinase 25 mg/ml 0.96 
15 µM tRNALys   209 µM 14.35 
56 µM L-lysine  2 mM 2.80 
    H2O       108.90 
0.75 µM LysRS   14.4 µM 10.42 
            200 
 Incubate at 37°C for 10min. 
 
2) Quench the reaction with 0.1X total volume of 3M NaOAc, pHRT=5 
3) Extract the reaction mixture with equal volume of cold phenol (pH=6.7), keep the 
upper aqueous layer 
4) extract the aqueous layer with an equal volume of chloroform, keep the upper 
aqueous layer 
5) add 4X volume of 100% ethanol, mix well and precipitate for 1 hour at -80°C 
6) spin down the precipitation at 18,000g at 4°C for 30min 
7) remove the supernatant carefully and keep the white precipitant 
8) resuspend the pellet in 30-70µl of 10mM KOAc (pH 5) 
9) buffer exchange a Micro Bio-Spin 6 column with 10mM KOAc (pH 5) 
10) buffer exchange the suspension by applying to the Bio-Spin 6 column  
11) aliquot and flash freeze the final product in liquid nitrogen and store at -80°C 
Assessing the aminoacylation yield using FPLC 
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1) Determine the concentration of the tRNALys by UV-Vis absorbance at 260nM. The 
extinction coefficient for tRNALys is 260nm = 760000 M-1cm-1 
2) The yield is determined by separation of each species by hydrophobic interaction 
chromatography (HIC) with the following buffers: 
tRNA HIC Buffer A:  1.7 M NH4SO4 
    10 mM NH4OAc, pH 6.3* 
tRNA HIC Buffer B: 10% Methanol 
    10 mM NH4OAc, pH 6.3* 
 
*Note that this is the pH of the 1 M NH4OAc stock solution, not the final HIC 
Buffer pH. The final solution does not need to be pH adjusted. 
3) Dilute 0.1 nmoles of tRNA (one or two aliquots, depending on the final 
concentration) with 60-70 µL of tRNA HIC 
4) tRNALys does not separate well on HIC, therefore a uncharged tRNALys must be run 
as a reference to determine the precise elution time of tRNALys and Lys-tRNALys 
Assessing the aminoacylation yield using acid-PAGE gel 
NOTE: this protocol never worked for Bridget for some reason…. 
1) Prepare a 6% acid PAGE gel into long (16cm x 24cm) plates, using spacers and 
.75mm comb: 
stock 
conc. unit chemical   amount   
40 % acrylamide/bis 19:1 6.1 ml 
60.05 g/mol urea (MW=60.05) 18 g 
    H2O   15.5 ml 
        40 ml 
add 500μl 10% APS and 25μl TEMED to polymerize the gel 
allow to polymerize at room temperature for at least 30min 
 
2) Pre-chill the gel and running buffer at 4°C 
3) Assemble the gel running apparatus and flush the wells 3-4 with a syringe 
4) Mix approximately 100pmol of tRNA sample with 2X acid PAGE loading buffer, 
make sure to include a reference lane 
5) Run gel in the cold room for 16h at 190V (overnight); make sure the gel does not 
heat up, turn down the power if needed 
6) Once the gel is done running, carefully disassemble the apparatus and keep the gel 
in a gel box 
7) Stain the gel with 0.1% Toluidine blue stain for 1min with agitation 
8) Destain the gel in water until bands are visible or overnight 
 
Assessing the aminoacylation yield using radioactive assay 
*It looks like we do not add pyrophosphatase in our reaction in the Gonzalez lab.  
1) Radio-labeling of un-aminoacylated tRNA: 
2) Incubate the reaction for 5min at 37°C 
Chapter 5 Materials and methods 
137 
 
3) The reaction is diluted to a larger volume (such as 100μl or 200μl) with water to 
make extraction simpler 
4) Extract with equal volume of phenol (pH 6.7) once 
5) Extract with equal volume of chloroform once 
6) Add in 1/10 volume of 3M NaOAc, pH 5 and 4X volume of 100% ethanol 
7) Allow precipitation for at least 1hr/1hr30min 
8) Spin down 14000rpm, 4°C for 20min 
9) Buffer exchange to tRNA buffer using P6 column 
10) Take the concentration of the tRNA using UV/Vis 
 
Aminoacylation of radioactively-labeled tRNA 
 Follow protocols from the previous section, combine P-32-labeled tRNA and 
unlabeled (nonradioactive) tRNA to make up sufficient amount for aminoacylation 
reaction: 
1) Combine radioactively-labeled tRNA with sufficient amount of non-
radioactively-labeled to setup labeling reaction:  





200 mM Tris-HCl, pH=7.5 1 M 10.00 
25 mM KCl   2 M 0.63 
15 mM MgCl2  1 M 0.75 
2 mM BME   1 M 0.10 
5 mM ATP  0.1 M 2.50 
10 mM PEP   0.3 M 1.67 
12 µg (?) pyruvate kinase 25 mg/ml 0.48 
15 µM 
P-32 tRNALys 11.76 µM 25.00 
tRNALys   84.3 µM 5.41 
56 µM L-lysine  2 mM 1.40 
    H2O       -0.54 
0.75 µM Lys aaRS   14.4 µM 2.60 
            50.00 
Incubate at 37°C for 10min. 
2) Quench the reaction with 0.1X total volume of 3M NaOAc, pHRT=5 
3) Extract the reaction mixture with equal volume of cold phenol (pH=6.7), keep the 
upper aqueous layer 
4) extract the aqueous layer with an equal volume of chloroform, keep the upper 
aqueous layer 
5) add 4X volume of 100% ethanol, mix well and precipitate for 1 hour at -80°C 
6) spin down the precipitation at 18,000g at 4°C for 30min 
7) remove the supernatant carefully and keep the white precipitant 
8) resuspend the pellet in 30µl of 10mM KOAc (pH 5) 
 
P1 Nuclease digestion and Visualizing Aminoacylation Efficiency using TLC 
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1) Wash TLC plate with nanopure water and allow to air dry in a chemical hood 
2) Take 1ul of radioactively-labeled, aminoacylated sample and add 4ul of P1 
nuclease (take extreme care when using RNase) 
3) Incubate the reaction at room temperature for 10min  
4) Repeat step 2-3 for a radioactively-labeled, but not aminoacylated sample as a 
reference 
5) To obtain the best loading range, serial dilute in 200mM NaOAc pH 5 
6) Spot 0.5-1ul sample at the bottom (above solvent line) of the TLC 
7) Run TLC with TLC running buffer in TLC chamber until the solvent front is ~1-
2cm from the top, approximately 45min 
8) All the TLC plate to air dry 
9) Wrap in plastic wrap and exposure on a phosphoimager screen for approximately 
5-6 hours, or overnight (depending on the strength of radioactivity) 
10) Scan and analyze the result with ImageQuant 
 
5.1.2.5 Cy Dye Labeling of tRNA Body 
The Cy Dye labeling of tRNAPhe and tRNALys both take place at the primary aliphatic 
amino group of the 3-(3-amino-3-carboxypropyl)-uridine at position 47 (acp3U47) with 




tRNAPhe labeling buffer: 50 mM HEPES (pH = 8.0) and 0.9 M NaCl 
 
Protocol 
1) Reaction ~10nmol of un-aminoacylated tRNAPhe/Lys with 20-30 fold excess 
Cy3/5-NHS ester in tRNAPhe labeling buffer at concentration of ~100µM and ~2-
3mM respectively at 30C for 8 hours, followed by overnight incubation at 4°C 
2) Quench the labeling reaction by adding 0.1X volume of 3M NaOAc, pH=5.5 
3) Extract the reaction with equal volume of phenol (pH=6.7) multiple times until 
the phenol layer contains no visible free dyes, approximately 6-7 times 
4) Save the phenol layers and back extract with 0.25X volume of 0.4M NaOAc, 
pH=5.5 
5) Combine the original aqueous layer and back-extracted aqueous layer 
6) Extract both with equal volume of chloroform twice to remove excess phenol, 
keep the aqueous layer 
7) Precipitate the tRNAs in the aqueous layer with 4X volume of ethanol at -80°C 
for at least 1 hour, or overnight 
FPLC Purification of Cy-labeled tRNAs 
1) Spin down the ethanol precipitation at 18,000g for 30 minutes 
2) Carefully remove the supernatant, leaving the pellet, which is visible color of the 
Cy dye, be sure that all supernatant is removed 
3) Resuspend the pellet in approximately 70-100µl tRNA HIC Buffer B 
4) Spin down at 18,000g for 1 minute to confirm full resuspension 
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5) The labeled vs. unlabeled tRNAs are separated on HIC using the following buffers: 
tRNA HIC Buffer A:  1.7 M NH4SO4 
    10 mM NH4OAc, pH 6.3* 
tRNA HIC Buffer B: 10% Methanol 
    10 mM NH4OAc, pH 6.3* 
 
6) Combine the labeled tRNAs fraction from FPLC and concentrate using an 
Amicon centrifugal filtration device 
7) Buffer exchange the tRNA into water 
 




5.1.2.6 Cy Dye Labeling of tRNA AA 
 This protocol is based on the thesis of Professor Scott Blanchard (page 157-161) 




tRNA Dialysis and Storage Buffer: 5mM KOac (pHRT 6.1), 10mM KCl, 0.2mM MgOAc 
TAE buffer, pH 9.5: 40mM Tris-Oac, 1mM EDTA, pH to pHRT 9.56 with acetic acid 
 
Protocol 
Aminoacylation of tRNAfMet with Met 
1) Reaction setup: (~5nmol tRNA) 





1 X 1X AF buffer 5 X 50.00 
20 µM tRNAfMet 197 µM 25.38 
80 µM cold Met  1000 µM 20 
    H2O      153.89 
0.02 µM MetRS  6.9 µM 0.72 
            250.00 
 
Incubate at 37°C for 10min 
2) Quench the reaction with 0.1X total volume of 3M NaOAc, pHRT=5 
3) Extract the reaction mixture with equal volume of cold phenol (pH=6.7), keep the 
upper aqueous layer 
4) extract the aqueous layer with an equal volume of chloroform, keep the upper 
aqueous layer 
5) add 4X volume of 100% ethanol, mix well and precipitate for 1 hour at -80°C 
6) spin down the precipitation at 18,000g at 4°C for 30min 
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7) remove the supernatant carefully and keep the white precipitant 
8) resuspend the pellet in ¼ volume of tRNA dialysis and resuspension buffer (~60μl) 
9) buffer exchange a Micro Bio-Spin 6 column with tRNA dialysis and resuspension 
buffer  
10) buffer exchange the suspension by applying to the Bio-Spin 6 column 
Dye labeling 
1) Lyophilize away all liquid in a speed-Vac. For volume ~70µl, this step will take 
~5-6 hours 
2) Resuspend the lyophilized tRNA in 10µl water 
3) Add 80ul 4mM NHS dye in 100% DMSO 
4) Immediately adjust pH to 9 by adding 10µl 1M triethanolamine-HCL (TEA) 
buffer pH37 = 9.2 
5) Incubate at 37°C for 8 hours 
6) Quench the reaction by diluting 5X with tRNA dialysis and resuspension buffer 
(~400µl) 
7) Add 1/10 volume of 3M NaOAc pH25= 5.5 
8) Extract with equal volume, cold phenol pH = 6.7 
9) Take the aqueous layer; the organic phenol layer contains most of the dye 
10) Back extract the phenol layer with 0.25 volume 0..4M NaOAc pH25= 5.5 
11) Repeat step 8-10 second time to the aqueous layer and combine together 
(including the back extraction). The phenol layer in the second extract showed 
little color of the dye, suggesting most free dye has been removed from aqueous 
layer 
12) Chloroform extract twice with an equal volume (~600µl). An opaque interface 
between the aqueous and organic layer is formed. Do not take the opaque 
contamination 
13) add 4X volume of 100% ethanol (can be done in multiple tubes), mix well and 
precipitate for 1 hour at -80°C or overnight  
14) spin down the precipitation at 18,000g at 4°C for 30min 
15) The overnight precipitation is color of the dye, directly resuspend in HIC buffer A 
(~100ul) 
FPLC separation of free dye and labeled tRNA 
1) Pre-equilibrate the system with both Buffer A and Buffer B 
tRNA HIC Buffer A:  1.7 M NH4SO4 
    10 mM NH4OAc, pH 6.3* 
tRNA HIC Buffer B: 10% Methanol 
    10 mM NH4OAc, pH 6.3* 
 
2) Equilibrate the column and a 150ul loop with Buffer A 
3) Spin down the resuspended labeled tRNA at 18,000g for 1min to remove potential 
precipitant 
4) Inject the sample and run with appropriate FPLC program 
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5) Collect the appropriate fractions containing labeled tRNA 
6) Combine and buffer exchange the fractions with a 15-ml Amicon centrifuge 
filtration device  into tRNA buffer (at least 1000 fold) 
7) Further concentrate in a 500ul Amicon centrifuge filtration device to a small 
volume 
8) Determine the concentration of the tRNA and dye by UV-Vis absorbance 
9) Aliquot and store at -80°C 
5.1.3 Preparation of mRNAs 
The mRNAs are prepared in-house by run-off in vitro transcription. The mRNAs used for 
microscopy experiments were further hybridized with biotinylated DNA oligo for 
anchoring to microscope slide surface.  
 
 
5.1.3.1 In vitro transcription of mRNAs 
This protocol is based on Dr. Jinyi Fei’s thesis. 
  
Materials 
LB culture of plasmid: ~150-200ml 
Maxi-prep kit: 
BamHI enzyme 
Agrose gel: 1-1.5% 
20X T7 Buffer: 800 mM Tris-HCl ((pH37°C = 8.1), 20 mM Spermidine and 0.2% Triton 
X-100 
500mM EDTA, pHRT=8: 
mRNA Buffer: 10 mM Tris-OAc (pH37°C = 7.5), 1 mM EDTA and 10 mM KCl. 
Denaturing PAGE: 9% 
Amicon 500ul filtration device 
 
Protocol 
1) prepare plasmid DNA containing the desired mRNA construct using a Maxi-prep 
kit (Qiagen) 
2) linearize the plasmid DNA with BamHI restriction enzyme, or other restriction 
enzymes, designed to the 3’-end of the mRNA construct 
3) purified the linearization reaction by phenol and chloroform extraction, followed 
by ethanol precipitation 
4) check the linearization reaction by agarose gel to confirm that linearization is 
completed 
5) determine the concentration of the linearized plasmid by UV-Vis absorption at 
260nm 
6) setup an analytical Mg+2 sweep as followed: (can change Mg+2 range if needed) 
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final unit   stock unit 1 2 3 
1 X T7 buffer 20 X 0.5 0.5 0.5 
5 mM DTT 200 mM 0.25 0.25 0.25 
various mM MgCl2 1 M 0.42 0.3 0.5 
various ug DNA 2 ug/ul 0.75 0.75 0.75 
4 mM NTP 100 mM 0.4 0.4 0.4 
  unit 
T7 
polymerase     1 1 1 
    H2O     6.68 6.80 6.60 
        Total 10 10 10 
at 37°C for approximately 3 hours. White precipitation should appear in the 
reaction 
 
7) quench the reaction by 1/10 volume of 500mM EDTA, pH8, the white precipitant 
should disappear 
8) prepare a 9% denaturing PAGE gel 
9) pre-run the gel for 30min at constant 300V, make sure to wash the wells with 
buffer and remove air bubbles at the bottom of the gel 
10) add 2X running buffer (with dye) to the analytical reactions and load the gels, 
make sure to include reference lanes (such as old mRNA or tRNA sample with 
known size) 
11) run the gel for approximately 1hr 45min at constant 300V 
12) stain the gel finished gel with 0.1% toluene blue stain for 1min with agitation 
13) destain the gel in water until visible bands; fully destain overnight 
14) select the Mg+2 condition with most product and least side-products (usually 
smaller sizes) 
15) scale up the reaction by at least 50 times, 0.5-1ml final reaction size 
16) quench the reaction by 1/10 volume of 500mM EDTA, pH8, the white precipitant 
should disappear 
17) buffer exchange the final product into mRNA buffer using an Amicon centrifugal 
filtration device, buffer exchange at least 3 times 
18) determine the concentration of the mRNA by UV-Vis absorption 
19) run an 9% denaturing PAGE gel to confirm final product 
 
5.1.3.2 Preparation of biotinylated-DNA Hybridized mRNAs for microscope  
This protocol is adapted from the mRNA:bi-DNA hybridization protocol written by Sam 
Sternberg and reference: 
“It is complementary to the 5’ end of in vitro transcribed mRNAs derived from the pUC-
gp32.1-20 vector, and places a biotin near the 5’ end of the mRNA.” 





1X Hybridization Buffer: 10 mM Tris-OAc, 150 mM KCl, 0.5 mM EDTA 
Biotin-DNA: (5’)-TGT GTA AGT TTT AGG TTG ATT TG/3Biotin/-(3’) 
 
Protocol 
1) The reaction is consist of 1:10 molar ratio of mRNA (in mRNA storage buffer, 
10mM Tris-OAc, 0.1mM EDTA, 10mM KCl) and biotin-DNA in final buffer of 
1X hybridization buffer 
2) Mix all components together and adjust the buffer 
3) Heat to 95°C for 2mintues 
4) remove the heat block and let the heat block slowly cool by sitting on bench top at 
room temperature 
5.1.4 Preparation of ribosomal complexes 
This section describes the general protocol for preparing different kinds of ribosomal 
complexes for different experiments. 
 
5.1.4.1 Preparation of ribosomal complexes for radioactive experiments 
This is a generalizable protocol for preparing ribosomal complexes carrying a radioactive 
dipeptide using S35-fMet-tRNAfMet and Zaher Buffer C, which promote misincorporation 
of tRNAs. Note that the total amount of EF-Tu and tRNAs are in great molar excess, 
compared with other standard procedure in the group. 
 
Materials 
5X Zaher Buffer C: 100mM HEPES-KOH, pH7.6, 750mM NH4Cl, 22.5mM MgCl2, 
10mM spermidine, 0.25mM spermine, 20mM BME 
 
Protocol 
Making Ribosomal Complex: 
1) Tight-coupled 70S pre-initiation mix 
vol (uL)     cocn(uM) 
amt 
(pmol) 
3.23  70S  8.35 27 
0.24   IF1  148 35 
0.12  IF2 225 27 
0.13   IF3 263 35 
0.40  GTP 50mM  
3.00   5X Zaher Buffer C    
3.88   H2O     
11.00     
10min 37°C, then keep at room temperature 
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2) 70S Complex Formation 
vol (uL)     cocn(uM) 
amt 
(pmol) 
11.00  Tight-coupled 70S   
1.29   M(AUA)F mRNA 63 81 
1.84  S
35 fMet-tRNA  22 40.5 
0.87   H2O     
15.00     
20min 37°C, then keep on ice 
 
3) 10mM GTP Charging Mix 
vol (uL)     cocn(uM) 
amt 
(pmol) 
3  H2O   
1   GTP 50mM   
0.5  Phosphoenolpyruvate 0.3M  
0.5   pyruvate kinase     
5     
 
4) EF-Tu/EF-Ts Mix 
vol (uL)     cocn(uM) 
amt 
(pmol) 
2.05  EF-Tu 110 225 
0.00   EF-Ts 101 0 
0.00   H2O     
2.05     
 
5) EF-Tu(GTP)/EF-Ts 
vol (uL)     cocn(uM) 
amt 
(pmol) 
2.05  EF-Tu/EF-Ts mix   
2  GTP charging mix    
3  5X Zaher Buffer C   
0   H2O     
7.05     
 
6) LysT3/EF-Ts 
vol (uL)     cocn(uM) 
amt 
(pmol) 
7.05  EF-Tu(GTP)/EF-Ts   
6.75   Lys-tRNALys  12 81 
0.13   H2O     
13.93     
1min 37°C, then 1min on ice 





vol (uL)     cocn(uM) 
amt 
(pmol) 
1.03  EF-G 87 90 
0.41  GTP Charing mix     
0.00   H2O     
1.44     
 
8) LysT3 Delivery and EF-G Translocation 
vol (uL)     cocn(uM) 
amt 
(pmol) 
15.00  70S Complex   
1.44  EF-G    
13.93  LysT3/EF-Ts    
30.37     
10min 37°C, buffer exchange in p6 
9) Flash freeze aliquoted samples in liquid nitrogen and store at -80°C. 
 
 
5.1.4.2 Preparation of ribosomal complexes for fluorescence experiments 
This is a generalizable protocol for preparing ribosomal complexes for smFRET 
experiments. The example shown here is for preparing aEC with Lys-tRNALys(Cy3). 




5X Zaher Buffer C: 100mM HEPES-KOH, pH7.6, 750mM NH4Cl, 22.5mM MgCl2, 
10mM spermidine, 0.25mM spermine, 20mM BME 
 
Protocol 
Prepare sucrose gradient: 
1) Prepare 5X buffer as followed: 
     5X  
final 







pH7.5 1000 mM 2.00 
70 mM NH4Cl 2000 mM 3.50 
7.5 mM MgCl2 1000 mM 0.75 
0.5 mM EDTA 500 mM 0.10 
6 mM BME 14300 mM 0.04 
    H2O     13.61 
     20 




2) Prepare 10% and 40% sucrose buffers: 
  high Mg+2 
  10% 40% 
5X buffer A 8 8 
60% sucrose 6.67 26.67 
H2O 25.33 5.33 
 40 40 
3) Pipet 6 ml 10% sucrose solution into each tube. 
4) Using a syringe with needle, place 40% sucrose solution underneath 10% sucrose 
solution until the interface between solutions reaches the marked line (~6 ml). 
5) Close tubes with rubber caps carefully to expel all air. 
6) Level Biocomp Gradient Master. 
7) Set Gradient Master: 
 SW41 short sucrose 10-40% wv 
 step 1 of 1 1:48/81.5°/17 rpm 
8) Chill gradients to 4°C in cold room for at least 2 hours. 
 
 
Making ribosomal complex: 
1) Tight-coupled 70S pre-initiation mix 
vol (uL)     cocn(uM) 
amt 
(pmol) 
3.23  70S  8.35 27 
0.24   IF1  148 35 
0.12  IF2 225 27 
0.13   IF3 263 35 
0.40  GTP 50mM  
3.00   5X Zaher Buffer C    
3.88   H2O     
11.00     
10min 37°C, then keep at room temperature 
 
2) 70S Complex Formation 
vol (uL)     cocn(uM) 
amt 
(pmol) 
11.00  Tight-coupled 70S   
1.29   M(AUA)F mRNA 63 81 
1.84  fMet-tRNA  22 40.5 
0.87   H2O     
15.00     
20min 37°C, then keep on ice 
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3) 10mM GTP Charging Mix 
vol (uL)     cocn(uM) 
amt 
(pmol) 
3  H2O   
1   GTP 50mM   
0.5  Phosphoenolpyruvate 0.3M  
0.5   pyruvate kinase     
5     
 
4) EF-Tu/EF-Ts Mix 
vol (uL)     cocn(uM) 
amt 
(pmol) 
2.05  EF-Tu 110 225 
0.00     101 0 
0.00   H2O     
2.05     
 
5) EF-Tu(GTP)/EF-Ts 
vol (uL)     cocn(uM) 
amt 
(pmol) 
2.05  EF-Tu/EF-Ts mix   
2  GTP charging mix    
3  5X Zaher Buffer C   
0   H2O     
7.05     
 
6) LysT3/EF-Ts 
vol (uL)     cocn(uM) 
amt 
(pmol) 
7.05  EF-Tu(GTP)/EF-Ts   
4.79   Lys-tRNALys (Cy3) 16.9 81 
2.09   H2O     
13.93     
1min 37°C, then 1min on ice 
 
7) EF-G 
vol (uL)     cocn(uM) 
amt 
(pmol) 
1.03  EF-G 87 90 
0.41  GTP Charing mix     
0.00   H2O     
1.44     
 
 
Chapter 5 Materials and methods 
148 
 
8) LysT3 Delivery and EF-G Translocation 
vol (uL)     cocn(uM) 
amt 
(pmol) 
15.00  70S Complex   
1.44  EF-G    
13.93  LysT3/EF-Ts    
30.37     
10min 37°C 
9) Remove 100μl from the top of the sucrose gradients 
10) Load the sample to the top of the sucrose gradient 
11) Spin gradient at 25,000 RPM, slow acceleration and deceleration with SW40 rotor 
at 4°C for 12 hours (alternatively, 23,000 RPM for 15 hours) 
12) Isolate the gradients with gradient analyzer as described previously, collect the 
70S fraction. 
13) Flash freeze the aliquoted samples in liquid nitrogen and stored at -80°C 
5.1.5 Preparation of Release Factors 
The release factors were cloned into pProEX-htb vector with restriction site KasI and 
KpnI. The RFs construct contains a His6 purification tag, followed by a Tev protease 
cleavage site at the N-terminus. The protein purification protocol for RF1/2 is a general 
protocol for purifying most translation factors.  
  
5.1.5.1 Purification of RF1 and RF2 
This protocol is based on Professor Ruben Gonzalez’s pProEX protein purification 
protocol from 2014.   
 
Materials 
TB broth: containing glycerol; prepared the night before, cooled at room temperature 
overnight without antibiotics 
Cell Storage buffer 
Lysis and Equilibration buffer: 20mM Tris-HCl, pH4=7.5/pHRT=6.9, 300mM NaCl, 
10mM Imidazole, pHRT=8, 2mM BME 
Wash buffer: 20mM Tris-HCl, pH4=7.5/pHRT=6.9, 300mM NaCl, 30mM Imidazole, 
pHRT=8, 2mM BME 
Elution buffer: 20mM Tris-HCl, pH4=7.5/pHRT=6.9, 500mM NaCl, 250mM Imidazole, 
pHRT=8, 2mM BME 
5X Tev Protease buffer: 100mM Tris-HCl, pH4=7.5/pHRT=6.9, 1M NaCl, 0.5% Triton-
X, 10mM BME 





1) prepare a 50ml overnight culture in a flask containing the appropriate antibiotics 
(RF1/2: carbenecillin and kanamycin) at 37°C with shaking  at 250rpm 
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2) next morning inoculate 1L of TB media (with appropriate antibiotics) with 50ml 
overnight culture 
3) allow the cell to grow until the exponential phase of OD600 ~ 0.8-1.0, 
approximately 2 hours 
4) collect ~50ul media as the pre-induction sample, immediately add 4X SDS 
sample buffer 
5) induce with IPTG to a final of 1mM IPTG (usually with 1M IPTG stock, 1:1000 
dilution) 
6) allow induction for approximately 3 hours at 37°C 
7) keep ~50ul media as the post-induction sample, immediately add 4X SDS sample 
buffer 
8) harvest the cells by spinning down at 4,000 rpm in a JA-10 rotor, 15min 
9) decant the supernatant and transfer the cell pellet to a 50ml falcon tube for storage 
10) freeze the pellet with liquid nitrogen and store at -80°C, alternative, continue to 
next section 
11) run a SDS-PAGE gel to check for induction 
 
 
Cell Lysis and Batch Binding 
1) resuspend the cell pellet on ice in ~20ml of lysis buffer with a serological pipette 
2) French press the sample twice at 1,100 psi, in an ice-cold French press cylinder 
3) Spin down the lysate with JA-17 rotor at 12,000 rpm, 20min at 4°C 
4) Decant the supernatant to a 50ml falcon tube, store the pellet on ice 
5) Equilibrate ~4ml of 50% Ni-NTA beads (2ml bead volume) in a plastic column 
with 15ml lysis buffer 
6) Add the equilibrated Ni-NTA  to the supernatant in 50ml tube 
7) Seal the 50ml tube cap with parafilm and incubate on a rotator in cold room for 1 
hour 
8) Gently spin down the beads at no more than 800 rpm in Sorvall Legend centrifuge 
9) Gently decant most supernatant, take care not to disturb the beads by leaving 
small volume of supernatant 
10) Transfer the beads to a plastic column, allow the supernatant (lysate) to flow 
through completely 
11) Keep 50ul of flow-through, immediately add 4X SDS sample buffer 
12) Wash the beads with 25ml lysis buffer 
13) Keep 50ul of flow-through, immediately add 4X SDS sample buffer 
14) Wash the beads with total of 100ml Wash buffer 
15) Keep 50ul of flow-through, immediately add 4X SDS sample buffer 
16) After the wash buffer flow through completely, elute the buffer with ~15ml of 
elution buffer, collect the elution as multiple fractions (typically 4 fractions) or as 
one giant fraction (if known without other contaminants) 
17) Keep 30ul of flow-through, immediately add 4X SDS sample buffer 
18) Run a SDS-PAGE gel (10-12%) to visualize each stage collected (supernatant, 
flow-through, washes and elution) and confirm purity of elution 
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Tev Protease Cleavage and Dialysis 
1) Wash and pre-soak dialysis tubing (MWCO = 10,000 Da) in water for at least 
30min 
2) Tie and clip one end of the dialysis tubing and soaked in pre-chilled 1X Tev 
protease buffer 
3) Combine elution and ~1-2mg of Tev protease, transfer to the dialysis tube 
4) Tie the tubing, leaving small volume of air inside the tubing to help flotation 
5) Dialyze in ~1L of pre-chilled 1X Tev protease buffer overnight with gentle, 
constant stirring in the cold room 
Removal of Tev Protease and His-Tags 
1) Gently cut open the dialysis tubing and transfer the protein sample to a 50ml falcon 
tube 
2) Keep 50ul protein sample, immediately add 4X SDS sample buffer 
3) Run an SDS-PAGE gel (10-12%) to assess cleavage 
4) If the cleavage is >90%, process to next step, if not, add additional 1mg of Tev 
protease and dialyze against fresh 1X Tev protease buffer until cleavage is >90% 
5) Equilibrate 3ml of 50% Ni-NTA slurry (1.5ml bead volume) with 1X Tev protease 
buffer 
6) Add imidazole to the sample to a final concentration of 30mM final 
7) Combine the beads and the sample in 50ml falcon tube 
8) Incubate for 30min on a rotator in the cold room 
9) Decant the beads and sample to a plastic column, collect the flow-through 
10) Keep 10ul protein sample, immediately add 4X SDS sample buffer 
11) Buffer exchange the protein sample with an Amicon centrifuge filtration device for 
at least 5 times (or 10,000 fold) with 2X translation factor buffer, or dialyze against 
2X translation factor buffer, then concentrate 
12) Do not over-concentrate the protein (keeping ~100-200uM concentration), make 
the final concentration slightly higher, combine with equal volume of 100% 
glycerol to make final 50% glycerol and 1X translation factor buffer  
13) Determine the concentration of the protein by Bradford assay or UV-Vis 
absorbance 
14) Run an SDS-PAGE gel (10-12%) to confirm complete removal of Tev protease and 
uncleaved proteins 
Note: Tev Protease may be produced as an approximately 50kDa pre-protein that is later 
cleaved (autocatalytically?) into the final active 27.5kDa protease. 
 
 
5.1.5.3 Purification of RF3 
The purification protocol of RF3 is exactly the same until after removal of Tev protease. 
 




Extended Dialysis of RF3 
1) Post Tev protease removal, transfer RF3 protein sample to a new, pre-washed 
dialysis tubing 
2) Dialyze against ~1L of 2X translation factor buffer with gentle stirring 
3) Exchange the buffer approximately every 6-12 hours 
4) Repeat for ~4 days to remove guanine nucleotides 
5) Concentrate the fully dialyzed protein with an Amicon centrifugal filtration 
device 
6) combine with an equal volume of 100% glycerol to make final 50% glycerol and 
1X translation factor buffer 
7) Determine the concentration of the protein by Bradford assay or UV-Vis 
absorbance 
 
5.1.5.4 Cy Dye Labeling of RF2 
 
Materials 
P6 desalting columns 
Cy3 Mon-Maleimide: GE, cat# PA13131 
Cy5 Mono- Maleimide: GE, cat# PA15131 
1X labeling buffer: 100mM Tris-OAc, 50mM KCl, 1mM T-cep 
 
Protocol 
Cy Dye labeling reaction 
1) Buffer exchange the protein sample into 1X labeling buffer using a pre-
equilibrated P6 desalting column (or multiple P6, each P6 max at 75μl of sample) 
2) Determine the protein concentration by Bradford assay or UV-Vis absorbance 
3) Calculate the amount of Cy dye needed for 20X excess of protein (for example, if 
protein is 130μM(75μl)=9750pmol, then Cy dye needed is 195nmol) 
4) Resuspend approximate amount of Cy dye in small volume of anhydrous DMSO 
(~10μl) 
5) Determine the actual concentration of Cy dye by UV-Vis absorbance, keep the 
final DMSO volume in the labeling reaction to less than 10% total 
6) Add 20X excess Cy dye into the protein sample, quickly mix by pipetting 
7) Incubate at room temperature in the dark (in drawer or in aluminum foil) for 
approximately 2-3 hours 
8) Quench the reaction by adding 2X translation factor buffer containing BME to 
approximately 500μl 
Separation of free Cy dye using FPLC 
1) Pre-equilibrate a gel-filtration column and a 500μl loop with 2X translation 
buffer; typically done overnight 
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2) Spin down the labeling reaction at 13,000 rpm for 1min to remove potential 
precipitant (carefully make sure there isn’t any precipitant, do not inject to FPLC 
if there are visible precipitation of proteins) 
3) Using a 500μl Hamilton syringe, carefully inject the labeling reaction into the 
loop without any air bubble 
4) Run an appropriate FPLC program such as following: 
5) Collect the appropriate fractions containing RF1/2, which elute at approximately 
60ml  
6) Combine and concentrate the fractions with an Amicon centrifuge filtration 
device to a final volume of 100-200μl 
Separation of unlabeled and labeled protein using FPLC 
1) Pre-equilibrate the system with buffer A and buffer B 
2) Pre-equilibrate the HIC column and a 500μl loop with Buffer A 
3) Add 2X buffer B to the concentrated protein sample to final volume of 500ul 
4) Using a 500ul Hamilton syringe, carefully inject the labeling reaction into the 
loop without any air bubble 
5) Run an appropriate FPLC program 
7) Collect the appropriate fractions containing Cy dye labeled RF1/2 
8) Combine and buffer exchange the fractions into 2X translation buffer with an 
Amicon centrifuge filtration device  (at least 1000 fold) 
9) Further concentration the labeled protein using a 500ul Amicon device 
10) Add equal volume of 100% glycerol and store at -20 
11) Determine the labeled protein concentration by the UV-Vis absorbance of the Cy 
dye  
 
5.1.5.5 Quencher dye conjugation of RF2 
 
Materials 
QSy9 C5 Maleimide: Life Technologies, cat#Q-30457 
1X labeling buffer: 100mM Tris-OAc, 50mM KCl, 1mM T-cep 
 
Protocol 
Quencher dye conjugation reaction 
1) Buffer exchange the protein sample into 1X labeling buffer using a pre-
equilibrated P6 desalting column (or multiple P6, each P6 max at 75μl of sample) 
2) Determine the protein concentration by Bradford assay or UV-Vis absorbance 
3) Calculate the amount of Cy dye needed for 20X excess of protein (for example, if 
protein is 130μM(75μl)=9750pmol, then Cy dye needed is 195nmol) 
4) Resuspend approximate amount of Cy dye in small volume of anhydrous DMSO 
(~10μl) 
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5) Determine the actual concentration of Cy dye by UV-Vis absorbance, keep the 
final DMSO volume in the labeling reaction to less than 10% total 
6) Add 20X excess Cy dye into the protein sample, quickly mix by pipetting 
7) Incubate at room temperature in the dark (in drawer or in aluminum foil) for 
approximately 2-3 hours 
8) Quench the reaction by adding 2X translation factor buffer containing BME to 
approximately 500μl 
Separation of free Cy dye using FPLC 
1) Pre-equilibrate a gel-filtration column and a 500μl loop with 2X translation 
buffer; typically done overnight 
2) Spin down the labeling reaction at 13,000 rpm for 1min to remove potential 
precipitant (carefully make sure there isn’t any precipitant, do not inject to FPLC 
if there are visible precipitation of proteins) 
3) Using a 500μl Hamilton syringe, carefully inject the labeling reaction into the 
loop without any air bubble 
4) Run an appropriate FPLC program 
5) Collect the appropriate fractions containing RF1/2, which elute at approximately 
60ml  
6) Combine and concentrate the fractions with an Amicon centrifuge filtration 
device to a final volume of 100-200μl 
 
Separation of unlabeled and labeled protein using FPLC 
1) Pre-equilibrate the system with buffer A and buffer B 
2) Pre-equilibrate the HIC column and a 500μl loop with Buffer A 
3) Add 2X buffer B to the concentrated protein sample to final volume of 500μl 
4) Using a 500μl Hamilton syringe, carefully inject the labeling reaction into the 
loop without any air bubble 
5) Run an appropriate FPLC program  
7) Collect the appropriate fractions containing Cy dye labeled RF1/2 
8) Combine and buffer exchange the fractions into 2X translation buffer with an 
Amicon centrifuge filtration device  (at least 1000 fold) 
9) Further concentration the labeled protein using a 500μl Amicon device 
10) Add equal volume of 100% glycerol and store at -20°C 
11) Determine the labeled protein concentration by the UV-Vis absorbance of the Cy 
dye  




5.2 Biochemical assays for determining rate of peptide release 
This is a generalizable protocol for measuring the rate of peptide release using dipeptide 
release assay. Variables such as concentrations of ribosomal complexes and RFs, length 
and increments of time course depend on the experimental goals. 
 
Materials 
Cellulose TLC plates: (EMD Millipore 1055770001)  
Stoddard Solvent: (VWR EM-SX0995-1) 
eTLC Running Buffer: 20% glacial acetic acid, 0.5% pyridine 
 
Protocol 
Collection of peptide release time course 
1) Pre-incubate S35 radioactively-labeled ribosomal complexes and RF mixture in 
two separate tubes, in Buffer M at room temperature for 5 minutes 
2) Combine the two mixtures upon initiation of the time course reaction 
3) Take small samples (1μl) at indicated time points and quench with equal volume 
of ice-cold 25% formic acid 
4) Collect a sample react with 1M KOH at the end of the time course for total 
releasable dipeptide 
5) Either store the sample or proceed to eTLC or go get a bubble tea 
 
Visualization and quantitation of dipeptide with eTLC: 
1) Trim one side of the eTLC plates off by ~1.5cm to allow the plate to fit inside the 
eTLC running tanks 
2) Mark the center of the eTLC plate with a pencil  
3) Using a pipette, spot ~0.4μl-1μl of the time course samples alone the center of the 
eTLC plates, leaving at least 0.5cm space between each spot 
4) Allow the spots to air dry until invisible (~5min) 
5) Place a plastic serological pipet at the top edge of the eTLC, parallel to the spots, 
use a p1000 pipette, drip 1ml-2ml eTLC running buffer near the serological pipet 
6) Slowly roll the running buffer down using the serological pipet until buffer is near 
the sample spots, but not touching 
7) Allow running buffer to slowly diffuse to the sample spots 
8) Repeat step 5-7 for the bottom edge of the eTLC plate 
9) Allow the running buffer to diffuse and cover the entire eTLC plate 
10) Insert the eTLC plate into the eTLC running tank, containing eTLC running 
buffer at the bottom layer and Stoddard Solvent on the top layer. Note down the 
direction of electric flow. 
11) Run the eTLC at constant voltage of 1200V for 30min 
12) After turning off the power and unplug the wire, remove the eTLC plate and 
allow the plate to air dry completely in a fume hood 
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13) Wrapped the dried eTLC plate with plastic wraps completely and exposed to a 
phosphorimaging screen overnight 
14) Scan the phosphorimaging screen with Typhoon scanner 
15) Analyze the production of tripeptide over time with ImageQuant software 
16) For the time course, fit the data with a single exponential with the form: 
 𝑦 = 𝐴(1 − 𝑒−𝑘𝑥) + 𝑐  
where, 
c = account for the background release at time 0s  
A = the extent of the reaction 
k = the rate constant 
5.3 Microscope data collection 
 
5.3.1 Preparation of microscope slide for smFRET experiments 
 
Materials 
Drilled quartz slides 
mPEG-SVA MW5000 (Laysan Bio Catalog # mPEG-SVA-5000-1G) 
Biotin-PEG-SVA MW5000 (Laysan Bio Catalog # Biotin-PEG-SVA-5000-1G) 
 
Protocol 
Cleaning and preparing the slides and coverslips 
1) carefully put 10 quartz slides on a plastic holder with one space apart from 
each slide and put 12 coverslips on a ceramic rack without spacing 
2) degrease the slides and coverslips by sonicating in 100% ethanol for 15min in 
their corresponding “degrease” plastic containers 
3) rinse well with water (at least 3 times) 
4) activate the slides and coverslips by sonicating in 1M KOH for 15min in their 
corresponding “activate” plastic containers 
5) rinse well with water (at least 5 times) 
6) fill containers with water and sonicate both slides and coverslips for 5min 
7) pour out the water, tap and dry the plastic holder and ceramic rack with 
kimwipe without touching any slides or coverslips, remove as much water as 
possible to speed up drying 
8) allow the slides and coverslip to air dry on the benchtop for approximately 
45min, the slides and coverslip should be almost completely dried 
9) Flame the slides and coverslips with propane torch 
1) Each slide should be slowly passed 4 times (approximately 1 inch from the 
metal head) on each slide; no visible water should be left on the surface, 
place the flamed slides on a glass holder 
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2) Each coverslip should be quickly passed 3 times (approximately 2.5 
inches from the metal head) on each slide; no visible water should be left 
on the surface, place the flamed coverslips on a new ceramic rack 
10) Allow the flamed slides and coverslips to cool for approximately 30-45min, 
until no longer hot 
Silanize the slides and coverslips 
1) Fill the “silanization 1” containers with 100% acetone, for both 250ml for 
the slides and 140ml for the coverslips 
2) Add vectabond solution to the “silanization 1” containers, 4.5ml for the 
slides (into 250ml acetone, 1.8% final) and 2.5ml for the coverslips (into 
140ml acetone, 1.8% final) 
3) Fill the “silanization 2” containers with 50% acetone and 50% water, 
250ml total for the slides and 140ml total for the coverslip; this is for 
quenching the reaction 
4) Transfer the slides from glass holder to a plastic holder 
5) Place the plastic holder with slides into the silanization 1 solution 
containing Vectabond, slowly rotate the container to stir (do not mix by 
dipping in and out the solution) for total of 2min 
6) Quench the reaction by transferring the holder into “silanization 2” 
solution, slowly rotate the container to stir for total of 2min 
7) Decant the quenching solution and rinse with water (at least 5 times) 
8) Allow to sit in water for 10min 
9) Repeat step e-h for the coverslips on the ceramic rack 
10) pour out the water, tap and dry the plastic holder and ceramic rack with 
kimwipe without touching any slides or coverslips, remove as much water 
as possible to speed up drying; the slides and coverslips must be 
completely dried before proceed to the next step, this will take 
approximately 2-3 hours 
Prepare the biotin-PEG and PEG derivatization 
1) place the slides flat on a home-made slide holder with the “blown-out” side of the 
drilled holes facing up 
2) dissolve 10mg of biotin-PEG-SVA (MW 5000) in 1ml ice-cold water, vortex 
thoroughly 
3) add 60ul of dissolved biotin-PEG-SVA to 60mg of mPEG-SVA (MW 5000) 
4) add 600ul of ice-cold 100mM potassium borate, pH=8.4 to the mPEG-SVA 
mixture, immediately vortex for ~10s and quickly spin down for 1min 
5) pipet 60ul of the mixture to each slide 
6) using a coverslip forceps, gently place coverslips to each slide, make sure there 
are no air bubble between the slides and the coverslips; remove air bubble by 
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tapping the coverslips; be sure the drilled hole area is completely covered by the 
coverslips 
7) overlap the last two coverslips with each other with 60ul of mixture slightly rotate 
8) incubate the slides and the coverslips at room temperature in the dark for 1 hour; 
check within the first 10min to make sure the coverslips did not slide and still 
cover the drilled holes 
9) mark the lower right-hand corner of each slide and coverslip with pairing numbers 
(1 and 1.. etc) before removing the coverslips from the slides onto a ceramic rack 
10) dissolve another aliquot of 60mg mPEG-SVA in 660ul of ice-cold 100mM 
potassium borate, pH=8.4 
11) pipet 60ul of the mixture to each slide and coverslips 
12) using a coverslip forceps, gently place coverslips to each slide and reassemble the 
previous setup, make sure there are no air bubble between the slides and the 
coverslips and make sure the drilled hole area is completely covered by the 
coverslips 
13) incubate the slides and the coverslips at room temperature in the dark for 1 hour; 
check within the first 10min to make sure the coverslips did not slide and still 
cover the drilled holes 
14) transfer the coverslips to a ceramic holder and the slides to a plastic holder 
15) wash the slides in water vigorously for at least 20min 
16) wash the coverslips in water gently for at least 15-20min 
17) tap and dry the plastic holder and ceramic rack with kimwipe without touching 
any slides or coverslips, remove as much water as possible 
18) transfer the slides to a glass holder container and transfer the ceramic rack with 
coverslips into a plastic container, keeping the lid open and allow drying 
overnight 
5.3.2 Preparation of microscope flow-cell 
 
Preparation of microfluidic channels 
1) place a pegulated slide on the slide holder 
2) cut doubled-sided tape into small strips (approximately 3mm x 8cm)  
3) gently place the strips between drilled holes to generate channels of flow-cells 
4) place the coverslip on top of the strips, make sure to place the coverslip on the 
strips, do not retry if failed 
5) use a PCR tube/eppendrof tube, gently press on the coverslip (on top of the 
adhesive strips) to ensure a good seal between the channel 
6) cut away excess adhesive strips with a blade 
7) seal the opening on the two sides using fast-drying epoxy glue (5min epoxy 
adhesive) 
8) allow the sealed slide to sit on the slide holder to cure for 1hour or overnight, do 
not keep a sealed slide unused for more than a week 
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Preparation of microfluidic channels for experiments 
1) Wash the microfluidic channel with 200uL of TP50 buffer 
2) Flow in 20uL Block Solution and allow it to incubate for 5min 
3) Flow in 20uL Strep-Block Solution and allow it to incubate for 5min 
4) Wash away the solution with 200uL of TP50 buffer 
5) Exchange the buffer into experimental buffer of choice by flowing in 100uL of 
experimental buffer of choice  
6) Dilute the ribosomal complex to appropriate concentration (approximately 50pM, 
or determined experimentally) in the experimental buffer of choice 
7) Flow in 20-100uL of diluted ribosomal complexes, allow it to incubate for 5min 
8) Wash away excess complex with 100uL (or more) of experimental buffer of 
choice 
9) Prepare 30-50uL imagining buffer containing oxygen scavenging system 
a. Typically  
b. can contain excess protein factors or other reagents, depends on the 
experimental setup 
c. when working with excess protein factors, use 10% Image Block Solution 
(prepared using an experimental buffer) 
10) Flow in 30-50uL Imagining Solution, no incubation 
 
5.3.3 General experimental setup and imagining for steady-state smFRET 
experiments 
 
Experimental Setup for RF2 titration and RF3 titration 
1) Prepare the micro-fluidic channel as described  
2) Pre-incubate the imagining solution (example, solution containing 1uM RF2q and 
10uM RF3 and 1mM GTP) at room temperature without oxygen scavenging 
system 
3) Add OSS immediately before flowing into the channel 
4) Setup the microscope (typically 2-3min) as described 
5) Collect movies at: 
Camera setting 
Laser power: ~25mW 
Frame rate: 100ms/frame 
Movie length: 1200 frames 
6) Takes ~20 movies, be sure to check the buffer with a pH paper afterward to make 
sure the pH remain neutral 
 
 
5.4 smFRET data analysis 
 
All scripts to complete the analysis and initial molecule identification were written in 
MATLAB by Jason Hon. The following information is prepared by Jason Hon and the 
details of the procedure are described in his thesis. 
 




1) Time trajectories of single-Cy3 fluorophores were isolated from movies recorded 
of TIRF slides by modeling the background with a gamma distribution and 
locating spots that correspond to a p<0.01 and finding the unique local maximum 
pixel 
2) Time trajectories were next evaluated in five stages: 
a. every time trajectories was filtered with a 2nd order FIR filter with to a 
sampling rate of 1 Hz, a downsampling factor of 10 
b. the derivative was taken to identify transitions, and time trajectories 
lacking any dips below a given threshold were removed. This pool 
corresponds to time trajectories that meet three criteria which led to reason 
that they could be inauthentic or difficult to analyze complexes (they 
never show a binding/blinking event, they never bleach, and their signal-
to-noise ratio (SNR) is very low) 
c. every time trajectories is truncated at its latest blinking, binding, or 
bleaching event (with the exception of series that have a blinking/binding 
event but never bleach, which were included in their entirety) and 
calculated the autocorrelation coefficient of the truncated series – every 
time trajectories with an end time correlation coefficient > 0.96 was 
automatically considered to have bleached without a binding or blinking 
event.  
d. the pool of remaining molecules were manually sifted through and 
classified them as either (1) containing, (2) not containing a transition 
from the high intensity to the low intensity state, or (3) possessing 
transitions between three intensity states.  
e. each time trajectories was fit with fluctuations between 2 or more states 
using an appropriately populated (2 or 3 state) vbHMM.  
f. kmeans algorithm was used on the posterior rate constants from these 
disconnected models to calculate priors for ensemble subpopulation 
analysis; in the case of 3-state time trajectories, this was repeated twice. At 
this point, the unlabeled-RF2 experiment was introduced into inference as 
a very strong prior. To complete the analysis, we combined the posterior 
pseudocounts from 3-state traces with those from 2-state traces and 
calculated aggregated rate constants using the formulae in the Supplement. 
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Appendix A A list of mRNA constructs 
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Appendix B Mass spectrometry of tRNALys 
 
The following information is prepared by Dr. Lewis Brown (Biology Department, 
Columbia University): 
We were able to attempt analysis in negative ion mode modeled after the work of 
Hossain et al. 2007 (there is little literature on oligo MALDI). We used 2', 4』, and 6』
Trihydroxyacetophenone monohydrate (THAP) as a MALDI matrix. The results are 
attached. In summary, the peaks that we detected represent 60.5% of the sequence of 
tRNALys from E. coli: 
GGGUCGUUAGCUCAGDDGGDAGAGCAGUUGACUSUU6APCAAUUG7XCGCA
GGTPCGAAUCCUGCACGACCCACCA. 
We detected 10 of 14 predicted m/z values (see attached Excel spreadsheet). 
The oligo of your particular interest (ACCCACCA) which was characteristic of the E. 
coli Lys-tRNA and with theoretical m/z of 2449.39 was observed as strong peak at 
2449.13 m/z (external calibration) and at 2449.40 m/z (internal calibration). Internal 
calibration was done with predicted peaks at 1301.183 m/z and 2242.285 m/z arising 
from the sample itself. The predicted mass at 4964.632 m/z was not observed that all. 
This is not surprising in view of the similar lack of detection of this mass in the more 






























Gp 362.049 -   -   G1:G1 363.057 
Gp 362.049 -   -   G2:G2 363.057 
Gp 362.049 -   -   G3:G3 363.057 
Gp 362.049 -   -   G19:G19 363.057 
Gp 362.049 -   -   G53:G53 363.057 
AGp 691.101 -   -   A23:G24 692.109 
UCGp 973.115 973.0673 0.0477 973.1092 0.0058 U4:G6 974.123 
UUGp 974.099 974.0440 0.0550 974.0861 0.0129 U28:G30 975.107 
DDGp 978.13 978.0790 0.0510 978.1216 0.0084 D16:G18 979.138 
CAGp 996.142 996.0697 0.0723 996.1148 0.0272 C25:G27 997.15 
CAGp 996.142 996.0697 0.0723 996.1148 0.0272 C50:G52 997.15 
DAGp 999.142 999.0833 0.0587 999.1288 0.0132 D20:G22 1000.15 
TPCGp 1293.156 1293.0675 0.0885 1293.1551 0.0009 T54:G57 1294.163 
CACGp 1301.183 1301.0942 0.0888 1301.1830 0 C65:G68 1302.191 
UUAGp 1303.151         U7:G10 1304.159 
7XCGp 1433.225         746:G49 1434.233 
CUCAGp 1607.208 1607.0710 0.1370 1607.2066 0.0014 C11:G15 1608.216 
AAUCCUGp 2242.285 2242.0460 0.2390 2242.2850 0 A58:G64 2243.293 
ACCCACCA 2449.398 2449.1291 0.2689 2449.4032 0.0052 A69:A76 2450.405 
ACUSUU6APCAAUUGp 4963.624         A31:G45 4964.632 
Mean Deviation 
(Internal calibrants 
















Appendix C Mass spectrometry of RF2 
 
The following information is prepared by Dr. Antonius Koller from the Proteomics 
Shared Resource facility at Columbia University Medical Center. 
 
50pmol of protein from each sample was reduced with 5mM DTT and alkylated with 
10mM iodoacetamide. Trypsin was added and the protein samples were digested 
overnight at 37°C. 
1pmol of peptides were spotted onto MALDI target and analyzed by MALDI-TOF on a 
Bruker UltrafleXtreme. 
The peptide 184-194 includes the QSY9-conjugation position. The disappearance of the 
peaks in both RF2(QYS9)-A and RF2(QSY9)-B indicate QSY9-conjugation occurs at the 







Appendix D RF2(QYS9) kinetic subpopulations with 
photophysical subpopulation 
 
The transition rates between the high- and low-intensity states (kind,hilow and 
kind,lowhi) of each Cy3-intensity versus time trajectories were calculated using the 
transition matrix derived from Hidden Markov Model (HMM) inference of each time 
trajectory. To visualize the distribution of the rate pairs, the kind,hilow versus kind,lowhi of 
every dynamic Cy3 time trajectory at 1µM RF2(QSY9) on the aEC is plotted as a single 
data point on a scatterplot (Appendix D). A subpopulation HMM with hierarchical 
constraints was used to classify and determine the consensus transition rates of each 
kinetic subpopulation (khilow and klowhi). In calculating the consensus transition rates of 
the subpopulations, the non-fluctuating time trajectories were distributed into each kinetic 
subpopulation based on the weight of their evidence values. Three kinetic subpopulations 
were identified: (1) a subpopulation consisting of time trajectories with rate constants 
equal to those of Cy3 photoblinking, which was directly measured in the presence of 
unlabeled RF2 (Appendix D colored green), (2) a subpopulation consisting of time 
trajectories with a bound state lifetime of ~3s (Appendix D and Figure 2-13 colored red), 
(3) a subpopulation consisting of time trajectories with a bound state lifetime 
commensurate with the experimental framerate of 100ms/frame (Appendix D and Figure 
2-13 colored blue). The majority of the non-fluctuating time trajectories were distributed 
into the Cy3 photoblinking subpopulation due to the timescale of their high-intensity 
state.  
In addition, the transition rates of each subpopulation were calculated for different 




above. The Cy3 photoblinking subpopulation showed no RF2(QSY9) concentration 
dependence on both khilow and klowhi, which further supports the classification of the 
dynamic time trajectories from this subpopulation into a subpopulation governed by Cy3 
photophysical noise as opposed to Cy3 fluorescence quenching caused by binding of 
RF2(QSY9) (Appendix D, colored green). On the other hand, there are two 
subpopulations consistent with authentic RF2(QSY9) binding subpopulations with klowhi 
showing linearly dependence of RF2(QSY9) concentration and essentially no dependence 
on the khilow (Appendix D and Figure 2-13 colored red and blue). The origin of the two 
binding subpopulations is unclear, however, lack of interconversion between the two 
subpopulations during our experimental timescale suggests that this heterogeneity is 
likely arise from difference in ribosomal complexes and not difference in RF2. 
Furthermore, the relative size of the two populations also remain relatively constant as a 






Kinetic subpopulations of RF2 binding to the mismatched complex. 
(A) A scatterplot of transition rate from high-intensity state to low-intensity state 
(kind,hilow) versus transition rate from low-intensity state to high-intensity state 
(kind,lowhi) of 1μM RF2(QSY9), the colors showing different subpopulations 
(green, red and blue) of RF2 binding kinetics as determined by ensemble-level HMM; 
(B) Examples of Cy3 time trajectories from each kinetic subpopulation of the 1uM 
RF2(QSY9) on mismatched complex data set; Cy3-intensity time trajectories is colored 




Calculated “ensemble” transition rates from high-intensity state to low-intensity state 
for each subpopulation as a function of RF2(QSY9) concentration; error bars represent 
95% confidence interval;  (D) Calculated “ensemble” transition rates from low-
intensity state to high-intensity state for each subpopulation as a function of 







Appendix E EFRET histograms compiled from two-state 
or three-state time trajectories from EC and aEC 
 
 
FRET histograms of two- and three-state time trajectories. 
(A) A FRET histogram compiled from two-state time trajectories with 1μM 
RF2(QSY9) and 0nM RF3. (B) A FRET histogram compiled from three-state time 





















































































11 RF1 256C + 328C - Carbenicillin pProEx-
HTb 
 
12 RF1 141C + MTase - Carbenicillin pProEx-
HTb 
 














































Carbenicillin p33?  
20 p33 (taq) DNA 
polymerase-2 
TOP10 Carbenicillin p33?  
21 p33 (taq) DNA 
polymerase-3 
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32 short mRNA-MFK DH5a Carbenicillin pUC119 pg32.1-20, 
AUG UUU 
AAA  <--- WT 
33 long mRNA-MKK DH5a Carbenicillin pUC119 pg32.1-200 
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Appendix G Matlab scripts for data analysis 
 
automatic_data_analysis.m script 




%  num = {'-1.','-2.','-3.','-4.','-5.','-6.','-7.','-8.','-9.','-
10.',... 






%    '-11.','-12.','-13.','-14.','-15.'}; 
num = {'_1','_2','_3','_4','_5','_6','_7','_8','_9','_10'}; 
% num = {'_11','_12','_13','_14'}; 
%  
xsize = 256; 
ysize = 512; 
for rk = 1:length(num) 
    pathlib(rk) = dir(['*2016*' num{rk} '_MMStack*tif']); 
    data = tiffread2(pathlib(rk).name); 
    grid.x = zeros(ysize,xsize); 
    grid.y = grid.x; 
    for rrk = 1:ysize 
        grid.x(rrk,:) = 1:xsize; 
    end 
    for rrk = 1:xsize 
        temp = 1:ysize; 
        grid.y(:,rrk) = temp(:); 
    end 
    grid.x = grid.x(:); 
    grid.y = grid.y(:); 
    disp(pathlib(rk).name); 
    for rrk = 1:length(data) 
        temp = data(rrk).data(:,1:256); 
        sf = fit([grid.x grid.y],double(temp(:)),'poly33'); 
        corrected_data{rk,rrk} = double(temp)-
reshape(sf(grid.x,grid.y),ysize,xsize); 
    end 
end 
flatten = 0; 
 
 
% powers = {'_8mW' '12mW' '18mW' '24mW' '34mW'};  




% concs = {'0nM','500nM','1000nM','1500nM'}; 
% pathlib = dir(['*' concs{rk} '*stopflow.tif']); 
% for rrk = 1:length(pathlib) 




%     disp(pathlib(rrk).name) 
%     for rk = 1:length(z) 
%         corrected_data{rrk,rk} = double(z(rk).data); 
%     end 
% end 
 
% pathlib = dir(['*Flattened.mat']); 
% out = load(pathlib(1).name); 
% corrected_data = out.corrected_data; 
% flatten = 1; 
% pathlib = dir(['*2015*tif']); 
% % corrected_data = corrected_data(2:end,:); 
% clear out 
 
temp_cy3 = []; 
% temp_cutoffs = []; 
for zk = 1:size(corrected_data,1) 
    cy3 = corrected_data(zk,:); 
    temp_thingy = cy3{1}(:); 
    [a,b] = normfit(temp_thingy); 
    cutoffgen = @(x) normcdf(x,a,b)-0.96; 
    thresh = fzero(cutoffgen,1e3); 
    h.num = 0; 
    for nk = 1:20 
        if nk==1 
            ok = 0; 
            while ~ok 
                if flatten 
                    [~,hh] = 
immerge2(cy3{nk},cy3{nk},[thresh(1,:);thresh(1,:)],1); 
                    guess = input('Input lines to remove. Empty if no 
lines.'); 
                elseif ~flatten && zk == 1 
                    [~,hh] = 
immerge2(cy3{nk},cy3{nk},[thresh(1,:);thresh(1,:)],0); 
                    guess = input('Input lines to remove. Empty if no 
lines.'); 
                else 
                    guess = []; 
                end 
                if isempty(guess) 
                    ok = 1; 
                else 
                    for rrk = 1:length(cy3) 
                        cy3{rrk} = [cy3{rrk}(:,1:guess(1)) 
cy3{rrk}(:,guess(2):end)]; 
                        offset(rrk,:) = min(cy3{rrk}(:))-1; 
                        cy3{rrk} = cy3{rrk}-offset(rrk,:); 
                    end 
                    [a,b] = normfit(cy3{1}(:)); 
                    cutoffgen = @(x) normcdf(x,a,b)-0.96; 
% this threshold was adapted as necessary to accommodate the loading in 
%a given set of movies 
                    thresh = fzero(cutoffgen,thresh); 
                end 
                close all 




        else 
            [~,hh] = 
immerge2(cy3{nk},cy3{nk},[thresh(1,:);thresh(1,:)],0); 
        end 
        hh.num = sum(sum(hh.indc_merge)); 
        if hh.num>h.num 
            h = hh; 
        end 
    end 
 
    rule = h.indc_merge; 
    % define a rule that sets where all the dots will be 
    z = find(rule(:)==1); 
    [x,y] = ind2sub(size(cy3{1}),z); 
    count = 1; 
    out.ycoord{zk} = x; 
    out.xcoord{zk} = y; 
%     z = sub2ind(size(cy3{1}),take(:,1),take(:,2)); 
%     clear take 
    % be extra carful none of the addresses overlap 
    % nab all the addresses 
%      
%     if flatten 
%         tempvar = tiffread2(pathlib(zk).name); 
%         for rk = 1:length(tempvar) 
%             cy3{rk} = double(tempvar(rk).data); 
%         end 
%     end 
    % draw from the raw data instead of the flattened data 
     
 
    trace_cy3 = zeros(length(z),length(cy3)); 
    cutoffs = zeros(length(z),length(cy3)); 
    for rk = 1:length(cy3) 
        temp1 = cy3{rk}(:); 
%         trace_cy3(:,rk) = temp1(z); 
        if ~flatten 
            [b,sss] = normfit(temp1(~isnan(temp1)&~isinf(temp1))); 
            trace_cy3(:,rk) = temp1(z)-b; 
        else 
            trace_cy3(:,rk) = temp1(z); 
        end 
    end 
    trace_cy3 = trace_cy3'; 
    temp_cy3 = [temp_cy3 trace_cy3]; 
    out.index_{zk} = zk*ones(length(z),1); 
end 
% use the rule to find all the concurrent intensities from cy3 and cy5 
 
clear cy3 
trace_cy3 = temp_cy3; 
out.trace_cy3 = trace_cy3; 
t1 = 1:size(trace_cy3,1); 
count = 1; 
for rk = 1:size(trace_cy3,2) 
    templ = diff(decimate(fliplr(out.trace_cy3(:,rk)'),10)); 




    temp2 = []; 
    temp = 10*find(templ>180,1); 
    if ~isempty(temp) 
        zed = templ(find(templ>180,1)); 
        temp2 = 10*find(templ<-zed*3/4,1); 
    end 
    if ~isempty(temp) 
        if ~isempty(temp2) 
            if temp2<temp 
                cy3{count} = out.trace_cy3(:,rk); 
                traces(:,count) = out.trace_cy3(:,rk); 
                count = count+1; 
            else 
                cy3{count} = out.trace_cy3(1:end-temp-15,rk); 
                traces(:,count) = out.trace_cy3(:,rk); 
                count = count+1; 
            end 
        else 
            cy3{count} = out.trace_cy3(1:end-temp-15,rk); 
            traces(:,count) = out.trace_cy3(:,rk); 
            count = count+1; 
        end 
%     else 
%         plot(trace_cy3(:,rk),'color',[0 .5 0]) 
%         ylim([-max(trace_cy3(:,rk))-500 500+max(trace_cy3(:,rk))]) 
%         xlim([min(t1) max(t1)]) 
%         legend(['Cy3 ' num2str(rk) '/' num2str(size(trace_cy3,2))]) 
%         ax = gca;    
%         [x,y] = getpts(ax); 
%         if y>0 
%             cy3{rk} = out.trace_cy3(1:round(x),rk); 
%             traces(:,count) = out.trace_cy3(:,rk); 
%             count = count+1; 
%         end 
    end 
end 
 
clear temp temp2 temp3 
count = 1; 
for rk = 1:length(cy3) 
    acf{rk} = ifft(fft(cy3{rk}).*conj(fft(cy3{rk}))); 
    if ~isempty(acf{rk}) 
        temp{count} = cy3{rk}; 
        temp2{count} = acf{rk}; 
        temp3(:,count) = traces(:,rk); 
        count = count+1; 
    end 
end 
cy3 = temp; 
acf = temp2; 
traces = temp3; 
ender = zeros(length(cy3),1); 
 
for rk = 1:length(cy3) 
    t = length(acf{rk})/2; 





cutoff = 0.95; 
% cutoff = 0.99; 
 
clear corrected_data 
for rk = 1:length(cy3) 
    if ender(rk,:)>cutoff 
        vb{rk}.ideals = mean(cy3{rk})*ones(length(cy3{rk}),1)/1e4; 
    else 
        thresh = multithresh(cy3{rk}); 
        [vb{rk},~] = vmp_hmm_modular_ada(cy3{rk}/1e4,2,[0 mean([thresh 
max(cy3{rk})])]/1e4); 
    end 
    try 
        vb{rk}.ideals*2; 
    catch 
        vb{rk}.ideals = mean(cy3{rk})*ones(length(cy3{rk}),1)/1e4; 
    end 
end 
 
rk = 1; 
taken = zeros(length(vb),4); 
bad_ones = []; 
bad_fits = []; 
threestate = []; 
y = 0; 
while rk < 1+length(vb) 
    try 
        vb{rk}.ideals*2; 
    catch 
        vb{rk}.ideals = ones(length(cy3{rk}),1)*mean(cy3{rk})/1e4; 
    end 
    if ender(rk,:)<cutoff 
        t = 1:length(cy3{rk}); 
        tt = 1:size(traces,1); 
        
plot(t,cy3{rk},tt(length(t):length(tt)),traces(length(t):length(tt),rk)
,t,vb{rk}.ideals*1e4) 
        ylim([-max(cy3{rk})-500 max(cy3{rk})+500]) 
        legend(['Cy3 ' num2str(rk) '/' num2str(length(cy3))]) 
        y = input('empty is good, 0 is bad, 1 is go back, 2 is a bad 
fit, 3 is three-state, 4 is manually fix photobleaching'); 
        if y == 1 
            rk = rk-1; 
            taken(rk,:) = zeros(4,1); 
        elseif y == 0 
            taken(rk,1) = 1; 
            rk = rk+1; 
        elseif isempty(y) 
            taken(rk,2) = 1; 
            rk = rk+1; 
        elseif y == 2 
            taken(rk,3) = 1; 
            rk = rk+1; 
        elseif y == 3 
            taken(rk,4) = 1; 
            count = count+1; 




        elseif y == 4 
            [pts1,pts2] = getpts(gca); 
            if isempty(pts1) 
                pts1 = 10; 
            end 
            cy3{rk} = traces(1:min([size(traces,2) round(pts1)]),rk); 
            [vb{rk},~] = vmp_hmm_modular_ada(cy3{rk}/1e4,2,[0 
mean([thresh max(cy3{rk})])]/1e4); 
        end 
    elseif y == 1 
        rk = rk-1; 
        taken(rk,:) = zeros(4,1); 
    else 
        rk = rk+1; 
    end 
end 
out.taken = taken; 
threestate = find(taken(:,4)==1); 
bad_fits = find(taken(:,3)==1); 
bad_ones = find(taken(:,1)==1); 
 
rk = 1; 
while rk < 1+length(bad_fits) 
    t = 1:length(cy3{bad_fits(rk,:)}); 
    
plot(t,cy3{bad_fits(rk,:)},tt(length(t):length(tt)),traces(length(t):le
ngth(tt),bad_fits(rk,:))) 
    ylim([-max(cy3{bad_fits(rk,:)})-500 max(cy3{bad_fits(rk,:)})+500]) 
    legend(['Cy3 ' num2str(rk) '/' num2str(length(bad_fits))]) 
    guess = input('Place a guess; empty gives a 1-state solution.'); 
    tries = 1; 
    if isempty(guess) 
        vb{bad_fits(rk,:)}.ideals = 
mean(cy3{rk})*ones(length(bad_fits(rk,:)),1)/1e4; 
        rk = rk+1; 
    else 
        ok = 0; 
        while ~ok 
            [vb{bad_fits(rk,:)},~] = 
vmp_hmm_modular(cy3{bad_fits(rk,:)}/1e4,2,guess/1e4); 
            
plot(t,cy3{bad_fits(rk,:)},tt(length(t):length(tt)),traces(length(t):le
ngth(tt),bad_fits(rk,:)),t,vb{bad_fits(rk,:)}.ideals*1e4) 
            ylim([-max(cy3{bad_fits(rk,:)})-500 
max(cy3{bad_fits(rk,:)})+500]) 
            legend(['Cy3 ' num2str(rk) '/' num2str(length(bad_fits))]) 
            y = input('Nothing is good, 0 is try again, 1 is quit'); 
            if isempty(y) 
                ok = 1; 
                rk = rk+1; 
            elseif y==0 
                ok = 0; 
                guess = input('Place a guess; empty gives a 1-state 
solution.'); 
                    if isempty(guess) 





                        rk = rk+1; 
                        ok = 1; 
                    end 
            elseif y==1 
                bad_ones(end+1,:) = rk; 
                ok = 1; 
                rk = rk+1; 
            end 
        end 
    end 
end 
 
logical_bad = zeros(length(cy3),1); 
for rk = 1:length(bad_ones) 
    logical_bad(bad_ones(rk,:)) = 1; 
end 
logical_threestate = zeros(length(cy3),1); 
for rk = 1:length(threestate) 
    logical_threestate(threestate(rk,:)) = 1; 
end 
 
rates = zeros(length(vb),2); 
for rk = 1:length(vb) 
    try 
        if length(unique(vb{rk}.ideals))==2 
            temp = 1./vb{rk}.rate(~eye(2,2)); 
            rates(rk,:) = fliplr(temp(:)'); 
        end 
    end 
end 
out.logical_bad = logical_bad; 
out.vb = vb; 
out.rates = rates; 
out.cy3 = cy3; 
out.ender = ender; 
out.threestate = logical_threestate; 
 
len = zeros(length(vb),1); 
for rk = 1:length(vb) 
    try 
        len(rk,:) = length(unique(vb{rk}.ideals)); 
    end 
end 
 
tracelen = zeros(length(vb),1); 
for rk = 1:length(cy3) 
    tracelen(rk,:) = length(cy3{rk}); 
end 
 
cy3 = out.cy3; 
vb = out.vb; 
rates = out.rates; 
logical_bad = out.logical_bad; 
logical_threestate = out.threestate; 
for rk = 1:length(cy3) 





scaled = scaled(~logical_bad&~logical_threestate); 
vb_run = vb(~logical_bad&~logical_threestate); 
rates = rates(~logical_bad&~logical_threestate,:); 
temp = rates(rates(:,1)>0,:); 
k=2; 
out.vmp_xi = vmp_xi_consensus(scaled,vb_run,temp,k,[]); 
rate = zeros(length(out.vmp_xi.vbem),2); 
for rk = 1:length(out.vmp_xi.vbem) 




if k ==3 
    colormat = [1 0 0;0 .5 0;0 0 0]; 
else 
    colormat = [0 .5 0;1 0 0]; 
end 
for rk = 1:size(rates,1) 
%     if rates(rk,1)<.6930||rates(rk,1)>.6933 
        
plot(log10(rates(rk,1)),log10(rates(rk,2)),'Marker','.','LineStyle','no
ne','color',out.vmp_xi.conprob(rk,:)*colormat) 




xlabel('log(Low to High Rate Constant)');ylabel('log(High to Low Rate 
Constant)') 
pathlib = dir('*2016*tif'); 






% following code is only necessary if the fit looks like shit 
 
% dynamic_traces = rates(:,1)>0; 




% [~,rule] = sort(out.vmp_xi_dynamic_only.consensus_rates(:,1)); 
% slower_traces = ones(size(rates,1),1); 
% cluster3 = out.vmp_xi_dynamic_only.conprob(:,rule(3))>.5; 
% count = 1; 
% for rk = 1:size(slower_traces,1) 
%     if dynamic_traces(rk,:) 
%         if cluster3(count,:) 
%            slower_traces(rk,:) = 0; 
%         end 
%         count = count+1; 
%     end 
% end 








% close all 
% hold on 
% colormat = [0 .5 0;1 0 0]; 
% colormat3s = [1 0 0;0 .5 0;0 0 0]; 
% count1 = 1; 
% count2 = 1; 
% for rk = 1:size(rates,1) 
%     if slower_traces(rk,:) 
%         
plot(log10(rates(rk,1)),log10(rates(rk,2)),'Marker','.','LineStyle','no
ne','color',out.vmp_xi_slower_only.conprob(count1,:)*colormat) 
%         count1 = count1+1; 
%     else 
%         
plot(log10(rates(rk,1)),log10(rates(rk,2)),'Marker','.','LineStyle','no
ne','color',[0 0 0]) 
%         count2 = count2+1; 
%     end 
% end 
% xlim([-3 1]); 
% ylim([-4 1]); 
% xlabel('log(Low to High Rate Constant)');ylabel('log(High to Rate 
Constant)') 
%  
% c3_sum = sum(out.vmp_xi_dynamic_only.conprob(:,rule(3))); 
% other_sum = sum(out.vmp_xi_slower_only.conprob); 
% k = [c3_sum other_sum(:)']; 
% out.subpopulation_fraction = k./sum(k); 
%  







% threestate analysis 
 
% cy3 = out.cy3; 
% threestate = out.threestate; 
% for rk = 1:length(cy3) 
% ok = 0; 
%     if threestate(rk,:) 
%         plot(cy3{rk}) 
%         while ~ok 
%             guess = input('guess'); 
%             [vb3s{rk},~] = 
vmp_hmm_modular_ada(cy3{rk}/1e4,3,guess/1e4); 
%             plot([cy3{rk} vb3s{rk}.ideals*1e4]) 
%             ok = input('continue'); 
%             if ok ~= 1 
%                 ok = 0; 




%         end 
%     end 
% end 
% rates3s = zeros(length(cy3),6); 
% for rk = 1:length(cy3) 
%     if threestate(rk,:) 
%         temp = 1./vb3s{rk}.rate; 
%         temp = temp; 
%         temp = temp(~eye(3,3)); 
%         rates3s(rk,:) = temp; 
%     end 
% end 
% out.vmp_xi_3state = 
vmp_xi_consensus(scaled(threestate),vb3s(threestate),rates3s(threestate
,:),2,[]); 
% out.vb3s = vb3s; 
% out.rates3s = rates3s; 
% pathlib = dir(['*2015*tif']); 
% z = pathlib(1).name; 







% rk = 1; 
% picks = find(v.conprob(:,2)>.5); 
% count = 1; 
% while rk < 1+length(picks) 
%     plot([out.trunc_cy3{picks(rk)} out.vb{picks(rk)}.ideals*1e4]) 
%     y = input(''); 
%     if isempty(y) 
%         rk = rk+1; 
%     elseif y == 0 
%         bad(count,:) = rk; 
%         count = count+1; 
%         rk = rk+1; 
%     elseif y == 1 
%         guess = input('guess'); 
%         ok = 0; 
%         if isempty(guess) 
%             out.vb.ideals{picks(rk)} = 
ones(length(scaled{picks(rk)}),1)*mean(scaled{picks(rk)}); 
%         else 
%             while ~ok 
%                 try 
%                     [out.vb{picks(rk)},~] = 
vmp_hmm_modular(scaled{picks(rk)},2,guess/1e4); 
%                     plot([out.trunc_cy3{picks(rk)} 
out.vb{picks(rk)}.ideals*1e4]) 
%                     ok = input('ok?'); 
%                     if ok~=1 
%                         ok = 0; 
%                     end 
%                 catch 




%                 end 
%             end 
%         end 
%         rk = rk+1; 
%     else 
%         rk = rk+1; 
%     end 
% end 
% rates = zeros(length(out.vb),2); 
% for rk = 1:length(out.vb) 
%     try 
%         if length(unique(out.vb{rk}.ideals))==2 
%             temp = 1./out.vb{rk}.rate'; 
%             rates(rk,:) = temp(~eye(2,2)); 
%         end 





%  ( Y ) 
%  (. .) 
% o(")(") 
% 
% bunny bunny bunny bun! 
% disclaimer: Jason did not do this. 
 
 
